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ABSTRACT OF DISSERTATION 
 
 
 
 
DISCOVERY OF NEW ANTIMICROBIAL OPTIONS AND EVALUATION OF 
AMINOGLYCOSIDE RESISTANCE ENZYME-ASSOCIATED RESISTANCE 
EPIDEMIC 
 
The extensive and sometimes incorrect and noncompliant use of various types of 
antimicrobial agents has accelerated the development of antimicrobial resistance (AMR). 
In fact, AMR has become one of the greatest global threat to human health in this era. The 
broad-spectrum antibiotics aminoglycosides (AGs) display excellent potency against most 
Gram-negative bacteria, mycobacteria, and some Gram-positive bacteria, such as 
Staphylococcus aureus. The AG antibiotics amikacin, gentamicin, kanamycin, and 
tobramycin are still commonly prescribed in the U.S.A. for the treatment of serious 
infections. Unfortunately, bacteria evolve to acquire resistance to AGs via four different 
mechanisms: i) changing in membrane permeability to resist drugs from entering, ii) 
upregulating efflux pumps for active removal of intracellular AGs, iii) modifying the 
antimicrobial target(s) to prevent drugs binding to their targets, and iv) acquiring resistance 
enzymes to chemically inactivate the compounds. Amongst all, the acquisition of resistance 
enzymes, AG-modifying enzymes (AMEs), is the most common resistance mechanism 
identified. Depending on the chemistry each enzyme catalyzes, AMEs can be further 
divided into AG N-acetyltransferases (AACs), AG O-phosphotransferases (APHs), and 
AG O-nucleotidyltransferases.  
 
To overcome AME-related resistance, we need to better understand these resistance 
enzymes and further seek ways to either escape or inhibit their actions. In this dissertation, 
I summarized my efforts to characterize the AAC(6') domain and its mutant enzymes from 
a bifunctional AME, AAC(6')-Ie/APH(2")-Ia as well as another common AME, APH(3')-
IIa. I also explained my attempt to inhibit the action of various AAC enzymes using metal 
salts. In an effort to explore the current resistance epidemic, I evaluated the resistance 
against carbapenem and AG antibiotics and the correlation between the resistance profiles 
and the AME genes in a collection of 122 Pseudomonas aeruginosa clinical isolates 
obtained from the University of Kentucky Hospital System. Besides tackling the resistance 
mechanisms in bacteria, I have also attempted to explore a new antifungal option by 
repurposing an existing antipsychotic drug, bromperidol, and a panel of its derivatives into 
 
a combination therapy with the azole antifungals against a variety of pathogenic yeasts and 
filamentous fungi. 
 
KEYWORDS: aminoglycoside-modifying enzyme (AME), enzyme engineering, substrate 
promiscuity, enzyme kinetics, minimum inhibitory concentrations (MICs), drug 
combination. 
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Chapter 1. New trends in the use of aminoglycosides 
Despite their inherent toxicity and the acquired bacterial resistance that continuously 
threatens their long-term clinical use, aminoglycosides (AGs) still remain valuable 
components of the antibiotic armamentarium. Recent literature showed that the AGs’ role 
has been further expanded as multi-tasking players in different areas of study. This chapter 
aims at presenting some of the new trends observed in the use of AGs in the past decade 
that is related to this dissertation, along with the current understanding of their mechanisms 
of action in various bacterial and eukaryotic cellular processes. 
 
1.1. INTRODUCTION 
The 2-deoxystreptamine (2-DOS) aminoglycosides (AGs) are a group of naturally 
occurring and semi-synthetic aminocyclic sugars (Figure 1.1). AGs can be structurally 
classified as 4,5-disubstituted AGs (e.g., neomycin B (NEO), paromomycin (PAR), and 
ribostamycin (RIB); note: although neamine (NEA) is a 4-monosubtituted AG, we included 
it in the 4,5-disubstituted AGs in Figure 1.1 as its structure is comprised in their scaffolds) 
as well as 4,6-disubstituted AGs (e.g., amikacin (AMK), kanamycin A and B (KANA and 
KANB), tobramycin (TOB), gentamicin (GEN), geneticin (G418), netilmicin (NET), and 
sisomicin (SIS)). Other AG scaffolds include the monosubstituted AGs (e.g., apramycin 
(APR) and hygromycin (HYG)), and streptomycin (STR). 
 
AGs’ broad-spectrum of activity against pathogenic bacteria has favored them as a valuable 
class of antibiotics for the past 70 years.1 Studies of their antibacterial mode of action have 
revealed that AGs bind both to the aminoacyl site (A-site) of the 16S rRNA of bacteria, 
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where they perturb the “proof-reading” process that ensures protein translation fidelity,2 
and to the 50S ribosomal subunit, inhibiting translocation and ribosome recycling.3-4 
 
 
Figure 1.1. Structures of parent AGs discussed in this chapter. The 2-deoxystreptamine (2-DOS) ring is 
depicted in blue. 
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Naturally occurring AGs are produced by Streptomyces and Micromonospora soil 
bacteria,5 which proactively methylate their ribosome to survive the bactericidal action of 
AGs’ secondary metabolites.6 This mechanism, along with the decrease in AG uptake and 
the emergence of aminoglycoside-modifying enzymes (AMEs), has significantly plagued 
the clinical efficacy of AGs.7 AMEs, in particular, have been a serious threat to AGs’ long 
term use and more than 100 of them have been identified.8 These enzymes, which include 
AG N-acetyltransferases (AACs), AG O-phosphotransferases (APHs), and AG O-
nucleotidyltransferases (ANTs) (Figure 1.2A) act through chemical modifications of the 
structures of AGs. Indeed, AACs catalyze the transfer of an acetyl group from acetyl 
coenzyme A (AcCoA) to the amine functionalities of AGs, while APHs and ANTs use 
ATP (and in some cases GTP)9-12 to transfer a phosphate and an adenosine (guanidine) 
monophosphate moieties, respectively, to the hydroxyl groups of AGs (Figure 1.2B). 
Unlike other AACs, which are regiospecific, the newly discovered enhanced intracellular 
survival (Eis) is a versatile enzyme that can acetylate different amine positions of AGs.13-
22 
 
Soon after its introduction in the therapeutic regimen of tuberculosis, STR, the first AG 
ever discovered, displayed toxic side effects. Nephrotoxicity and ototoxicity, which are the 
most common adverse effects associated with AG antibiotics, have also hampered their 
clinical effectiveness. These serious shortages have sparked considerable interests in the 
scientific community. Our group has recently provided a comprehensive overview of AG 
antibiotics1 and the recent approaches that have been developed to triumph over AMEs’ 
actions.23 Of special note, the combination of AGs with AME inhibitors can be a potentially 
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effective tactic to revive the usefulness of these drugs against AG-resistant strains. This 
was inspired by the clinical success encountered by the co-administration of b-lactams and 
b-lactamase inhibitors.24 The search for Eis inhibitors enabled the development of a high-
throughput screening (HTS) method that facilitated the identification of 25 active 
compounds out of 23,000 tested.22 While waiting for HTS to be applied to the other classes 
of AMEs, existing AME inhibitors could be utilized in the meantime. These include the 
APH(3')-IIIa inhibitor ankyrin repeat protein,25-26 the APH(2")-IVa inhibitor quercetin,27 
the APH(9)-Ia inhibitor CKI-7, which was co-crystallized with APH(3')-IIIa,28 and the 
bifunctional enzyme AAC(6')-Ie/APH(2")-Ia inhibitor aranosin.29 The 3-
(dimethylamino)propylamine moiety was also found to be an essential scaffold for 
ANT(2")-Ia and APH(3')-IIIa inhibitors.30 
 
 
Figure 1.2. A. Sites that are targeted by the different AMEs. Unlike other AMEs that are regiospecific, 
Eis can multi-acetylate AGs. B. Chemical modifications catalyzed by AMEs. 
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Also worth mentioning is the development of AGs that could both tightly bind to the 
bacterial ribosome and disrupt the protein synthesis machinery and also be poor substrates 
of AMEs. This has eventually led to the synthesis of:  
 
i) Structurally constrained AGs – Originally designed to resemble the locked conformation 
of AG when bound to the bacterial A-site, a variety of rigidified NEO, PAR, NEA, and 
KANA derivatives were synthesized (Figure 1.3).31-37 Although they all displayed a 
decreased antibacterial activity compared to the parent AGs, the NEO and the KANA-
restricted derivatives (through methylene linkers between the 2'-NH and 5"-C as well as 
the 2'-oxygen and 5-oxygen, respectively) were still quite active, with MIC values ranging 
from 2.5 to 64 µg/mL. Additionally, the NEO-restricted derivatives were poor substrates 
of Staphylococcus aureus ANT(4') and Mycobacterium tuberculosis AAC(2')-Ic. 
 
Figure 1.3. Structures of conformationally constrained AGs. 
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ii) AG dimers – Following evidence that dimerized parent AGs may have improved binding 
affinity towards RNA,38 series of homo- and heterodimeric AGs were developed with the 
goal of investigating their ability to target the bacterial A-site.39-43  In addition, some NEA 
dimers, linked at the 5-position via amides and 1,2-hydroxyamines (Figure 1.4), could 
evade the action of the AMEs AAC(6')-Ii, APH(3')-IIIa, and AAC(6')-Ie/APH(2")-Ia better 
than the parent compounds.39 Furthermore, a TOB homodimer was shown to be a poor 
substrate of TOB-targeting AMEs AAC(6')-Ie/APH(2")-Ia, AAC(6')-Ib', and ANT(4').43 
The use of AG dimers has, however, not been limited to targeting bacterial ribosome. In 
fact, AG dimers also found application as binders of RNA hairpin loops,44-45 as binders of 
the dimerization initiation site of the HIV-1 genomic RNA,46 the HIV-1 Rev response 
element,47 and HIV-1 trans-acting responsive sequence.48 AG monomers and dimers have 
also found to be useful as inhibitors of anthrax lethal factor.49-51 
 
 
Figure 1.4. Representative TOB and NEA dimers with different linker attachments. Note: NEO-NEO, 
NEO-TOB, KAN-KAN, and KAN-TOB dimers have also been reported in the literature.38, 41-43, 47 
 
iii) Guanidinylated AGs – By replacing the amine or hydroxyl moieties with a guanidine 
functionality in TOB, AMK, KANA, NEO, NEA, PAR, and APR, the Nizet and Tor groups 
were able to develop a library of AG derivatives, with most of them displaying an enhanced 
antibacterial activity, which correlated with higher affinity to bacterial A-site.52 
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We will discuss herein the antibacterial modes of action of AGs as well as some of the 
novel applications of AGs that have been investigated in the last decade, including as 
antifungal agents, as amphiphiles, and as potential treatment of genetic diseases arising 
from premature termination codons (PTCs). New ways to alleviate AG-induced ototoxicity 
will also be examined, with reference to the solely non-toxic AG APR and the prospective 
clinical candidate plazomicin (PLZ). 
 
1.2. AMINOGLYCOSIDES MODE OF ACTION: BINDING TO THE RIBOSOME 
AGs have long been known to exert their antibacterial functions by binding to the bacterial 
ribosome and interfering with protein translation. To further probe their mechanism of 
action, different approaches have been developed and employed in the past decades, 
including fluorescence-based assays,3, 53-56 computational simulations,57-58 microarray 
assays,59-63 and X-ray crystallography.4, 64-65 As a result, AGs have been demonstrated to 
bind not only to the ribosomal decoding A-site on the 16S rRNA, causing miscoding in the 
nascent polypeptide, but also to the helix 69 (h69) in the large 50S ribosomal subunit, 
which is critical in the processes of mRNA/tRNA translocation and ribosome recycling. 
 
1.2.1. Aminoglycosides binding to the A-site 
As a canonical model of AG binding, the interactions between AGs and the decoding A-
site on the 30S ribosomal subunit have been extensively studied. AGs bind to a highly 
conserved set of nucleotides on helix 44 (h44) of the 16S rRNA (Figure 1.5A). The 
carbohydrate rings of AGs stack to the RNA, thereby stabilizing the bound complex at the 
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A-site by hydrogen-bonding and H2O-mediated interactions.57, 65-67 For 4,6-disubstituted 
2-DOS AGs, the presence of a 4'-OH or a 2'-NH2 group on ring I was reported to be critical 
in assisting proper targeting of the ribosome by the antibiotics. However, the substitution 
pattern on ring III was found to have minimal effect on drug targeting.67 In the case of 4,5-
disubstituted 2-DOS AGs, the stacking effect of ring I was complemented by rings III and 
IV, which enhanced AG-rRNA complex stabilization.66 Appending of an aromatic moiety 
at the 2"-position of PAR was found to improve the drug susceptibility of bacterial resistant 
strains, thereby providing further details for the mechanisms of AG binding.57 
 
Figure 1.5. A. Representation of the internal loop structure of h44. B. Representation of h44 of the 16S 
rRNA showing residues destacking upon AG binding. 
 
Binding of AGs to the 16S rRNA was reported to extrude the A1492 and A1493 residues 
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the rRNA. Such change disturbed the fidelity of aminoacyl-tRNA selection.68 rRNA 
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complex, was fluorescently-tagged to investigate NEO and h44 interactions.56 Other 
residues, such as the purine/pyrimidine switches 1411•1489 and 1410•1490, were reported 
to have minimal effect on MIC values while 1409•1491 was found to be critical for AG 
susceptibility.69 
 
In addition to the bacterial ribosomes, AGs have also been known to bind with lower 
affinity to the mammalian ribosomes, causing undesired side effects. In the aim of 
achieving higher selectivity of AGs towards their bacterial target, both AG and ribosome 
modifications have been investigated. 4',6'-O-acetal and 4'-O-ether modifications of PAR 
have been shown to impart greater sensitivity to A1408G, G1491C, and G1491A mutations, 
characteristic of prokaryotic-eukaryotic ribosome differences.70 Applying nucleobase-
conjugated AGs as probes, the A-site was reported to discriminate its ligand structures and 
conformations.71 Conversely, in a study where KANA, TOB, NEA, and NEO derivatives 
were examined in a microarray-based assay against a library of internal loops in a two-
dimensional combinatorial screening analysis, AGs were found to be non-selective and 
each preferentially bound to a different internal loop. For instance, KANA preferably 
bound to 1x1 internal loops with C•A mismatches, and the stability of the internal loop 
structure correlated with the binding affinity to AGs.60-63 Anderson and Mecozzi further 
investigated the minimum sequence required for PAR binding to the A-site via a 
computational approach.58 A combination of molecular dynamics, free-energy calculations, 
and in vitro binding assays showed that the 11-nucleotide:10-nucleotide duplex RNA was 
minimal to provide stable PAR binding, whereas smaller dupleces lost the complex 
stability and the accessibility for PAR.58 
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1.2.2. Aminoglycosides binding to h69 
Although most AGs bind to the decoding A-site and introduce amino acids from near-
cognate aminoacyl-tRNAs into the nascent polypeptides, this effect alone was postulated 
to be insufficient justification of AGs’ antibacterial effect. Instead, some AGs, including 
NEO, PAR, and TOB, have been identified to have a secondary binding site at the major 
groove of h69 of the 23S rRNA of the 50S ribosomal subunit.64, 72 Crystallography data 
revealed that h69 forms direct contact with the A-/P-site tRNAs, as well as the decoding 
center, by looping around the interface of the two subunits and forming an inter-subunit 
bridge (B2). Due to the vital position of h69 in the 3D structure, the binding of AGs to h69 
hinders the ribosomal movement/global conformational rearrangement when the 30S 
rotates around the 50S ribosomal subunit in racquet-like movement around the L1 stalk 
domain.73 This concerted movement, assisted by ribosome recycling factor (RRF) and 
GTPase elongation factor G (EF-G), occurs in multiple steps during protein translation, 
especially translocation and ribosome recycling processes. Therefore, AGs’ mechanism of 
inhibiting the global conformational rearrangement is a vital contribution to their 
antibacterial properties.4 
 
During translocation, the aminoacyl-tRNA first orients itself perpendicularly to the 30S 
and 50S subunits at the A-site, which is considered the classical configuration. Post peptide 
bond formation and prior to translocation, intermediate states where the 3'-terminus and 
the acceptor stems of tRNAs proceed to the next site on the large subunit while the 
anticodon stems remain fixed on the 30S subunit are referred to as the “hybrid” states.74-75 
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Two distinct hybrid-state intermediates have been elucidated by the Blanchard’s group via 
single-molecule fluorescence resonance energy transfer (smFRET).76 Studies have shown 
that AGs binding to h69 halted the pre-translocation complex at post peptidyl transfer. The 
dynamics of AG binding to pre-translocation complex revealed high-affinity (h44) and 
low-affinity (h69) binding sites on the ribosome. While most AGs bind to h44 only and 
stabilize the classical state, NEO was shown to stabilize the hybrid states at the low-affinity 
site upon saturation of h44.3 To further study NEO inhibition on the ribosomal global 
conformational rearrangement, pre-steady state smFRET and dynamics studies 
demonstrated that NEO binding to h69 excluded RRF binding to the ribosome and 
attenuated the 30S subunit rotation with respect to the large subunit that normally promotes 
the conformational switch from the classical to the hybrid configuration. Crystal structures 
also confirmed NEO binding to h69, where the latter forms an inter-subunit bridge B2 and 
interacts with helices h24 and h45 of the 30S subunit.64 
 
At the end of each translation cycle is the dissociation of the ribosome complex, where the 
same racquet-like movement is involved as in translocation. RRF binds to h69 and extrudes 
it away from the inter-subunit surface, causing the 30S subunit to dissociate from the 50S. 
However, AG binding to h69 makes the complex inaccessible to the RRF, and therefore, 
locked in the bound form, inhibiting ribosome recycling.4 Confirming previous results, 
Agris and co-workers further compared the affinity of NEO and GEN to Escherichia coli 
and human h69. They reported that AGs bind to human h69 with lower affinity than to E. 
coli h69, which shed light into AG antibiotics target selectivity.72 
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AGs are structurally diverse, and therefore, bound to function by different mechanisms. 
Puglisi and co-workers reported the various mechanisms of APR, GEN, and PAR, which 
were confirmed by nuclear magnetic resonance (NMR) spectroscopy.53 APR was found 
not to displace A1492 and A1493 residues at the decoding center but rather to block the 
translocation process. GEN and PAR, on the other hand, exhibited a different mode of 
action whereby they destacked h44, leading to significant miscoding in the nascent 
polypeptide. 
 
Tracing back the efforts that have been put forth in the investigation of how AGs perform 
their antibiotic functions, a greater picture has been revealed. However, the unobserved 
part of the iceberg still remains elusive yet inviting. Along this line, more untouched 
functions of AGs are starting to be discovered. In addition to causing amino acid 
misincorporation and inhibiting translocation and ribosome recycling, Foster and 
Champney reported that AGs hinder the 30S ribosome assembly, which brings up an 
unexplored mechanism of AG antibiotics.77 Any further knowledge we gain on the 
mechanism of action of AGs is certainly a step towards defeating bacterial infections, 
especially in the rapidly emergence resistant bacterial strains. 
 
1.3. AMPHIPHILIC AMINOGLYCOSIDES 
Owing to the recrudescence of antibiotic resistance by pathogenic bacteria and the promise 
of cationic amphiphiles as potent antimicrobial agents with new mechanisms of action, a 
novel class of antibacterial agents known as amphiphilic AGs came into being. Several 
groups have devoted tremendous efforts in the development of AG derivatives that bear in 
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their structure hydrophobic moieties connected to the cationic hydrophilic AG. Linear alkyl 
chains, ranging from C6 to C20, have been introduced through an amide bond at the 5"-
position of NEO,78-81 and the 6"-position of KAN82 and TOB.83 They have also been linked 
to TOB and PAR as thioethers at the 6"- and 5"-positions, respectively.84-86 Other 
hydrophobic residues investigated include (i) amino acids/peptides, which have been 
attached to the nitrogen atom of AGs through an amide bond,79 a lysine moiety,87 or a 
triazole ring;88-89 and (ii) aromatic rings, attached at the oxygen atom, to form polyethers 
and/or polycarbamates of NEA, PAR, NEO, KAN, and AMK.90-93 This led to the discovery 
of potent amphiphilic AGs with revived antibacterial activity. For example, the C16 and C18 
lipid chains conferred to NEO a 32-fold improvement in antibacterial activity against 
MRSA, while the C16 lipid chain decreased the MIC of KAN from 128 to 2 µg/mL against 
Canadian clinical isolates of MRSE, and the C14 lipid chain rendered TOB 64 times more 
active against E. coli BL21 (DE3) (Eis) and Streptococcus mutans UA159. Aromatic rings 
also considerably ameliorated the MIC values of NEO, KAN, NEA, and PAR. 
 
Amphiphiles, such as cationic peptides, have been shown to exert their antimicrobial 
activities by disrupting the bacterial membranes via three main models: the toroidal, barrel-
stave, and carpet models.94 With the aim of investigating the mode of action of antibacterial 
amphiphilic AGs, the Garneau-Tsodikova and Fridman groups showed that amphiphilic 
AGs in the form of 6"-thioether TOB analogues target the bacterial membrane rather than 
the traditional bacterial ribosome.84 Similar results were also observed by the Chang95 and 
the Mingeot-Leclercq96 groups, who synthesized 5"-derivatized NEO as well as 3'- and 6-
modified NEA, respectively. 
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1.4. AMINOGYCOSIDES AS ANTIFUNGAL AGENTS 
AGs have long been used for the treatment of bacterial infections in humans and animals, 
but their ability to bind to the eukaryotic ribosomes, though with lower affinity when 
compared to the prokaryotic ribosomes, has been a continuous step back. This limitation 
has, however, been exploited to explore new targets of AGs. Recently, Lee and co-workers 
have investigated the activities of PAR, NEO, RIB, and STR against six crop pathogenic 
oomycetes (Phytophthora and Pythium species) and ten common fungi.97 All four AGs 
manifested modest to excellent antioomycete activity, with non-existent activity against 
several true fungal species. PAR displayed the strongest in vitro and in vivo inhibitory 
effect on various plant pathogens, including P. capsici and P. infestans, which are 
responsible for red pepper and tomato late blight diseases, respectively. Even though fungi 
are most often associated with crop diseases, they still remain an important problem in 
human and veterinary medicine that needs to be addressed.  
 
Pythiosis is an infectious disease caused by the fungus P. insidiosum that affects dogs, cats, 
horses, and even humans. The in vitro susceptibility of 24 P. insidiosum isolates was 
measured against four naturally occurring AGs (PAR, GEN, NEO, and STR).98 With in 
vitro MIC values ranging from 32 to 128 µg/mL, which are all higher than the safe plasma 
concentration of 30 µg/mL, these AGs could not be used therapeutically. It has, however, 
been observed that when used in conjunction with compounds that increase their cellular 
uptake in fungi, AGs could exert their fungicidal activity at lower, and possibly safer, 
concentrations. This is the case of HYG, a structurally unusual AG produced by S. 
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hygroscopicus that kills bacteria and fungi through protein biosynthesis inhibition. The 
membrane-disrupting agent polymyxin B was found to work synergistically with HYG, 
enabling this latter to inhibit the growth of Saccharomyces cerevisiae cells at a lower 
concentration than that expected from its own MIC value.99 
 
Fungal and oomycete infections are responsible for huge economic loss generated from 
plant diseases. Current strategies to control these infections include the direct application 
of chemical fungicides. Although potentially useful as agrofungicides, the majority of AG 
antibiotics are clinically used for the treatment of human bacterial pathogens. Their 
involvement in plant disease management could then promote bacterial resistance, reduce 
the soil concentration of the agrofungicide AG, or change its structure. To overcome this 
problem, AG derivatives possessing antifungal activities with no antibacterial capabilities 
were pursued.  
 
KANB is a classical AG antibiotic isolated from the soil bacterium S. kanamyceticus and 
has long been used for its broad-spectrum activity against Gram-negative and Gram-
positive bacteria. One of its analogue, FG08 (Figure 1.6), which bears a 3"-OH group, a 
linear C8 alkyl chain at the 4"-position, and is deoxygenated at the 6"-position, showed 
little to no antibacterial activity, but inhibited the growth of various yeasts, oomycetes, and 
true fungi, with in vitro MIC values between 3.9 and 31.3 µg/mL.100 The antibacterial to 
antifungal activity “switch” in FG08 was attributed to the octyl chain, which conferred 
some amphiphilic properties to the AG. The susceptibility studies of Fusarium 
graminearum, a fungus responsible for the crop disease Fusarium Head Blight (FHB), to 
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FG08 revealed that at concentration close to in vitro MIC, FG08 afforded prophylactic 
protection to FHB-susceptible wheat seedlings against F. graminearum. FG08 was also 
capable of suppressing FHB disease. FG08 was shown to exert its antifungal activity 
through permeation of the fungal membrane.100-101 This property of certain AGs to disrupt 
the membrane of fungi has also been observed with bacteria. 
 
 
Figure 1.6. Modifications at the 3"-, 4"-, and 6"-positions of the antibacterial KANB result in the 
antifungal agent FG08. 
 
1.5. READING THROUGH THE FAULTY “STOPS” AT THE PREMATURE 
TERMINATION CODONS 
Pathogenic PTCs result from various mutations, including nonsense mutations, insertions 
or deletions, and/or alternative splicing events. In these diseases, PTCs are introduced prior 
to the natural stop codons, thereby leading to the production of truncated and, often times, 
defective proteins. AG interaction with eukaryotic ribosomes also sparked their new 
application as PTC suppressing compounds. AG binding to the mammalian 18S rRNA A-
site, which is homologous to the 16S rRNA in bacterial ribosome complex, has been 
proposed to promote near-cognate aminoacyl-tRNA misincorporation at PTC site and 
allow random read-through for full-length protein production in in-frame PTC diseases 
(Figure 1.7).102-103 Various AGs, including parent drugs and their derivatives, have been 
exploited for their read-through promoting activities in PTC diseases such as cystic fibrosis 
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(CF), Duchenne muscular dystrophy (DMD), Rett syndrome (RTT), and other PTC 
disorders (Figure 1.8). 
 
1.5.1. Cystic fibrosis (CF) 
CF arises from mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene, which encodes a transmembrane cAMP-gated chloride channel in the 
epithelium. Studies have shown that several parent AGs, such as AMK and GEN, promote 
read-through of the PTC and increase the level of functional CFTR in mouse models and 
patient samples.104-106 Furthermore, co-administration of AGs with poly-L-aspartic acid 
showed enhancement of the PTC suppression of GEN by 20-40%.107 A combination of the 
two drugs increased the level and duration of PTC suppression as well as reduced the 
toxicity of GEN. In addition to parent AGs, their derivatives have also been exploited for 
higher efficacy and lower toxicity. Several AG derivatives, such as NB30, NB54, NB74, 
NB84, and NB124 (Figure 1.8) have been reported to suppress PTC at higher potency and 
lower toxicity compared to parent AGs.108-110 
 
1.5.2. Duchenne muscular dystrophy (DMD) 
DMD presents lethal X-linked pathology that lacks the protein dystrophin in the muscle 
fibers, leading to progressive muscle degeneration. Nonsense mutations in the genetic 
sequence of dystrophin account for about 15% of all DMD cases.111 Glucocorticoids were 
the only beneficial treatment but possessed significant side effects, calling for more efforts 
to develop AGs as treatments for DMD.112 
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As a result of the enormous size of dystrophin, an extensive number of PTCs has been 
identified. GEN-treated mdx mouse showed rescued vascular parameters monitored by 
nitric oxide-dependent vascular functions.113 A study in patient samples also confirmed 
GEN as an effective PTC suppressing compound.114 
 
 
Figure 1.7. Proposed mechanism of AG-induced PTC read-through. A. Eukaryotic ribosome complex 
during normal protein translation elongation. B. Elongation arrest at the PTC site due to nonsense 
mutations results in translation abortion and truncated protein product. C. Binding of AG to PTC site 
allows random incorporation of an amino acid from a near-cognate aminoacyl tRNA and read-through at 
the PTC site. 
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Figure 1.8. Structures of synthetic AG derivatives used for PTC-associated diseases. Note: Some of the 
NB series molecules have been shown to display reduced ototoxicity compared to G418. 
 
As AGs exhibit various efficacies under distinct conditions, patients with different genetic 
variations at PTC can be subjected to different treatments. For example, PTCs with TGA 
mutations generally show better therapeutic response to GEN than patients with nonsense 
mutations TAA or TAG.115 
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1.5.3. Rett syndrome (RTT) 
In contrast to DMD that only affects males, RTT is an X-linked PTC disorder solely 
impacts females. The PTCs for RTT are usually found in the MeCP2 gene, which encodes 
methyl CpG-binding protein 2 (MeCP2) involved in epigenetic control of gene expressions. 
Common mutations in RTT were investigated in transiently transfected HEK-293 cells. 
The read-through activity was recovered by multiple AGs, including GEN and G418, and 
weakly by AMK, while PAR was reported to have no read-through promoting activity for 
these mutations in RTT.116-117 However, it was also reported that these AGs, though 
showing PTC suppressing properties in vitro, had no read-through activity effect at 
therapeutic dose.116 As the most prevalent mutation, R168X was also tested against PAR 
derivatives NB30, NB54, and NB84.  Even though NB30 was not as promising, NB54 and 
NB84 both showed better efficiency than GEN as PTC suppressing drugs.118-119 
 
1.5.4. Spinal muscular atrophy (SMA) 
SMA is a neurodegenerative disorder that results from the absence of survival motor 
neuron-1 (SMN1) and symptomized by progressive atrophy of the limb and trunk muscles. 
SMN genes are present in two nearly identical copies (SMN1 and SMN2) that differ by a C 
(SMN1) to T (SMN2) transition, leading to an alternative splicing pattern of SMN1 of the 
mRNA. The PTC in SMN1 results in a truncated non-functional protein that cannot be 
functionally compensated by SMN2.120 As AGs are used to suppress PTCs, studies have 
also utilized AGs to treat SMA to restore functional protein production.121 The Lorson’s 
group tested 20 synthetic AGs that belong to either the 4,5- or 4,6-disubstituted 2-DOS 
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families. Six of them, TC001, TC003, TC007, TC032, JL022, and JL023 (Figure 1.8) were 
shown to increase the number of “gems”, which is indicative of the alleviation of SMA 
disease progression, and functional protein level.121 One of the six compounds, TC007, 
was further characterized in an animal model and proved to partially restore phenotype.122-
123 
1.5.5. Other PTC diseases 
Type I Usher disease,124-125 congenital muscular dystrophy (CMD),126 ataxia-telangiectasia 
(A-T),127 coagulation factor VII deficiency,128 mucopolysaccharidosis type I-Hurler 
disease,129 various types of cancer,130-131 and other types of genetic disorders132-133 have 
been investigated for the full-length protein production response after treating with AGs or 
their derivatives. Overall, GEN and G418 are the two most commonly tested AGs that 
improve PTC read-through. The response to AG treatment is dose- and context-
dependent.115 
 
Long-term AG treatment, which produces significant toxicity and bacterial resistance, has 
promoted the development of AG derivatives that possess higher potency and less toxicity. 
For instance, NB74 was reported to have a half-maximal lethal concentration (LC50) of 
25.8 mM in HEK-293 cells, which is about 10 times higher than the LC50 for GEN at 2.5 
mM and 20 times higher than that for G418 at 1.3 mM.110 NB74 was also shown to decrease 
cochleotoxicity (LC50 = 140.0 µM) compared to G418 (LC50 = 0.7 µM) (Figure 1.8).134 
There have been discoveries made on other read-through promoting compounds in order 
to achieve lower toxicity than parent AGs, for instance the organic compound PTC124. 
However, the lower potency and large variations in the cellular response within each 
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treatment has limited the use of PTC124 as a general treatment for multiple PTC 
diseases.135-136 Therefore, the research on AGs supressing PTC, especially by their 
derivatization for improved potency and reduced toxicity, remains promising and inviting. 
 
1.6. NEW WAYS TO ALLEVIATE AMINOGLYCOSIDE TOXICITY 
Toxicity has always been and still remains a serious impediment to the long-term clinical 
use of AGs. Indeed, a few years after the discovery of STR and its introduction in the 
therapeutic regimen of tuberculosis, patients’ kidneys and inner ear impairment were 
observed, resulting in AG-induced nephrotoxicity and ototoxicity, respectively.137 
 
Nephrotoxicity arises from the small accumulation of AG drugs in the kidney cortex as a 
result of their uptake in the epithelial cells of the renal proximal tubules, following their 
glomerular filtration and excretion from the bloodstream by the urinary system.138 
Nephrotoxicity is a reversible process due in part to the regeneration capability of tubular 
cells139 and the ability of dialysis to diminish AG accumulation in the kidneys. Ototoxicity, 
on the other hand, leads to permanent and irreversible hearing loss. AGs’ damage to the 
inner ear has been shown to be directed to the vestibular organ140 and the outer hair cells 
located in the cochlea.141-142 It was reported that ≤15% of AG-treated patients developed 
vestibulotoxicity, while 2 to 25 % experienced cochleotoxicity.143-144 Another estimate of 
ototoxicity incidence in patients administered AGs was shown to lie between 3 to 33%.142 
 
Approaches to reduce or protect against AG-induced nephrotoxicity have previously been 
reviewed.145 Since it is less aggressive than its ototoxicity counterpart, we will briefly focus 
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on understanding the mechanisms of AG-induced ototoxicity for a better appreciation of 
current ways utilized to alleviate it. A more detailed presentation of the mechanisms of AG 
ototoxicity has recently been reported.137 
 
1.6.1. Mechanisms of ototoxicity 
Following their uptake by inner ear sensory hair cells,146-150 parenterally and topically 
administered AGs appear to induce ototoxicity either through the formation of reactive 
oxygen species,151 activation of cochlear N-methyl-D-aspartate (NMDA) receptors,152 or 
increase of nitric oxide synthase activity.153-154 Individuals carrying the maternally 
inherited mutations A1555G or C1494T, which are both localized on the A-site of the 
human mitochondrial 12S rRNA, have also been shown to be more vulnerable to AG 
ototoxicity.155-158 With the mitochondrion appearing to be a common denominator in all 
these mechanisms, mitochondrial protein synthesis may then be an essential target in AG 
ototoxicity.  
 
Böttger and co-workers engineered hybrid bacterial ribosomes, whose decoding site 
mimiced that of the human mitochondrial 12S rRNA, and also contained either the A1555G 
or C1494T congenital deafness mutations.159-160 The protein translation fidelity in these 
hybrid mitochondrial ribosomes (mitoribosomes) appeared to be disturbed in the presence 
of AGs. This misreading process could then lead to hair cell death, i.e. AG ototoxicity. 
Francis and co-workers, however, recently showed that inhibition of the cytosolic, rather 
than mitochondrial, protein synthesis better compares to AG-induced hearing loss.161 In 
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vivo studies reported by Baasov and co-workers tipped the scale towards mitochondrial 
protein synthesis inhibition as the major contributor to AG ototoxicity.134 
 
Several antioxidants, including salicylate,162 aspirin,163 N-acetylcysteine,164-165 
mitoquinone,166 dexamethasone,167 melatonin,167 tacrolimus,167 SkQR1,168 have been 
shown to bear otoprotective properties when used in conjunction with AGs. The use of 
NMDA receptor antagonists has also been shown to alleviate AG-induced ototoxicity.169 
 
Novel AG derivatives with reduced toxicity have also been designed based on the 
correlation that has been shown between the AGs’ structural scaffold and their toxicity. It 
was reported that reducing the number of amino groups on AGs may lead to reduced 
toxicity.170 Furthermore, a decrease in basicity of the amino groups, as a result of 
neighbouring group effect, was shown to also influence AG toxicity.171 
 
1.6.2. Apramycin 
Apramycin (APR, Figure 1.1) is an AG produced by the microorganism S. tenebrarius172 
with unique structural features that allow it to escape bacterial resistance other legacy AGs 
are usually subjected to. It is a potent antibiotic with growth inhibitory action against Gram-
positive and Gram-negative bacteria.173 It has found applications in veterinary medicine, 
but its use in humans is currently prohibited. Recent findings have shown that APR does 
not display the characteristic ototoxicity generally observed with AGs.174 As a matter of 
fact, in a mice organ of Colti explant model, APR was found not to trigger the loss of hair 
cells in the base of cochlear at a concentration of 0.2 mM, a dose at which GEN completely 
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destroyed those hair cells. Minimal hair cells loss was only noticeable at 2 mM APR. Even 
in in vivo ototoxicity studies performed in guinea pig by measuring the auditory brain 
response at 12 kHz and the loss of hair cells, APR was less toxic than GEN. Since the 
ototoxicity of AGs has been correlated to their limited selectivity in preferentially binding 
bacterial ribosomes over mammalian ones,159-160 it was interesting to find that APR does 
not significantly upset the mitochondrial ribosome as the other AG antibiotics do. Indeed, 
while APR exhibited comparable protein synthesis inhibitory activities in bacterial and 
hybrid human cytosolic ribosomes with GEN, TOB, KAN, and NEO, it perturbed the 
protein synthesis in hybrid human mitochondrial (wild-type and A1555G mutant) 
ribosomes to a much lesser extent. These results were further confirmed in eukaryotic 
rabbit reticulocyte ribosomes and in vitro mitochondrial in organelle translation assay. 
Analysis of the crystal structure of the APR-Thermus thermophiles 30S subunit h44 
complex, together with the aprosamine-induced misreading of mitohybrid ribosomes, 
revealed that ring III of APR may prevent A1492 residue to puck out and may thus be 
essential in poorly inducing misreading in mitochondria. In the future, it will be fascinating 
to develop APR derivatives that retain these key structural features that will allow them to 
overcome ototoxicity and see if they will be able to find applications in the treatment of 
human bacterial infections. 
 
1.6.3. New AG: Plazomicin 
Plazomicin (PLZ), originally known as ACHN-490, is a semi-synthetic “neoglycoside” 
developed by Achaogen (San Francisco, CA, U.S.A.) that has shown great promise in 
alleviating nephrotoxicity and ototoxicity. Derived from SIS, PLZ has been shown to 
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exhibit enhanced in vitro potency against AG-susceptible and AG-resistant pathogens.175 
It was active against most Enterobacteriaceae species at a concentration below 4 µg/mL.175 
Indeed, it displayed an MIC50/90 value of 0.5/1 µg/mL against 3050 E. coli clinical isolates 
from New York176 and 1/1 µg/mL against 26 Enterobacter spp. gathered from Athens, 
Greece.177 Interestingly, it even exhibited an MIC90 value of 1 µg/mL against a large 
collection of unique-patient Klebsiella pneumoniae isolates, including those producing 
carbapenemases (KPC) (blaKPC-containing isolates), which was at least 32-fold lower than 
the clinically used AGs AMK, GEN, and TOB.176, 178 However, PLZ was found to be 
inactive against any Enterobacteriaceae isolates carrying the ribosomal methyltransferase-
encoding genes ArmA and/or RmtC.175, 179 It was also inactive against Providencia stuartii 
(MIC >64 µg/mL), as a result of the inactivation by the AAC(2')-I enzyme. In general, PLZ 
has been shown to overcome the action of most AG resistance enzymes.175 
 
When evaluated against nocosomial pathogens Acinetobacter baumannii and 
Pseudomonas aeruginosa, PLZ was moderately active with MIC50/90 of 8/16 µg/mL and 
8/32 µg/mL, respectively180 and quite active against AG-resistant staphylococci (MIC50/90 
= 1/1 µg/mL).175 
 
In light of these promising in vitro results, the in vivo efficacy of PLZ was tested in 
animals.181 In a septicemia model, PLZ was able to increase the survival rate of mice 
infected with E. coli ATCC25922 (ED50 = 0.6 mg/kg) and P. aeruginosa ATCC27853 
(ED50 = 8.3 mg/kg) over 7 days as a function of the dose administered. A murine 
neutropenic thigh model also confirmed that PLZ was capable of treating bacterial 
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infections caused by E. coli (susceptible and MDR), K. pneumoniae (susceptible, MDR, 
and strains expressing KPC), P. aeruginosa (susceptible), Serratia marcescens (with KPC 
phenotype), and S. aureus (MDR). 
 
1.7. PERSPECTIVE AND CONCLUSIONS 
AGs are broad-spectrum antibiotics that have long suffered from bacterial resistance and 
toxicity. While enormous efforts have been directed towards developing new strategies to 
minimize these accompanied side effects, novel applications of AGs as antifungal and 
genetic regulating compounds are also being investigated. 
 
The incessant need to better understand AGs’ mechanisms of action on the bacterial 
ribosomes has led researchers to the discovery of the h69 binding site, which could be 
another potential target of AGs and could be useful to develop novel AG drugs. The 
discovery of AME inhibitors and their use in combination with AGs also remain an 
interesting avenue to explore for counteracting bacterial resistance.  
 
In addition to their traditional role as antibacterial agents, AGs have also emerged as 
potential antifungal agents and we believe that in the future, it will be important to pay 
attention to the derivatization of AGs as cationic amphiphiles for the development of novel 
fungicides. The capacity of certain AGs to bind to eukaryotic ribosomes has also been 
exploited for the treatment of parasitic diseases and PTC disorders. Although more 
attention had been directed towards CF and DMD, it will be worthy investigating how 
parent AGs and their derivatives could help in treating other PTC disorders. However, it 
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should not be forgotten that ototoxicity is an intrinsic side effect of AGs. Priority should 
then be given to those parent compounds, such as APR, that have demonstrated limited 
toxicity to mammalian cells.  
 
There are currently only six AGs (AMK, GEN, NEO, PAR, STR, and TOB) that are 
approved by the US Food and Drug Administration for clinical use. However, with the 
renaissance experienced by AGs in the past decades, notably with the discovery of PLZ 
and its satisfactory results in clinical trials, there is great hope that new clinically useful 
AGs can still be discovered. Together with the promising use of AGs described herein, it 
thus becomes apparent that AGs remain a valuable potential source of drugs. 
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Chapter 2. Expanding aminoglycoside resistance enzyme regiospecificity by 
mutation and truncation 
Aminoglycosides (AGs) are broad-spectrum antibiotics famous for their antibacterial 
activity against Gram-positive and Gram-negative bacteria, as well as Mycobacteria. In the 
U.S.A., the most prescribed AGs, including amikacin (AMK), gentamicin (GEN), and 
tobramycin (TOB), are vital components of the treatment for resistant bacterial infections. 
Arbekacin (ABK), a semi-synthetic AG, is widely used for the treatment of resistant 
Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in Asia. 
However, the rapid development of bacterial resistance is limiting the clinical application 
of AG antibiotics. Of all bacterial resistance mechanisms against AGs, the acquisition of 
AG-modifying enzymes (AMEs) by the bacteria is the most common. It was previously 
reported that a variant of a bifunctional AME, the AG 6'-N-acetyltransferase-Ie/AG-2"-O-
phosphotransferase-Ia (AAC(6')-Ie/APH(2")-Ia), containing a D80G point mutation and a 
truncation after amino acid 240 modified ABK and AMK at a new position, the 4'''-amine, 
therefore, displaying a new change in regiospecificity. In this study, we aim to verify the 
altered regiospecificity of this bifunctional enzyme by mutation and truncation for the 
potential of derivatizing AGs with chemoenzymatic reactions. With the three variant 
enzymes in this study that contains either mutation only (D80G), truncation only (1-240), 
or mutation and truncation (D80G-1-240), we characterize their activity by profiling their 
substrate promiscuity, determine their kinetic parameters, and perform mass spectrometry 
in order to see how and where ABK and AMK were acetylated by these enzymes. We find 
that the three mutant enzymes possessed distinct acetylation regiospecificity compared to 
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the bifunctional AAC(6')-Ie/APH(2")-Ia enzyme and the functional AAC(6')-Ie domain 
(AAC(6')/APH(2")-1-194). 
 
2.1. INTRODUCTION 
The broad-spectrum aminoglycoside (AG) antibiotics are active against Gram-positive and 
Gram-negative bacteria, as well as Mycobacteria.1-4 Their broad-spectrum feature has 
given AGs a vital position in clinical settings for the treatment of severe bacterial 
infections. Amikacin (AMK), gentamicin (GEN), and tobramycin (TOB) are currently 
approved in the U.S.A. for systemic administration (Figure 2.1). On the other hand, the 
systemic use of kanamycin (KAN) is limited to the treatment of multidrug-resistant (MDR) 
tuberculosis. Neomycin B (NEO) is most commonly added to antibiotic ointments for 
topical applications. In addition to being used as antibiotics, AGs are also currently heavily 
investigated as antifungal agents5-10 as well as potential treatments for genetic disorders 
caused by premature termination codons, including but not limited to, cystic fibrosis and 
Duchene muscular dystrophy.3, 11-15 
 
Arbekacin (ABK, Figure 2.1), although not currently prescribed in the U.S.A., has been 
widely used in Asia for decades due to its excellent efficacy against MDR strains of 
Pseudomonas aeruginosa, Acinetobacter baumannii, and methicillin-resistant 
Staphylococcus aureus (MRSA).16 ABK is a semi-synthetic AG that has regained 
popularity over the past few decades. By appending an (S)-4-amino-2-hydroxybutyryl 
(AHB) group onto its precursor dibekacin, ABK was shown to possess better antimicrobial 
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activity than AMK and GEN, and to be less prone to the development of bacterial resistance 
compared to other AHB-lacking AGs. 
 
 
Figure 2.1. Structures of the various AGs and CIP tested in this chapter. 
 
As with most antibiotics, the extensive use of AGs led to the accelerated development of 
bacterial resistance to these drugs. Bacteria can develop resistance to AGs by (i) changing 
their cell envelope composition, resulting in reduced drug permeability, (ii) upregulating 
their efflux pumps, resulting in a decreased intracellular drug concentration, (iii) modifying 
the ribosome, preventing binding of AGs to their target, and (iv) acquiring AG-modifying 
enzymes (AMEs), also preventing binding of the chemically modified drugs to the 
ribosome target.17-22 AMEs, which represent the most common resistance mechanisms to 
AGs, can be classified into three families based on the distinct chemistry they catalyze: AG 
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N-acetyltransferases (AACs), AG O-phosphotransferases (APHs), and AG O-
nucleotidyltransferases (ANTs). AACs, the most common AMEs detected in bacteria that 
are resistant to AGs, catalyze the transfer of an acetyl group from acetyl-coenzyme A 
(AcCoA) onto the amine functionalities present on AG molecules. Studies have revealed 
that most AACs are regiospecific and modify only one amine moiety on AGs, as often 
designated in their names.23 One exception to this rule is Eis (enhanced intracellular 
survival), an AG multiacetylating protein upregulated in strains of M. tuberculosis 
displaying resistance to KAN.24-31 Research has shown that some acetylated AGs, after 
being “inactivated” by AACs, still retain antibacterial activity. Therefore, having 
additional resistance enzymes that further modify AGs at different positions can help 
bacteria to completely inactivate AGs, avoiding toxic effects from these AG metabolites. 
The ability of Eis to multiacetylate a variety of AGs at various positions poses special 
challenges when it comes to combating bacterial resistance. Eis protein homologues are 
also found in other mycobacterial strains29 as well as Anabaena variabilis,30 Bacillus 
anthracis,32 Gordonia bronchialis,33 Kocuria rhizophila,33 and Tsukamurella 
paurometabola.33 
 
Research efforts were inspired by the discovery of a new ABK metabolite in an ABK-
resistant MRSA strain in Japan, and subsequently led to the identification of a variant of 
the AAC(6')-Ie/APH(2")-Ia enzyme, from here on denoted as AAC(6')/APH(2") for 
simplicity.34-37 The reported variant enzyme contained a D80G point mutation in the 
AAC(6') domain of this bifunctional protein, which was reported to introduce a natural 
proteolytic cleavage after amino acid 240, resulting in a mutated and truncated protein. 
 34 
Compared to the wild-type (wt) protein that acetylates only at the 6'-position, the mutant 
truncated protein displayed a switch in regiospecificity to the 4'''-amine of ABK and AMK, 
which has not be observed in AACs before.35-36 The unique regiospecificity of the variant 
enzyme could provide special protection to the bacteria under exposure to AGs, as it would 
modify and inactivate AG antibiotics at a special position that is distinct from what the 
common resistance enzymes modify. 
 
Herein, we set off to verify the change in regiospecificity and examine whether both the 
D80G mutation and truncation are necessary for this change in regiospecificity. We first 
cloned, expressed, and purified various enzymes, including the AAC(6')/APH(2")-wt 
(previously cloned),38 the AAC(6')/APH(2")-D80G (with mutation only), the 
AAC(6')/APH(2")-1-240 (with truncation only), and the AAC(6')/APH(2")-D80G-1-240 
(with mutation and truncation) (Figures 2.2A and 2.3 and Tables 2.1-2.3). We then 
determined the substrate profiles of these enzymes with a panel of 14 AGs (ABK, AMK, 
apramycin (APR), geneticin (G418), GEN, hygromycin (HYG), KAN, neamine (NEA), 
NEO, netilmicin (NET), paromomycin (PAR), ribostamycin (RIB), sisomicin (SIS), and 
TOB) and 1 fluoroquinolone (ciprofloxacin, CIP) (Figure 2.1 and Table 2.4). We also 
determined the kinetic parameters for the AAC(6')/APH(2")-wt and the three different 
mutant enzymes with 7 selected AGs (ABK, AMK, KAN, NEA, NEO, SIS, and TOB) 
(Figures 2.4-2.7 and Table 2.5). After seeing the difference in the enzymatic 
regiospecificity between the AAC(6')/APH(2")-wt and mutant enzymes by performing 
mass spectrometry (MS) (and tandem mass spectrometry (MS2)), we cloned an additional 
AAC(6')/APH(2")-1-194 protein, which was previously reported to be the functional 
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AAC(6')-Ie domain (Figure 2.2A and Tables 2.1-2.3).39 We compared the activity of 
AAC(6')/APH(2")-wt, AAC(6')/APH(2")-1-240, AAC(6')/APH(2")-D80G, 
AAC(6')/APH(2")-D80G-1-240, and AAC(6')/APH(2")-1-194 on purified reaction 
mixtures containing acetylated ABK and AMK in order to see how and where these AG 
molecules were being modified by the AAC(6')/APH(2")-wt and mutants (Table 2.6 and 
Figures 2.8-2.10). 
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Figure 2.2. A. Schematic diagram of all mutant enzyme constructs generated and used in this study, 
including schematic diagram of AAC(6')/APH(2")-wt in green, as well as the truncated AAC(6')/APH(2")-
1-240 in yellow, the mutated AAC(6')/APH(2")D80G in turquoise, the mutated/truncated 
AAC(6')/APH(2")-D80G-1-240 in orange, and the truncated AAC(6')/APH(2")-1-194 in purple. A red X 
denotes the D80G single point mutation. B and C. Crystal structures of the AAC(6') domain (PDB ID: 
4QC6)40 of the bifunctional enzyme AAC(6')/APH(2") in surface (B) and cartoon (C) representations with 
the amino acids 1-79 in off white, D80 residue in red, and amino acids 81-179 in pale turquoise. The 
substrate KAN (green) is represented in its stick form with nitrogen and oxygen atoms colored blue and 
red, respectively. The CoA derivative (black) is on the backside of the structure. 
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2.2. RESULTS AND DISCUSSION 
2.2.1. Molecular cloning and expression of AAC(6')/APH(2")-wt and its mutant 
enzymes 
As postulated in previous studies,34-37 the change in regiospecificity of an 
AAC(6')/APH(2") mutant enzyme from the 6'- to 4'''-position could result from a D80G 
mutation and a D80G-induced truncation at amino acid 240. According to the published 
AAC(6') domain structure (PDB ID: 4QC6),40 D80 is a residue that lies on the surface of 
this globular protein and belongs to the beginning of an a-helix (Figures 2.2B and C). 
Mutation of this aspartate into a glycine was predicted to introduce a strong a -helix break, 
which in turn was suggested to abruptly change the protein conformation during folding, 
thereby introducing a proteolytic cleavage after amino acid 240 in the APH(2") domain of 
the bifunctional enzyme.36 Previous research on domain dissecting of this bifunctional 
AME39 and crystallographic knowledge on each of the two domains40-41 has revealed that 
the functional AAC(6') and APH(2") domains span from amino acids 1-194, and from 175 
to 479, respectively. The overlapped linker region between the two domains (amino acids 
175-194) had been proven to be critical for the activities for both domains.39 Therefore, the 
resulting truncated protein would contain the linker domain and 46 residues from the 
APH(2") domain in addition to the AAC(6') domain. Even though we were not successful 
in determining crystal structures to demonstrate how the D80G mutation and/or 1-240 
truncation would impact the protein conformation, we postulate that if the D80G mutation 
were to shift the rest of protein conformation during folding, the rest of the protein after 
the D80 residue, as represented by the pale turquoise portion, would change and impact the 
shape and size of the substrate binding pocket, as the residues after D80 compose half of 
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the AG binding site and the entire CoA binding site. Although structures of the bifunctional 
enzyme and of the AAC(6') domain have been modeled/determined, attempts at 
crystallizing the AAC(6')/APH(2")-D80G-1-240 proved unsuccessful so far. It is therefore 
difficult to prove how the protein would fold as a result of the mutation and/or truncation, 
especially since the D80G mutation occurred so early in the protein sequence.  
 
In order to verify whether both mutation and truncation are required for the change in AAC 
regiospecificity, we cloned three mutant enzymes that contained mutation only 
(AAC(6')/APH(2")-D80G), truncation only (AAC(6')/APH(2")-1-240), and both mutation 
and truncation (AAC(6')/APH(2")-D80G-1-240) with NHis6 tag. Expression in BL21 
(DE3) cells and purification with NiII-NTA resin yielded soluble proteins with yields 
between 6.3-13.9 mg/L of LB broth culture (Figures 2.2A and 2.3 and Tables 2.1-2.3). 
 
 
Figure 2.3. Coomassie blue-stained 15% Tris-HCl SDS-PAGE gel showing purified NHis6-tagged 
AAC(6')/APH(2") (59.0 kDa, lane 1), AAC(6')/APH(2")-D80G (59.0 kDa, lane 2), AAC(6')/APH(2")-1-
240 (30.9 kDa, lane 3), and AAC(6')/APH(2")-D80G-1-240 (30.9 kDa, lane 4). 6 µg of protein was loaded 
into each lane. 
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Table 2.2. SOE PCR strategies to generate all new AAC(6')/APH(2") constructs used in this study. 
Construct PCR 
round 
5' 
primer 
3' 
primer 
DNA template PCR product PCR 
product 
code 
Expected 
size (bp) 
aac(6')/aph(2")-1-240 1 1 3 aac(6')/aph(2")-wt (CHis) aac(6')/aph(2")-1-240 (NHis)  750 
aac(6')/aph(2")-D80G 1 1 5 aac(6')/aph(2")-wt (CHis) N-terminal half of 
aac(6')/aph(2")-D80G 
a 252 
 1 4 2 aac(6')/aph(2")-wt (CHis) C-terminal half of 
aac(6')/aph(2")-D80G (NHis) 
b 1216 
 2 1 2 PCR products a and b aac(6')/aph(2")-D80G (NHis)  1470 
aac(6')/aph(2")-D80G-1-
240 (NHis) 
1 1 5 aac(6')/aph(2")-wt (CHis) N-terminal half of 
aac(6')/aph(2")-D80G 
a 252 
 1 4 3 aac(6')/aph(2")-wt (CHis) C-terminal half of 
aac(6')/aph(2")-D80G-1-240 
(NHis) 
d 496 
 2 1 3  PCR products a and d aac(6')/aph(2")-D80G-1-240 
(NHis) 
 750 
aac(6')/aph(2")-1-194 1 1 6  aac(6')/aph(2")-wt (CHis) aac(6')/aph(2")-1-194 (NHis)  603 
 
Table 2.3. Purification yields of AAC(6')/APH(2") and mutant and/or truncated 
proteins.a 
Protein Yield (mg/L) 
AAC(6')/APH(2") (NHis) 10.1 
AAC(6')/APH(2")-1-240 (NHis) 13.9 
AAC(6')/APH(2")-D80G (NHis) 6.3 
AAC(6')/APH(2")-D80G-1-240 (NHis) 6.9 
AAC(6')/APH(2")-1-194 (NHis) 7.2 
aProtein yields were calculated based on absorbance at 280 nm. 
 
2.2.2. Establishment of the substrate profiles of AAC(6')/APH(2")-wt and its three 
mutant enzymes by UV-Vis assays 
In order to examine whether the AAC(6')/APH(2")-wt and its three mutant enzymes have 
different or similar substrate profiles, we performed UV-Vis assays with 14 AGs (ABK, 
AMK, APR, G418, GEN, HYG, KAN, NEA, NEO, NET, PAR, RIB, SIS, and TOB) and 
1 fluoroquinolone (CIP). We found that the AAC(6')/APH(2")-wt and its mutant enzymes 
Table 2.1. Primers used for the PCR amplification of the aac(6')/aph(2") gene for various constructs.a,b 
Gene 5' primer # 5' primer 3' primer # 3' primer 
aac(6')/aph(2")-wt 1 GATAAACATATGAATATAG
TTGAAAATGAAATATG 
2 TATATTCTCGAGTCAATCTTTA
TAAGTCCTTTTATAAATTTC 
aac(6')/aph(2")-1-240 1 GATAAACATATGAATATAG
TTGAAAATGAAATATG 
3 ATTATACTCGAGTTATTCTTTT
GCATA 
aac(6')/aph(2")-D80G 4 TATAAAATGTATggcGAGTT
ATATACT 
5 AGTATATAACTCgccATACATTT
TATA 
aac(6')/aph(2")-1-194 1 GATAAACATATGAATATAG
TTGAAAATGAAATATG 
6 ATTATCCTCGAGTCACTCAATT
AAATATTTCAT 
aThe introduced restriction sites are underlined for each relevant primer with 5' and 3' primers introducing an NdeI and an XhoI 
restriction sites, respectively. bThe D80G mutation is in lower-case for each primer. 
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were all most active against AMK, KAN, NEA, and TOB, and mildly active against ABK, 
GEN, NEO, NET, RIB, and SIS. These enzymes were not active against APR, G418, HYG, 
PAR, and CIP (Table 2.4). These results contradict the previous reports on 
AAC(6')/APH(2")-D80G-1-240 stating that this specific mutant was devoid of AAC(6') 
activity,36 as we found that AGs possessing 6'-amines were substrates of our mutant 
enzymes, whereas the AGs that do not possess 6'-amines, but instead comprise hydroxyl 
groups at the 6'-position, were not substrates of these mutant enzymes, indicating the 
mutant enzymes were likely to possess 6'-acetyltransferase activity. Additionally, 
AAC(6')/APH(2")-wt enzyme was previous reported to be capable of O-acetylating AGs, 
such as PAR, that lack 6'-amine.42 However, we did not observe such activity in our study. 
Given that ABK and AMK were the only AGs that possessed AHB groups, it was not clear 
whether acetylation was happening at the 6'-, 4'''-, or another amine position. We therefore 
later relied on MS and MS2 to decipher the position(s) modified by all of our enzymes (see 
below). 
Table 2.4. Substrate promiscuity for AAC(6')/APH(2")-wt and mutant 
constructs, including AAC(6')/APH(2")-1-240, AAC(6')/APH(2")-D80G, 
and AAC(6')/APH(2")-D80G-1-240. 
AG wt 1-240 D80G D80G-1-240 
ABK ~ -- ~ -- 
AMK ✓ ✓ ✓ ✓ 
APR ´ ´ ´ ´ 
G418 ´ ´ ´ ´ 
GEN -- -- ~ ~ 
HYG ´ ´ ´ ´ 
KAN ✓ ✓ ✓ ✓ 
NEA ✓ ✓ ✓ ✓ 
NEO ~ ~ ~ ~ 
NET -- -- -- -- 
PAR ´ ´ ´ ´ 
RIB -- -- -- -- 
SIS ~ ~ ~ ~ 
TOB ✓ ✓ ✓ ✓ 
CIP ´ ´ ´ ´ 
Activity is based on absorbance observed at 412 nm. All enzymes used in this 
assay are NHis6-tagged constructs. ´ = not a substrate, -- = poor substrate, ~ 
= moderate substrate, ✓ = great substrate. 
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2.2.3. Determination of kinetic parameters for AAC(6')/APH(2")-wt and its three 
mutant enzymes 
Next, we determined the kinetic parameters for AAC(6')/APH(2")-wt and its three mutant 
enzymes in order to gain insights into potential differences in enzyme behavior. We 
selected seven AGs (ABK, AMK, KAN, NEA, NEO, SIS, and TOB) that were assessed to 
be good substrates of the AAC(6')/APH(2")-wt and of its mutants in our substrate profiling 
experiments, and determined the Km, kcat, and kcat/Km values (in µM, min-1, and µM-1min-1, 
respectively) by fitting to a non-linear regression Michaelis-Menten equation (Figures 2.4-
2.7 and Table 2.5). In general, we found that for AAC(6')/APH(2")-wt enzyme, the 
substrates that showed the lowest and highest Km values were KAN (2.98 ± 0.67 µM) and 
NEO (102 ± 20 µM), respectively. While KAN consistently displayed the lowest Km values 
to all four enzymes, the substrates that displayed highest Km values were NEO (102 ± 20 
µM) for AAC(6')/APH(2")-wt, ABK (146 ± 17 µM) for AAC(6')/APH(2")-1-240; NEO 
(307 ± 51 µM) for AAC(6')/APH(2")-D80G, and ABK (331 ± 108 µM) for 
AAC(6')/APH(2")-D80G-1-240. As implied by the definition of Km values, the full-length 
enzymes shared similar preference in terms of binding efficiencies, so did the two truncated 
enzymes. As for the enzyme turnover rate (kcat), the values generally did not change 
drastically from AAC(6')/APH(2")-wt to its three mutants. Combining the binding affinity 
and enzyme turnover rate, we found that in some cases, i.e., with AMK as a substrate, 
mutation seemed to have slightly improved enzyme efficiencies. In other cases, with TOB 
as substrate, mutation did not cutback the overall enzyme efficiencies, but truncation did. 
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Figure 2.4. Kinetic curves for AAC(6')/APH(2")-wt (NHis) with various AGs. Insets include the Km and 
kcat values from a non-linear regression fit to the Michaelis-Menten equation. 
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Table 2.5. Kinetic parameters determined for AAC(6')/APH(2")-wt and the mutant enzymes, including AAC(6')/APH(2")-1-240, 
AAC(6')/APH(2")-D80G, and AAC(6')/APH(2")-D80G-1-240, with various AGs. 
AGs  AAC(6')/APH(2")-wt AAC(6')/APH(2")-1-240 AAC(6')/APH(2")-D80G AAC(6')/APH(2")-D80G-1-240 
ABK Km 77.9 ± 21.4 146 ± 17 109 ± 58 331 ± 108 
kcat 2.43 ± 0.14 2.55 ± 0.11 2.12 ± 0.36 5.16 ± 0.76 
kcat/Km 0.031 ± 0.009 0.017 ± 0.002 0.019 ± 0.011 0.016 ± 0.006 
AMK Km 30.7 ± 5.6 65.8 ± 6.6 31.1 ± 3.5 26.4 ± 5.2 
kcat 3.16 ± 0.20 7.75 ± 0.37 9.17 ± 0.34 6.59 ± 0.53 
kcat/Km 0.103 ± 0.020 0.118 ± 0.013 0.295 ± 0.035 0.250 ± 0.053 
KAN Km 2.98 ± 0.67 1.11 ± 0.28 0.779 ± 0.286 1.24 ± 0.35 
kcat 8.02 ± 0.57 5.64 ± 0.45 6.16 ± 0.73 9.09 ± 0.90 
kcat/Km 2.69 ± 0.64 5.10 ± 1.35 7.91 ± 3.05 7.33 ± 2.20 
NEA Km 8.12 ± 1.56 7.63 ± 0.57 11.7 ± 1.3 7.21 ± 1.14 
kcat 12.3 ± 0.7 8.33 ± 0.18 8.72 ± 0.29 6.82 ± 0.30 
kcat/Km 1.51 ± 0.30 1.09 ± 0.09 0.744 ± 0.084 0.946 ± 0.155 
NEO Km 102 ± 20 107 ± 19 307 ± 51 140 ± 19 
kcat 13.9 ± 1.1 7.33 ± 0.54 22.4 ± 2.0 11.9 ± 0.7 
kcat/Km 0.136 ± 0.029 0.068 ± 0.013 0.073 ± 0.014 0.084 ± 0.013 
SIS Km 49.9 ± 6.0 13.9 ± 3.7 67.9 ± 9.1 45.8 ± 5.6 
kcat 12.9 ± 0.6 4.15 ± 0.30 11.7 ± 0.7 10.5 ± 0.5 
kcat/Km 0.259 ± 0.033 0.298 ± 0.082 0.172 ± 0.025 0.229 ± 0.030 
TOB Km 15.0 ± 4.3 16.4 ± 1.7 7.46 ± 1.87 15.2 ± 3.0 
kcat 15.3 ± 1.7 10.7 ± 0.7 11.1 ± 0.9 9.38 ± 1.00 
kcat/Km 1.02 ± 0.32 0.651 ± 0.080 1.48 ± 0.39 0.618 ± 0.140 
All AGs presented in this table were found to be good substrates of the different AAC(6')/APH(2") (NHis) constructs according to our substrate profiling 
experiment results. Km, kcat, and kcat/Km values are presented in µM, min-1, and (µM-1min-1), respectively. 
 43 
 
Figure 2.5. Kinetic curves for AAC(6')/APH(2")-1-240 (NHis) with various AGs. Insets include the Km 
and kcat values from a non-linear regression fit to the Michaelis-Menten equation. 
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Figure 2.6. Kinetic curves for AAC(6')/APH(2")-D80G (NHis) with various AGs. Insets include the Km 
and kcat values from a non-linear regression fit to the Michaelis-Menten equation. 
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Figure 2.7. Kinetic curves for AAC(6')/APH(2")-D80G-1-240 (NHis) with various AGs. Insets include 
the Km and kcat values from a non-linear regression fit to the Michaelis-Menten equation. 
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2.2.4. Determination by MS and MS2 of the position(s) acetylated on ABK and AMK 
by AAC(6')/APH(2")-wt and its three mutant enzymes 
Since the substrate profile and the kinetic parameters of the AAC(6')/APH(2")-wt and 
D80G mutant and/or 1-240 truncated enzymes did not reveal significant difference between 
the four enzymes, we further looked into more sensitive techniques such as MS and MS2 
to decipher the potential switch in regioselectivity of these enzymes. We first incubated 
ABK with a single enzyme (AAC(6')/APH(2")-wt, 1-240, D80G, or D80G-1-240) and 1.5 
or 3 eq. of AcCoA. Theoretically, 1.5 eq. of AcCoA would be sufficient for at least one 
acetylation and 3 eq. of AcCoA would be sufficient for at least two acetylations on each 
AG molecule.  
 
As summarized in Figures 2.8-2.10 and Table 2.6, we found that the AAC(6')/APH(2")-wt 
enzyme modifies ABK solely on the 6'-position with either 1.5 or 3 eq. of AcCoA, 
indicated by only an AcABK peak at 595.3297 m/z and a fragmentation pattern aligning 
with that of 6'-AcABK in MS2. This strict regiospecificity displayed by AAC(6')/APH(2")-
wt enzyme agreed with previous findings.38 ABK modified by AAC(6')/APH(2")-1-240, 
D80G, or D80G-1-240 with 1.5 eq. of AcCoA resulted in only 6'-AcABK according to MS 
and MS2. However, each reaction with 3 eq. of AcCoA yielded not only 6'-AcABK, but 
also 6',4'''-diAcABK (637.3403 m/z). This suggested that AAC(6')/APH(2")-1-240, D80G, 
and D80G-1-240 enzymes preferred the 6'-position, but were also able to modify the 4'''-
amine given excess amount of AcCoA, expanding their original regiospecificity to a novel 
position, the 4'''-amine. Similar activities were observed among the three mutant enzymes. 
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Figure 2.8. Structures of A. ABK and B. AMK with the potential acetylation sites of interest in this study 
(6'- and 4'''-amine positions) denoted with red arrows. The exact mass of the parent ABK and AMK, 
monoacetylated ABK (AcABK) or AMK (AcAMK), and diacetylated ABK (diAcABK) and AMK 
(diAcAMK) are also listed under the structure. 
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Figure 2.9. Representative mass spectra of ABK control and ABK modified with various amount of 
AcCoA by various enzymes generated in this study either individually or sequentially. A. ABK control. 
B. ABK + AAC(6')/APH(2")-wt + AcCoA (3 eq.). C. ABK + AAC(6')/APH(2")-D80G-1-240 + AcCoA 
(1.5 eq.) (Note: using other mutant enzymes gave the same spectra). D. ABK + AAC(6')/APH(2")-D80G-
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1-240 + AcCoA (3 eq.) (Note: using different mutant enzymes gave the same spectra). E. ABK + 
AAC(6')/APH(2")-D80G-1-240 followed by wt + AcCoA (3 eq.) (Note: using various mutant enzymes 
first followed by wt and using the wt enzyme followed by various mutant enzymes gave the same spectra). 
F. ABK + AAC(6')/APH(2")-1-194 + AcCoA (1.5 eq.). G. ABK + AAC(6')/APH(2")-1-194 + AcCoA (3 
eq.). H. ABK + AAC(6')/APH(2")-1-194 followed by wt + AcCoA (3 eq.) (Note: using wt enzyme first 
followed by 1-194 enzyme gave the same spectra). The expected m/z ratios for ABK, AcABK, and 
diAcABK [m + H]+ were 553.3192, 595.3297, and 637.3403. 
 
 
Figure 2.10. Representative tandem mass spectra (MS2) of A. AcABK and B. diAcABK with predicted 
fragmentation. Fragments with m/z ratios between 100 to 600 for AcABK and between 100 to 700 for 
diAcABK were collected. The fragments of interests in each panel that indicated the position of acetylation 
were labeled both in the spectra and in the structure of AcABK and diAcABK with their calculated m/z 
ratios. Note: Each predicted fragment above or below a dash line was indicated with the corresponding 
calculated m/z ratio placed above or below the dash line, respectively. 
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Table 2.6. Summary of mass spectrometry results obtained by using a single enzyme or sequentially using two enzymes.a 
AG Enzyme 1 Enzyme 2 AcCoA (eq.) AG 6'-AcAG 6',4'''-diAcAG 
ABK ´ ´ ´ ✓   
wt ´ 1.5  ✓  
wt ´ 3  ✓  
1-240 ´ 1.5  ✓  
1-240 ´ 3  ++ ++ 
D80G ´ 1.5  ✓  
D80G ´ 3  ++ ++ 
D80G-1-240 ´ 1.5  ✓  
D80G-1-240 ´ 3  ++ ++ 
1-194 ´ 1.5  ✓  
1-194 ´ 3  ++ -- 
wt 1-240 3  -- ++ 
wt D80G 3  -- ++ 
wt D80G-1-240 3  -- ++ 
wt 1-194 3  ++ ++ 
1-240 wt 3  -- ++ 
D80G wt 3  -- ++ 
D80G-1-240 wt 3  -- ++ 
 1-194 wt 3  ++ ++ 
AMK ´ ´ ´ ✓   
wt ´ 1.5  ✓  
wt ´ 3  + -- 
1-240 ´ 1.5  ✓  
1-240 ´ 3  + -- 
D80G ´ 1.5  ✓  
D80G ´ 3  + -- 
D80G-1-240 ´ 1.5  ✓  
D80G-1-240 ´ 3  + -- 
1-194 ´ 1.5  ✓  
1-194 ´ 3  ✓  
wt 1-240 3  ++ + 
wt D80G 3  ++ + 
wt D80G-1-240 3  ++ + 
wt 1-194 3  ++ -- 
1-240 wt 3  ++ + 
D80G wt 3  ++ + 
D80G-1-240 wt 3  ++ + 
 1-194 wt 3  ++ -- 
a Reactions with a single enzyme were performed for 24 h prior to processing, whereas sequential reactions were 
performed by reacting with enzyme 1 for 24 h followed by enzyme 2 for 24 h. 
´ = enzyme or AcCoA not used in the reaction; ✓ = the only species detected; ++ = this species is of high abundance; + 
= this species is of moderate abundance; -- = this species is of very low abundance. 
 
Next, we incubated ABK with two different enzymes sequentially with either 
AAC(6')/APH(2")-wt as enzyme 1 (E1) then followed by AAC(6')/APH(2")-1-240, D80G, 
or D80G-1-240 as enzyme 2 (E2), or one of the mutant enzymes as E1 and wt as E2. The 
results were similar. We found that most of the ABK had been converted to 6',4'''-
diAcABK. Although previous research reported that the acetylation of AGs at a certain 
position can hinder further acetylation at other positions, i.e., it was reported that 
acetylation of NEO and SIS at their 3-position hindered the subsequent acetylation at 6'-
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position,38 we did not observe such phenomenon in this study regarding the 6'- and 4'''-
modification of ABK. The fact that we observed similar activity among all three mutant 
enzymes, either by one enzyme or by two enzymes sequentially, suggested that the D80G 
mutation and the 1-240 truncation were not both required for the expanded regiospecificity. 
Even though the D80G-1-240 enzyme could be the naturally occurring variant in the 
producing bacteria due to the D80G mutation, enzymes with either mutation or truncation 
alone, when expressed heterologously, can show altered regiospecificity, as indicated by 
MS and MS2 results. 
 
Structurally, the D80G mutation was first postulated to significantly change protein 
conformation.35-37 If the D80G mutation were to cause the protein conformation to be 
significantly altered during protein folding (i.e., five sixth of AAC(6')/APH(2")-D80G will 
fold differently from the wt protein conformation), the AAC(6')/APH(2")-D80G 
conformation could have an expanded active site in order to accommodate the substrate, 
ABK, to bind in various orientations and be modified at two distinct amine appendages. 
According to the published modeling/structure of AAC(6')/APH(2"), the substrate binding 
cavities of AAC(6') and APH(2") was reported to lie on the same side of the protein. Such 
close arrangement inspired suspicions that the two active sites facilitate substrate 
binding/channeling cooperatively. Given such rigid arrangement, the proteolytic cleavage 
at amino acid residue 240 that resulted from the mutation in the distant D80 residue might 
not in fact be random. The D80G mutation possibly altered protein conformation that 
rearranged the two active sites relative to each other might account for the alternative 
binding of ABK in the AAC(6') active site.40 Similarly, since AAC(6')/APH(2")-1-240 
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would contain an extra portion of the linker domain and the 46 residues from the APH(2") 
domain, this fairly large segment would also be highly possible of disrupting the native 
protein conformation of the AAC(6') portion by interacting with amino acid residues in the 
AAC(6') domain. Therefore, we postulated that the structural change in protein folding 
resulting from either the D80G mutation, the appendage of the linker region and the 46 
residues from APH(2"), or a combination on both could enlarge the enzymes’ substrate 
binding site to allow the acetylation of ABK at the 4'''-position. 
 
In order to test this hypothesis, we cloned and expressed the functional AAC(6') domain, 
which included residues 1-194 from the original AAC(6')/APH(2") bifunctional enzyme, 
herein denoted as AAC(6')/APH(2")-1-194 to test whether the AAC(6') domain alone 
would show the expanded regiospecificity. We included the linker region (175-194) in this 
construct in order to obtain a functional AAC(6'), but left out the 46 residues from the APH 
domain. We first modified ABK with AAC(6')/APH(2")-1-194 with 1.5 eq. of AcCoA and 
observed only 6'-AcABK in MS and MS2 (Figures 2.9 and 2.10). The reaction containing 
ABK, AAC(6')/APH(2")-1-194, and 3 eq. of AcCoA still yielded mostly 6'-AcABK. 
Sequentially modifying ABK with either AAC(6')/APH(2")-wt followed by 1-194, or 
AAC(6')/APH(2")-1-194 followed by wt resulted in both 6'-AcABK and 6',4'''-diAcABK 
as shown by MS and MS2. The results generated by using AAC(6')/APH(2")-1-194 enzyme 
were considerably different from those with AAC(6')/APH(2")-1-240, D80G, and D80G-
1-240 enzymes. We found that the ability of AAC(6')/APH(2")-1-194 at acetylating ABK 
at the 4'''-position was significantly lower compared to that of the other three mutant 
 53 
enzymes, confirming that the extra 46 residues from the APH(2") domain in our truncated 
enzymes indeed assisted the expansion of regiospecificity, as did the D80G mutation. 
 
Due to the structural similarities between ABK and AMK, we next obtained the MS and 
MS2 spectra for the same reactions with AMK instead of ABK in order to see whether the 
expansion of regiospecificity applies to AMK (Table 2.6 and Figures 2.8 and 2.11-2.12). 
We found that AMK, when modified by a single enzyme (AAC(6')/APH(2")-wt, 1-240, 
D80G, D80G-1-240, or 1-194) with 1.5 eq. of AcCoA, was converted to 6'-AcAMK only 
(628.3036 m/z). When AMK was co-incubated with a single enzyme (AAC(6')/APH(2")-
wt, 1-240, D80G, and D80G-1-240) and 3 eq. of AcCoA, we identified the majority of the 
product being 6'-AcAMK and trace amount of 6',4'''-diAcAMK (670.3141 m/z) whereas 
AAC(6')/APH(2")-1-194 with 3 eq. of AcCoA converted AMK to 6'-AcAMK only. This 
agreed with previous observation that AAC(6')/APH(2")-1-194 enzyme was more limited 
in its ability to acetylate AGs at various amine positions compared to AAC(6')/APH(2")-
1-240, D80G, and D80G-1-240 enzymes.  
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Figure 2.11. Representative mass spectra of AMK control and AMK modified with various amount of 
AcCoA by various enzymes generated in this study either individually or sequentially. A. AMK control. 
B. AMK + AAC(6')/APH(2")-wt + AcCoA (1.5 eq.). C. AMK + AAC(6')/APH(2")-wt + AcCoA (3 eq.). 
D. AMK + AAC(6')/APH(2")-D80G-1-240 + AcCoA (1.5 eq.) (Note: using other mutant enzymes gave 
the same spectra). E. AMK + AAC(6')/APH(2")-D80G-1-240 + AcCoA (3 eq.) (Note: using different 
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mutant enzymes gave the same spectra). F. AMK + AAC(6')/APH(2")-D80G-1-240 followed by wt + 
AcCoA (3 eq.) (Note: using various mutant enzymes first followed by wt and using the wt enzyme 
followed by various mutant enzymes gave the same spectra). G. AMK + AAC(6')/APH(2")-1-194 + 
AcCoA (3 eq.) (Note: using AcCoA (1.5 eq.) gave the same spectra). H. AMK + AAC(6')/APH(2")-1-194 
followed by wt + AcCoA (3 eq.) (Note: using wt enzyme first followed by 1-194 enzyme gave the same 
spectra). The expected m/z ratios for AMK, AcAMK, and diAcAMK [m + H]+ were 586.2930, 628.3036, 
and 670.3141. 
 
 
Figure 2.12. Representative tandem mass spectra (MS2) of A. AcAMK and B. diAcAMK with predicted 
fragmentation. Fragments with m/z ratios between 100 to 650 for AcAMK and between 100 to 700 for 
diAcAMK were collected. The fragments of interests in each panel that indicated the position of 
acetylation were labeled both in the spectra and in the structure of AcAMK and diAcAMK with their 
calculated m/z ratios. Note: Each predicted fragment above or below a dash line was indicated with the 
corresponding calculated m/z ratio placed above or below the dash line, respectively. 
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when we used AAC(6')/APH(2")-wt as E1 and AAC(6')/APH(2")-1-194 as E2, or 
AAC(6')/APH(2")-1-194 as E1 and AAC(6')/APH(2")-wt as E2, we observed different 
results: most of the AMK was converted into 6'-AcAMK and only trace amount of 6',4'''-
diAcAMK was detected. Once again, this supported our previous observation that 
AAC(6')/APH(2")-1-240, D80G, and D80G-1-240 were much more efficient at acetylating 
the 4'''-position after the enzyme regiospecificity was expanded. In addition, the different 
results observed between the acetylation of ABK and AMK by the same enzyme revealed 
an interesting phenomenon. Even though ABK and AMK structurally only differed by their 
2'-, 3'-, and 4'-substitutions on ring I, the enzymes were able to discriminate one AG over 
the other, as the expanded acetylation activity at the 4'''-location for ABK was much more 
efficient compared to that for AMK. 
 
In addition to MS and MS2, nuclear magnetic resonance (NMR) spectroscopy would also 
be a great tool to elucidate where and how ABK and AMK are being acetylated by 
AAC(6')/APH(2")-wt and its various mutant enzymes. However, with the limited amount 
of ABK that we received as a gift from Dr. Sergei Vakulenko (University of Notre Dame, 
U.S.A.) and the inability to obtain ABK from the U.S.A. market, MS remained the better 
and only instrument available to us to elucidate various enzyme behaviors with respect to 
ABK as a substrate. 
 
Acetylation of AGs by various AACs usually abolishes the antibacterial effect of these 
antibiotics. Therefore, acquiring these resistance enzymes can provide bacteria with 
advantages at surviving the presence of a xenobiotic. However, previous research has also 
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demonstrated that some AG metabolites, even after being chemically modified by AMEs, 
can still retain antibacterial activities. For instances, 6'-AcNEO has been shown to still 
possess antibacterial activity against Bacillus subtilis.38 Various ABK metabolites, 
including 2'-, 6'-, and 3"-AcABK have also been reported to retain weak to moderate 
antibacterial activities.44-46 In such circumstance, a single acetylation does not completely 
eliminate the antibacterial effect of AGs. Therefore, possessing any additional enzymes 
that are capable of acetylating at a secondary site on AGs and further inactivate these drugs 
can provide the bacteria substantial survival advantages. In the case of AAC(6')/APH(2")-
D80G-1-240, MRSA acquired/developed this mutant enzyme that further modifies the 4'''-
amine in addition to the 6'-amine. As a result, the bacteria can better survive ABK treatment 
in case the 6'-acetylated ABK still retains any antibacterial activity. 
 
In our study, we also used disk diffusion assays to examine whether ABK metabolites by 
various enzyme constructs generated in this study possess any antibacterial effect against 
a susceptible strain of E. coli MC 1061. We found that ABK metabolites modified with 
one enzyme alone (AAC(6')/APH(2")-wt, 1-240, or D80G-1-240), or with two enzymes 
sequentially (AAC(6')/APH(2")-1-240 followed by wt, or D80G-1-240 followed by wt) 
displayed no visible zone of inhibition, suggesting that these ABK metabolites retained no 
detectable antibacterial activity against this strain of bacteria by this assay. Another 
possibility to consider is that the acetylated ABK metabolites (6'-AcABK and 6',4'''-
diAcABK) may become less membrane permeable due to the chemical modification on the 
molecules by acetylation. If so, the ABK metabolites might become unable to cross the 
bacteria cell envelope and membrane to reach its target in the cytoplasm even if the ABK 
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metabolites might still be able to act on the ribosome and interfere with protein translation. 
In such scenario, we would not be able to observe any zones of inhibition produced by 
these ABK metabolites despite their inhibitory activity on the ribosome. The absence of a 
zone of inhibition with these ABK metabolites also suggested no product inhibition of these 
AAC(6')/APH(2") enzymes. 
 
2.3. CONCLUSIONS 
In this study, we explored the possibility of expanding AAC(6')/APH(2")-wt  
regiospecificity by introducing a D80G point mutation and/or 1-240 truncation (Tables 2.1-
2.3 and Figures 2.2-2.3). Even though AAC(6')/APH(2")-D80G-1-240 may be the 
naturally occurring mutant enzyme as a result of the D80G mutation in the MRSA strain 
where this mutant enzyme was originally discovered, we found that the three mutant 
enzymes we cloned in this study (AAC(6')/APH(2")-1-240, AAC(6')/APH(2")-D80G, and 
AAC(6')/APH(2")-D80G-1-240) showed similar substrate promiscuity (Table 2.4) and 
kinetic efficiency against various AGs (Table 2.5 and Figures 2.4-2.7). MS and MS2 with 
purified reaction mixtures with ABK as a substrate revealed that the three mutant enzymes 
showed preference to acetylate AGs at their 6'-amine positions, but can also modify the 
4'''-position given excess amount of AcCoA (Table 2.6 and Figures 2.8-2.10). This was not 
a complete switch of regiospecificity from the 6'- to the 4'''-position as reported before,35-
37 but rather an expansion, which the presence of mutation only or truncation only can also 
alter the protein catalysis in such way described above. We postulated the D80G mutation 
and/or 1-240 truncation could cause alteration in protein conformation during protein 
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during protein folding, resulting in an enlarged AG binding site that would accommodate 
ABK binding from various orientations.  
 
Moreover, we also found that these three mutant enzymes did not display the same activity 
with AMK as a substrate as did with ABK (Table 2.6 and Figures 2.8 and 2.11-2.12). Even 
though the mutant enzymes still displayed preference for 6'-amine of AMK, the ability to 
modify AMK at the 4'''-position was significantly lower compared to that when modifying 
ABK. This suggested an uncharacterized mechanism by which the enzymes were able to 
discriminate between ABK and AMK even though the two AG structures are extremely 
similar. 
 
Overall, bacteria evolved to possess AAC(6')/APH(2")-D80G-1-240, a variant enzyme of 
AAC(6')/APH(2") with expanded regiospecificity, to further protect the bacteria from any 
AG metabolites that might retain antibacterial activity after chemical modification and 
inactivation by AACs. The findings in this study can help us better understand the bacterial 
resistance mechanisms associated with AG antibiotics in order to better combat resistant 
bacteria. 
 
2.4. MATERIALS AND METHODS 
2.4.1. Materials and instrumentation 
The pET28 vector was purchased from Novagen (Gibbstown, NJ), TOP10 and BL21 (DE3) 
chemically competent E. coli cells were purchased from Invitrogen (Carlsbad, CA). 
Reagents for cloning, including restriction endonucleases, T4 DNA ligase, and Phusion 
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DNA polymerase (accompanied with appropriate buffers), were purchased from New 
England BioLabs (Ipswich, MA). DNA primers for PCR were purchased from Sigma-
Aldrich (Milwaukee, WI) and Integrated DNA Technologies (Coralville, IA). DNA 
sequencing was performed by Eurofins Genomics. AcCoA and DTNB were purchased 
from Sigma-Aldrich. AMK, GEN, KAN, NEA, NET, SIS, and TOB were bought from AK 
Scientific (Mountain View, CA). APR, G418, HYG, PAR, and RIB were purchased from 
Sigma-Aldrich. NEO was purchased from Tokyo Chemical Industry Co. Ltd. ABK was a 
generous gift from Dr. Sergei Vakulenko (University of Notre Dame, U.S.A.). CIP was 
purchased from Sigma-Aldrich. NiII-NTA used for affinity chromatography was purchased 
from Qiagen. 
 
E. coli cultures were grown in Thermo Scientific MaxQ 6000 incubators, and OD 
measurements were taken on a Thermo Spectronic Genesys 20. Centrifugation was 
performed by using a Thermo SorvallTM RC 6 Plus centrifuge. Cell disruption was achieved 
by sonication using a Qsonica sonicator ultrasonic processor (Newtown, CT). UV-Vis 
assays for the determination of kinetic parameters and substrate profiling were performed 
on a SpectraMax M5 plate reader. Mass spectra were recorded in positive mode using an 
AB SCIEX TripleTOFTM 5600 (AB SCIEX, Redwood city, CA) mass spectrometer and a 
Shimadzu HPLC system equipped with a DGU-20A/3R degasser, LC-20AD binary pumps, 
CBM-20A controller, and a SIL-20A/HT autosampler (Shimadzu, Kyoto, Japan). 
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2.4.2. Cloning of NHis6-tagged aac(6')/aph(2")-1-240, aac(6')/aph(2")-D80G, 
aac(6')/aph(2")-D80G-1-240, and aac(6')/aph(2")-1-194 genes in pET28a 
The wt AAC(6')/APH(2") DNA was previously cloned into pET22b and pET28a vectors 
to generate plasmid encoding for CHis6 and NHis6-tagged proteins.38 Here, the 
aac(6')/aph(2")-1-240, aac(6')/aph(2")-D80G, aac(6')/aph(2")-D80G-1-240, and 
aac(6')/aph(2")-1-194 genes were cloned into pET28a using the primers and cloning 
strategies listed in Tables 2.1-2.2, and Figure 2.2A, respectively. All genes were amplified 
by polymerase chain reaction (PCR) using the AAC(6')/APH(2")-wt DNA from the 
pAAC(6')/APH(2")-pET22b vector. PCR products were confirmed via agarose gel 
electrophoresis and purified by gel extraction (Qiagen QIAquick Gel Extraction Kit). The 
PCR amplified genes and empty pET28a vector were digested by using NdeI and XhoI for 
4 h at 37 °C and purified using Qiagen QIAquick PCR purification kit. The purified inserts 
and digested vector were ligated using T4 DNA ligase (5:1/insert:vector) overnight at rt to 
generate plasmids pAAC(6')/APH(2")-1-240-pET28a, pAAC(6')/APH(2")-D80G-
pET28a, pAAC(6')/APH(2")-D80G-1-240-pET28a, and pAAC(6')/APH(2")-1-194-
pET28a, which were directly transformed into E. coli TOP10 chemically competent cells 
for DNA isolation (Qiagen QIAprep Spin Miniprep Kit). After confirming the existence of 
desired gene insert into the pET28a vector by double digestion of the isolated DNA with 
NdeI and XhoI and DNA sequencing (Eurofins MWG Operon), the isolated plasmids were 
transformed into E. coli BL21 (DE3) chemically competent cells for protein expression 
and purification. 
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2.4.3. Overexpression and purification of AAC(6')/APH(2")-wt, AAC(6')/APH(2")-1-
240, AAC(6')/APH(2")-D80G, AAC(6')/APH(2")-D80G-1-240, and 
AAC(6')/APH(2")-1-194 NHis6-tagged proteins 
The E. coli BL21 (DE3) transformed with the pAAC(6')/APH(2")-1-240-pET28a, 
pAAC(6')/APH(2")-D80G-pET28a, pAAC(6')/APH(2")-D80G-1-240-pET28a, and 
pAAC(6')/APH(2")-1-194-pET28a constructs were inoculated into 2 × 1L of LB broth 
supplemented with 50 µg/mL of KAN and stirred at 200 rpm at 37 °C until the attenuance 
at 600 nm reached 0.5. Then, each culture was induced with 1 mM IPTG (final 
concentration) and incubated at 20 °C overnight (200 rpm). Cells were harvested by 
centrifugation at 5,000 rpm for 10 min at 4 °C and lysed in buffer A (50 mM Na2HPO4 (pH 
8.0 adjusted at rt), 300 mM NaCl, 10% glycerol) by sonication 2 min × 3 cycles, alternating 
between 2 s “on” and 10 s “off” for each cycle, resting for 2 min in between cycles) on ice. 
After removal of the cell debris by centrifugation at 16,000 rpm for 45 min at 4 °C, each 
enzyme was purified via NiII-NTA affinity chromatography by washing and eluting with 
buffer A containing imidazole in a gradient fashion (10 mL of 5 mM imidazole, 3 × 5 mL 
of 20 mM imidazole, 3 × 5 mL of 40 mM imidazole, and 3 × 5 mL of 250 mM imidazole). 
After analysis by SDS-PAGE, fractions containing pure protein were combined and 
dialyzed in 50 mM HEPES (pH 7.5 adjusted at rt) and 10% glycerol and stored at 4 °C or 
flash-frozen at -80 °C. By comparing the enzyme activity from the 4 °C and the -80 °C 
protein stocks, we found that being stored at 4 °C does not result in noticeable loss in 
enzymatic activities of the enzymes involved in this study compared to the enzymes stored 
at -80 °C. A sample SDS-PAGE gel of AAC(6')/APH(2")-wt, AAC(6')/APH(2")-1-240, 
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AAC(6')/APH(2")-D80G, and AAC(6')/APH(2")-D80G-1-240 is shown in Figure 2.3 with 
yields provided in Table 2.3. 
 
2.4.4. Establishment of the substrate profiles of AAC(6')/APH(2")-wt, 
AAC(6')/APH(2")-1-240, AAC(6')/APH(2")-D80G, and AAC(6')/APH(2")-D80G-1-
240 by UV-Vis assays 
In order to test whether the AAC(6')/APH(2")-wt and mutant enzymes could modify 
various AGs, we established their substrate profiles by UV-Vis assays. We tested a panel 
of 14 AGs (ABK, AMK, APR, G418, GEN, HYG, KAN, NEA, NEO, NET, PAR, RIB, 
SIS, and TOB) and 1 fluoroquinolone (CIP). Acetylation reactions were monitored by 
using a colorimetric UV-Vis assay in 96-well plates at 37 °C. Each reaction (200 µL total) 
contained 50 mM MES (pH 6.6 adjusted at rt), 2 mM DTNB, 150 µM AcCoA, 100 µM of 
various AG substrate, and were initiated by the addition of 5 µM enzyme (stored in 50 mM 
HEPES (pH 7.5) and 10% glycerol). The reaction progress was monitored by recording the 
absorbance at 412 nm every 20 s for 20 min. As presented in Table 2.4, whether the AG 
(or CIP) tested was a great, moderate, poor substrate, or not a substrate was arbitrarily 
determined in this study based on the absorbance at 412 nm (absorbance >0.8 was 
categorized as great substrate, absorbance of 0.4-0.8 was categorized as moderate substrate, 
absorbance of 0.1-0.4 was categorized as poor substrate, and absorbance <0.1 was 
categorized as not a substrate). 
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2.4.5. Determination of kinetic parameters for AAC(6')/APH(2")-wt, 
AAC(6')/APH(2")-1-240, AAC(6')/APH(2")-D80G, and AAC(6')/APH(2")-D80G-1-
240 
In order to determine the kinetic parameters of various enzymes with respect to AGs, we 
tested 7 selected AGs that were tested to be good substrates of the four enzymes in previous 
substrate profiling experiment (ABK, AMK, KAN, NEA, NEO, SIS, and TOB) by UV-
Vis assays in 96-well plates for 15 min at 37 °C. Reactions contained 50 mM MES pH 6.6 
(adjusted at rt), 2 mM DTNB, 0.05 µM enzyme, AcCoA (the concentration of AcCoA in 
the determination of kinetic parameters for each AG equals 1.5 eq. of the highest AG 
concentration) and were initiated by the addition of 50 µL of AG substrate of various 
concentrations to make the total reaction volume 200 µL. All experiments were performed 
in triplicates and the kinetic parameters were then calculated based on Lineweaver-Burke 
plots generated by using the Sigma Plot software version 9.0 (Table 2.5 and Figures 2.4-
2.7). 
 
2.4.6. Mass spectrometry 
In order to confirm the number of acetylation events and their positions, we subjected 
purified enzymatic reactions to mass spectrometry and tandem mass spectrometry. We 
performed reactions with 1 eq. of ABK or AMK modified by a single enzyme generated in 
this study with 1.5 eq. of AcCoA in order to see the preferred position of each enzyme (1.5 
eq. of AcCoA allowed for acetylation of one position on AG by the enzyme to be visualized 
by mass spectrometry), or with 3 eq. of AcCoA in order to see whether each enzyme is 
capable to transferring multiple acetyl groups onto one AG molecule. We then performed 
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sequential modification reactions where we set up reactions with 1 eq. of ABK or AMK 
with 3 eq. of AcCoA and a first enzyme (either the wt or any of the three mutants generated 
in this study). After completion of the reaction (24 h at 37 °C), we added a second enzyme 
(either any of the three mutants or the wt enzyme) and let the reaction go for an additional 
24 h at 37 °C in order to see whether the wt and mutants have different preference about 
the site of modification/acetylation on ABK and AMK. Each reaction (50 µL total) 
contained MES pH 6.6 (50 mM), AGs (100 µM) (either ABK or AMK), AcCoA (150 or 
300 µM), and various enzymes by themselves or in sequential orders (5 µM each). Reaction 
mixtures were subjected to cation solid phase extraction (Alltech, catalog # 209800), and 
eluted with 2% NH4OH. Elution fractions were dried in a vacuum centrifuge and 
redissolved in ddH2O (50 µL). 15 µL of each sample was directly injected using the ESI 
method with mobile phase composed of 0.1% formic acid in H2O onto the mass 
spectrometer. Species between m/z of 300 to 800 Da were collected by MS (Figures 2.9-
2.10). Species of interest with specific m/z ratios, including ABK (exact mass 552.3119 
Da), monoacetylated ABK (exact mass 594.3225 Da), diacetylated ABK (exact mass 
636.3330 Da), AMK (exact mass 585.2857 Da), monoacetylated AMK (exact mass 
627.2963 Da), and diacetylated AMK (exact mass 669.3069 Da), were collected and 
fragmented via tandem MS, as presented in Table 2.6 and Figures 2.8 and 2.11-2.12. 
 
2.4.7. Disk diffusion assays 
In order to assess the antibacterial activity of AME-modified ABK metabolites, we 
performed disk diffusion assays with reaction mixtures containing ABK modified by either 
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a single enzyme individually (i.e., AAC(6')/APH(2")-wt, AAC(6')/APH(2")-1-240, or 
AAC(6')/APH(2")-D80G-1-240), or two enzymes sequentially (i.e., AAC(6')/APH(2")-1-
240 followed by AAC(6')/APH(2")-wt, or AAC(6')/APH(2")-D80G-1-240 followed by 
AAC(6')/APH(2")-wt). Reaction conditions were as described in the MS experiments. 
After completion of the reactions (24 h at 37 °C), 15 µL of the reaction mixtures were 
spotted onto a sterile filter disks (~0.6 cm), air dried for 15 min, then placed on the LB-
agar surface. A fresh dilution of an overnight culture of E. coli MC 1061 strain in soft LB-
agar (100 µL culture in 10 mL of soft LB-agar) was thinly layered onto the hard LB-agar 
surface. The presence or absence of zones of inhibition were visually inspected after 
overnight incubation at 37 °C. 
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Chapter 3. Inhibition of aminoglycoside acetyltransferase resistance enzymes by 
metal salts 
Aminoglycosides (AGs) are clinically relevant antibiotics used to treat infections caused 
by both Gram-negative and Gram-positive bacteria, as well as Mycobacteria. As with all 
current antibacterial agents, resistance to AGs is an increasing problem. The most common 
mechanism of resistance to AGs is the presence of AG-modifying enzymes (AMEs) in 
bacterial cells, with AG acetyltransferases (AACs) being the most prevalent. Recently, it 
was discovered that Zn2+ metal ions displayed an inhibitory effect on the resistance enzyme 
AAC(6')-Ib in Acinetobacter baumannii and Escherichia coli. In this study, we explore a 
wide array of metal salts (Mg2+, Cr3+, Cr6+, Mn2+, Co2+, Ni2+, Cu2+, Zn2+, Cd2+, and Au3+ 
with different counter ions) and their inhibitory effect on a large repertoire of AACs 
(AAC(2')-Ic, AAC(3)-Ia, AAC(3)-Ib, AAC(3)-IV, AAC(6')-Ib', AAC(6')-Ie, AAC(6')-IId, 
and Eis). We identify AMEs in clinical isolates of various bacterial strains (two strains of 
A. baumannii, three of Enterobacter cloacae, and four of Klebsiella pneumoniae) and one 
representative of each strain purchased from the American Type Culture Collection. Lastly, 
we determine the MIC values for amikacin and tobramycin in combination with a zinc 
pyrithione complex. 
 
3.1. INTRODUCTION 
Aminoglycosides (AGs) are broad-spectrum bactericidal antibiotics that are used clinically 
for the treatment of serious bacterial infections.1-2 These antibiotics were originally isolated 
from Streptomyces and Micromonosporas,3 and display activity against Gram-positive, 
aerobic Gram-negative pathogenic bacteria, and Mycobacteria. Since the discovery of 
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streptomycin, the first-in-class AG isolated, many generations of AGs have been 
discovered with improved efficacy. This property has kept them clinically relevant despite 
their inherent oto- and nephrotoxicity. Currently, amikacin (AMK), gentamicin (GEN), and 
tobramycin (TOB) are the most commonly prescribed AGs for systemic administration in 
the U.S.A. against bacterial infections (Figure 3.1).4 Another AG, kanamycin (KAN), is 
also used systemically, but only to treat resistant strains of M. tuberculosis in patients who 
show no response to first-line anti-tuberculosis treatments. Other AGs, such as neomycin 
B (NEO), are found in antibiotic ointment formulations for topical use.5 
 
 
Figure 3.1. Structures of the AGs tested in this study. 
 
The increased importance and popularity of AGs has, unfortunately, led to lapses in 
antimicrobial stewardship. This, coupled with patient non-compliance to their prescribed 
drug regimen, has accelerated the development of resistance against AGs and reduced the 
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effective agents available for combating ever-evolving pathogens. The most common 
mechanism of bacterial resistance to AGs is the acquisition of AG-modifying enzymes 
(AMEs).6-7 Based on the reactions they catalyze, AMEs can be classified as AG N-
acetyltransferases (AACs), AG O-phosphotransferases (APHs), or AG O-
nucleotidyltransferases (ANTs), amongst which AACs are responsible for the majority of 
resistant infections. AACs modify AG substrates and disrupt their binding to the ribosome 
by transferring the acetyl group from acetyl-coenzyme A (AcCoA) onto amine moieties of 
the AG scaffolds. Although most AACs are regiospecific and only modify a single amino 
group, the unique enhanced intracellular survival (Eis) protein upregulated in resistant M. 
tuberculosis strains, is capable of acetylating AG substrates at several different positions.8-
10 
 
In an effort to overcome bacterial resistance, a large amount of time and money has been 
invested towards the development of inhibitors to these resistance enzymes. Most 
commonly, small organic molecules have been explored for this purpose. For example, in 
silico and high-throughput screening were used to identify small organic molecules capable 
of inhibiting AAC(6')-Ib11 and Eis,12 respectively. Traditional synthesis was utilized to 
identify 7-hydroxytropolone as an inhibitor of ANT(2"),13 and to generate a library of 45 
non-carbohydrate molecules containing a 1,3-diamine scaffold commonly found in AGs, 
which were found to be competitive inhibitors of ANT(2")-Ia and APH(3')-IIIa.14 
Bisubstrate inhibitors comprised of an AG (GEN or neamine) linked to an AcCoA-like 
molecule were also found to inhibit various AAC(3) and AAC(6') resistance enzymes.15-16 
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Interestingly, Zn2+ metal ions were recently reported to inhibit AAC(6')-Ib and reduce 
AMK resistance in Acinetobacter baumannii and Escherichia coli.17 Inspired by this study, 
we aimed to decipher whether metal ions could be used to inhibit a larger repertoire of 
AACs in a variety of bacterial strains. Herein, we explore the possibility of using Zn2+ and 
other ions (Mg2+, Cr3+, Cr6+, Mn2+, Co2+, Ni2+, Cu2+, Cd2+, and Au3+ in different salt forms) 
to inhibit various AACs, including AAC(2')-Ic (from M. tuberculosis),18-19 AAC(3)-Ia 
(from Serratia marcescens),20 AAC(3)-Ib from the bifunctional AAC(3)-Ib/AAC(6')-Ib' 
(from Pseudomonas aeruginosa),21-22 AAC(3)-IV (from E. coli),23 AAC(6')-Ib' from the 
bifunctional AAC(3)-Ib/AAC(6')-Ib' (from P. aeruginosa),21-22 AAC(6')-Ie from the 
bifunctional enzyme AAC(6')-Ie/APH(2")-Ia (from Staphylococcus aureus),24-26 AAC(6')-
IId from the bifunctional ANT(3")-Ii/AAC(6')-IId (from S. marcescens),27-28 and Eis (from 
M. tuberculosis).8 We identify various AME genes present in clinical isolates of A. 
baumannii, Enterobacter cloacae, and Klebsiella pneumoniae and compare their resistance 
enzyme profile to their susceptibility to a variety of clinical antibiotics. We also present 
MIC data for AMK and TOB in combination with a zinc complex, zinc pyrithione (ZnPT). 
 
3.2. RESULTS 
3.2.1. In vitro inhibition of AACs by metal salts 
To determine the inhibitory effect of different metal salts on the N-acetylating activity of 
AACs with various AGs, we first performed UV-Vis assays in 96-well plates (Figures 3.2 
and 3.3, and Table 3.1). Amongst the metal ions (Mg2+, Cr3+, Cr6+, Mn2+, Co2+, Ni2+, Cu2+, 
Zn2+, Cd2+, and Au3+) selected, Cu2+ salts (Cu(OAc)2, Cu(NO3)2, CuSO4) showed the most 
inhibitory activity against AACs in general. The presence of Zn2+ and Cd2+ ions also 
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resulted in generally lower AAC activity, with the exception of AAC(2')-Ic that was not 
well inhibited by Zn2+ or Cd2+. Eis also seemed to remain uninhibited by Zn2+ salts when 
tested with AMK, and by ZnSO4 when tested with other AGs. Actually, AAC(2')-Ic was, 
in general, only effectively inhibited by Cu2+ and Au3+. Interestingly, we noted that in 
general Ni2+ (NiCl2 and NiSO4) exerted moderate inhibition against the AAC(6') enzymes, 
but not AAC(6')-Ie (when tested with KAN or NEO) or other AACs. On the other hand, 
Au3+ inhibited all AACs tested with the exception of AAC(6')-Ie where only 6'-N-
acetylation of KAN was inhibited, and AAC(3)-Ib in the presence of GEN and sisomicin 
(SIS) where 3-N-acetylation was not inhibited. We also explored whether different anions 
affected the inhibitory ability of the same metal cation, yet with the Ni2+, Zn2+, Cu2+, and 
Cd2+ ions that we tested in different salt forms, we did not observe a noticeable difference 
in the enzyme activities amongst the different anions. 
 
Additionally, with few exceptions, we did not observe a difference in the metals’ inhibitory 
effect amongst various AGs across all enzymes studied. In addition, Eis showed the most 
reduction in activity in response to Au3+, which made Au3+ more effective as an inhibitor 
for Eis than Cd2+ and some Zn2+ salts. It was also noticeable that ZnSO4 did not inhibit Eis 
activity as much as the other Zn2+ salts did when tested with other AGs. This trend was 
also observed with AAC(3)-IV, suggesting that the SO42- ion may deteriorate the inhibitory 
effect of Zn2+. For the different AAC(3) enzymes, Zn2+ and Cd2+ showed the second best 
inhibitory effect after Cu2+, even though the AAC(3)-IV activity was higher when tested 
with ZnSO4 than when tested with other Zn2+ salts. Au3+ was also found to exert decent 
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inhibition of the AAC(3) enzymes with the exception of AAC(3)-Ib when tested with GEN 
and SIS. 
 
 
Figure 3.2. The inhibition of AAC enzymes by various metal salts with and without physiological 
concentration of NaCl. Activities with metal ion inhibitors are presented as a percentage of the activity of 
each AAC with AG without metal salts. The clinical relevant AGs, AMK, GEN, and TOB, are presented 
here. Other AGs, KAN, NEO, NET, and SIS, are presented in Figure 3.3. *As AuCl3 precipitated in 
HEPES pH 7.5 buffer with DTDP in the reaction mixture, it was not tested against AAC(6')-Ib' and 
AAC(6')-IId, and is therefore not presented in this figure. AAC(6')-Ib' and AAC(6')-IId were also not tested 
with the Cu2+ salts in the presence of 100 mM NaCl due to solubility issues. 
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Figure 3.3. The inhibition of AAC enzymes by various metal salts with and without physiological 
concentration of NaCl. Activities with metal ion inhibitors are presented as a percentage of the activity of 
each AAC with AG without metal salts. The AGs that are not presented in Figure 3.2, KAN, NEO, NET, 
and SIS, are presented here. *As AuCl3 precipitated in HEPES pH 7.5 buffer with DTDP in the reaction 
mixture, it was not tested against AAC(6')-Ib' and AAC(6')-IId, and is therefore not presented in this figure. 
AAC(6')-Ib' and AAC(6')-IId were also not tested with the Cu2+ salts in the presence of 100 mM NaCl due 
to solubility issues. 
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Table 3.1. Summary of inhibition of various AAC enzymes by metal salts in combination with different AGs (Note: these data are 
presented in Figures 3.2 and 3.3). 
Enzyme AG Metal 
  MgCl2 CrCl3 CrO3 MnSO4 CoCl2 NiCl2 NiSO4 Cu(OAc)2 Cu(NO3)2 CuSO4 
AAC(2')-Ica GEN 94 ± 9 72 ± 1 61 ± 2 102 ± 5 80 ± 10 96 ± 1 80 ± 6 17 ± 1 20 ± 4 15 ± 2 
 NEO 97 ± 4 43 ± 8 75 ± 8 94 ± 5 77 ± 11 69 ± 4 73 ± 3 14 ± 2 25 ± 5 27 ± 7 
 NET 49 ± 4 8.9 ± 1.6 3.9 ± 3.0 116 ± 13 22 ± 2 70 ± 6 54 ± 1 7.0 ± 0.7 9.4 ± 0.3 7.0 ± 1.5 
 SIS 108 ± 10 72 ± 8 86 ± 10 99 ± 2 79 ± 9 99 ± 1 92 ± 11 7.3 ± 0.9 9.4 ± 2.6 9.2 ± 1.2 
 TOB 90 ± 5 -- 49 ± 4 89 ± 2 53 ± 4 78 ± 1 65 ± 4 9.3 ± 1.2 17 ± 8 12 ± 6 
AAC(3)-Iaa GEN 84 ± 4 110 ± 6 79 ± 7 64 ± 9 66 ± 2 51 ± 2 69 ± 6 -- -- -- 
 NET 90 ± 10 110 ± 6 51 ± 4 61 ± 14 5.2 ± 0.7 15 ± 1 10 ± 2 32 ± 12 -- -- 
 SIS 78 ± 12 73 ± 5 73 ± 12 76 ± 7 26 ± 2 53 ± 12 31 ± 1 5.6 ± 1.0 25 ± 3 11 ± 2 
AAC(3)-Iba GEN 104 ± 25 61 ± 8 63 ± 16 66 ± 18 53 ± 9 31 ± 7 31 ± 1 -- -- -- 
 SIS 94 ± 17 67 ± 1 78 ± 2 108 ± 15 76 ±15 40 ± 9 76 ± 5 47 ± 12 -- -- 
AAC(3)-IVa GEN 95 ± 6 37 ± 5 76 ± 5 73 ± 7 80 ± 9 36 ± 3 69 ± 8 -- -- 4.0 ± 0.1 
 NEO 100 ± 19 86 ± 11 79 ± 4  85 ± 4 92 ± 11 95 ± 5 78 ± 5  20 ± 8 11 ± 4 11 ± 3 
 NET 128 ± 15 44 ± 3 98 ± 13 60 ± 1 102 ± 1 52 ± 2 58 ± 1 -- 25 ± 9 46 ± 13 
 SIS 88 ± 11 53 ± 13 108 ± 2 80 ± 6 117 ± 12 72 ± 9 90 ± 11 4.6 ± 2.5 -- 3.8 ± 1.6 
 TOB 105 ± 7 80 ± 4 55 ± 3 48 ± 2 126 ± 4 76 ± 7 84 ± 3 -- 6.9 ± 1.2 -- 
AAC(6')-Ib'b AMK 93 ± 5 85 ± 3 108 ± 6 92 ± 5 21 ± 1 3.9 ± 0.5 6.5 ± 0.5 -- -- -- 
 GEN 90 ± 4 73 ± 19 111 ± 4 86 ± 3 95 ± 5 35 ± 3 32 ± 4 -- -- -- 
 KAN 90 ± 3 39 ± 6 88 ± 3 71 ± 12 64 ± 7 21 ± 8 14 ± 1 -- -- -- 
 NEO 91 ± 6 76 ± 2 116 ± 3 73 ± 3 77 ± 5 9.1 ± 1.7 12 ± 1 -- 0.59 ± 0.17 -- 
 NET 77 ± 8 71 ± 7 129 ± 4 77 ± 2 50 ± 6 20 ± 3 8.2 ± 2.5 -- -- -- 
 SIS 94 ± 3 38 ± 2 125 ± 4 80 ± 3 83 ± 5 24 ± 2 19 ± 1 -- -- -- 
 TOB 103 ± 1 56 ± 1 100 ± 4 74 ± 6 79 ± 2 11 ± 2 15 ± 3 4.7 ± 0.4 5.5 ± 1.0 -- 
AAC(6')-Iea AMK 104 ± 1 57 ± 9 75 ± 1 100 ± 4 84 ± 4 10 ± 5 8.9 ± 0.4 -- -- -- 
 GEN 93 ± 3 77 ± 8 65 ± 6 85 ± 4 70 ± 2 18 ± 3 12 ± 2 -- -- -- 
 KAN 100 ± 8 88 ± 13 73 ± 4 106 ± 1 79 ± 1 60 ± 5 59 ± 4 -- -- -- 
 NEO 105 ± 8 36 ± 3 71 ± 4 77 ± 5 45 ± 2 113 ± 3 9.3 ± 0.7 -- 4.1 ± 1.0 2.9 ± 1.7 
 NET 99 ± 15 43 ± 3 43 ± 8 51 ± 11 45 ± 15 6.8 ± 2.4 -- -- 14 ± 1 7.2 ± 1.4 
 SIS 96 ± 2 46 ± 6 22 ± 4 74 ± 2 63 ± 5 6.5 ± 0.4 8.6 ± 2.0 1.6 ± 0.7 -- 2.7 ± 0.8 
 TOB 92 ± 7 109 ± 6 76 ± 14 130 ± 15 125 ± 8 32 ± 1 33 ± 3 7.9 ± 5.0 13 ± 2 7.9 ± 0.3 
AAC(6')-IIdb AMK 96 ± 6 63 ± 2 72 ± 4 28 ± 2 3.1 ± 1.2 0.72 ± 0.18 -- -- -- -- 
 GEN 119 ± 6 77 ± 9 122 ± 4 87 ± 5 86 ± 4 47 ± 9 38 ± 8 -- -- -- 
 KAN 96 ± 7 35 ± 13 95 ± 7 76 ± 1 27 ± 4 6 ± 3 2.0 ± 0.1 -- -- -- 
 NEO 95 ± 5 34 ± 2 125 ± 1 78 ± 3 35 ± 0.4 11 ± 4 9.9 ± 1.1 -- -- -- 
 NET 96 ± 6 47 ± 9 132 ± 2 101 ± 13 46 ± 3 6.5 ± 0.4 13 ± 2 -- -- -- 
 SIS 103 ± 2 84 ± 11 110 ± 1 77 ± 2 84 ± 2 14 ± 1 41 ± 3 -- -- -- 
 TOB 90 ± 23 26 ± 2 130 ± 15 110 ± 29 38 ± 15 12 ± 2 16 ± 3 -- -- -- 
Eisa AMK 73 ± 9 110 ± 1 87 ± 6 55 ± 5 41 ± 5 50 ± 2 41 ± 4 23 ± 10 22 ± 5 18 ± 2 
 KAN 78 ± 6 101 ± 8 102 ± 8 34 ± 8 10 ± 2 11 ± 3 12 ± 0.1 19 ± 1 18 ± 3 20 ± 3 
 NEO 98 ± 2 98 ± 3 90 ± 3 69 ± 4 29 ± 1 12 ± 1 11 ± 2 18 ± 1 4.5 ± 0.6 4.2 ± 0.1 
 NET 130 ± 2 115 ± 15 75 ± 14 58 ± 10 50 ± 13 33 ± 6 30 ± 4 41 ± 5 14 ± 5 19 ± 2 
 SIS 71 ± 2 107 ± 5 96 ± 3 45 ± 1 61 ± 6 41 ± 7 37 ± 4 46 ± 6 5.9 ± 3.7 -- 
 TOB 68 ± 1 130 ± 8 107 ± 8 109 ± 11 12 ± 5 26 ± 4 20 ± 5 28 ± 5 13 ± 1 13 ± 2 
-- Indicates that no enzymatic activity was detected. 
X Indicates that the Au3+ precipitated in HEPES pH 7.5 buffer in the presence of DTDP. 
a Reactions monitored by absorbance of reacted DTNB at 412 nm. 
b Reactions monitored by absorbance of reacted DTDP at 324 nm. 
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Table 3.1 cont. Summary of inhibition of various AAC enzymes by metal salts in combination with different AGs (Note: these data 
are presented in Figures 3.2 and 3.3). 
Enzyme AG Metal 
  Zn(OAc)2 ZnCl2 ZnBr2 ZnSO4 CdCl2 CdSO4 AuCl3 
AAC(2')-Ica GEN 87 ± 4 73 ± 13 57 ± 3 83 ± 7 88 ± 2 74 ± 1 -- 
 NEO 85 ± 7 60 ± 4 49 ± 7 80 ± 3 80 ± 1 72 ± 6 6.5 ± 1.7 
 NET 71 ± 8 71 ± 7 12 ± 3 58 ± 4 51 ± 3 21 ± 2 1.5 ± 0.1 
 SIS 59 ± 1 74 ± 5 70 ± 6 89 ± 11 64 ± 8 57 ± 5 10 ± 1 
 TOB 60 ± 3 62 ± 8 32 ± 5 66 ± 5 63 ± 6 44 ± 5 38 ± 1 
AAC(3)-Iaa GEN 4.2 ± 1.1 -- 2.1 ± 1.1 6.8 ± 2 3.7 ± 0.8 3.9 ± 0.9 -- 
 NET 15 ± 5 13 ± 3 11 ± 4 8.8 ± 1.1 7.3 ± 1.7 13 ± 0.2 28 ± 6 
 SIS 2.8 ± 1.4 2.0 ± 0.8 3.3 ± 1.1 1.6 ± 0.7 3.3 ± 1.1 3.6 ± 1.4 -- 
AAC(3)-Iba GEN 7.7 ± 4.2 1.9 ± 0.7 -- -- -- -- 74 ± 9 
 SIS 9.7 ± 3.9 -- 9.2 ± 3.1 -- 7.1 ± 3.4 4.2 ± 3.1 75 ± 5 
AAC(3)-IVa GEN 3.2 ± 0.3 1.9 ± 0.3 2.9 ± 0.4 27 ± 3 1.4 ± 0.3 1.2 ± 0.3 --  
 NEO 2.8 ± 0.8 2.5 ± 0.7 2.4 ± 0.7 15 ± 2 1.6 ± 0.7 1.1 ± 0.1 19 ± 3 
 NET 7.9 ± 0.4 5.2 ± 1.1 4.1 ± 0.6 32 ± 1 2.8 ± 0.3 3.6 ± 1.5 23 ± 0.3 
 SIS 4.1 ± 0.2 2.9 ± 0.3 3.4 ± 0.5 59 ± 1 1.5 ± 0.3 0.7 ± 0.3 5.8 ± 2.2 
 TOB 1.5 ± 0.3 2.9 ± 0.6 2.7 ± 0.4 39 ± 5 0.7 ± 0.4 1.1 ± 0.4 20 ± 3  
AAC(6')-Ib'b AMK 8.8 ± 2.7 1.3 ± 0.6 1.6 ± 0.2 7.5 ± 4.0 -- -- X 
 GEN -- 16 ± 4 5.5 ± 1.5 8.6 ± 0.2 2.4 ± 0.6 -- X 
 KAN -- 15 ± 3 5.1 ± 0.8 6.5 ± 2.4 6.0 ± 2.4 9.7 ± 3.4 X 
 NEO -- 5.2 ± 0.6 2.6 ± 0.4 3.8 ± 0.9 1.5 ± 0.4 2.9 ± 1.6 X 
 NET -- 5.5 ± 2.0 5.1 ± 0.2 13 ± 5 5.5 ± 1.9 5.0 ± 2.1 X 
 SIS -- 4.8 ± 0.5 5.1 ± 0.7 3.0 ± 0.5 4.8 ± 1.3 5.0 ± 0.8 X 
 TOB -- 13 ± 1 2.2 ± 0.1 4.3 ± 1.2 1.5 ± 0.4 2.3 ± 0.2 X 
AAC(6')-Iea AMK 1.7 ± 0.4 8.5 ± 0.8 2.9 ± 2.1 9.7 ± 1.4 9.3 ± 1.7 7.5 ± 2.1 54 ± 7 
 GEN -- 12 ± 2 4.9 ± 1.8 5.7 ± 1.7 4.9 ± 0.9 0.61 ± 0.21 38 ± 13 
 KAN 11 ± 4 4.4 ± 0.1 9.2 ± 3.3 14 ± 7 13 ± 5 19 ± 8 -- 
 NEO 5.8 ± 0.3 4.9 ± 1.6 6.6 ± 0.8 3.5 ± 1.0 0.67 ± 0.10 0.99 ± 0.44 41 ± 2 
 NET 3.0 ± 1.2 -- 26 ± 11 -- 4.9 ± 3.5 10 ± 4 87 ± 9 
 SIS 3.1 ± 0.7 3.2 ± 0.9 -- 0.62 ± 0.05 4.9 ± 0.6 0.44 ± 0.10 31 ± 18 
 TOB 10 ± 2 16 ± 3 4.7 ± 1.6 -- 6.8 ± 3.3 5.3 ± 2.3 106 ± 30 
AAC(6')-IIdb AMK 13 ± 5 1.5 ± 0.5 2.9 ± 0.3 2.4 ± 0.7 0.91 ± 0.36 1.1 ± 0.1 X 
 GEN -- 20 ± 2 12 ± 1 29 ± 4 13 ± 6 12 ± 2 X 
 KAN -- 8.6 ± 3.2 2.5 ± 0.6 7.4 ± 0.7 1.4 ± 0.4 3.1 ± 0.1 X 
 NEO 27 ± 8 9.9 ± 1.1 4.4 ± 1.4 1.4 ± 0.2 4.3 ± 1.7 3.7 ± 1.7 X 
 NET 6.3 ± 2.8 5.7 ± 2.3 8.6 ± 0.02 6.3 ± 1.7 0.34 ± 0.02 6.5 ± 0.4 X 
 SIS 9.8 ± 2.3 5.9 ± 1.1 12 ± 2 6.8 ± 1.6 11 ± 7 5.0 ± 1.7 X 
 TOB -- 11 ± 2 17 ± 3 10 ± 4 8.5 ± 1.8 8.1 ± 1.7 X 
Eisa AMK 57 ± 2 57 ± 2 48 ± 1 60 ± 12 23 ± 4 23 ± 2 3.9 ± 1.7 
 KAN -- 10 ± 1 10 ± 2 43 ± 3 4.4 ± 0.6 7.2 ± 1.8 -- 
 NEO 4.2 ± 0.8 6.5 ± 2.2 2.1 ± 0.2 67 ± 3 -- -- -- 
 NET 19 ± 3 23 ± 1 20 ± 1 87 ± 11 4.2 ± 0.9 6.3 ± 1.4 -- 
 SIS 5.5 ± 2.2 7.5 ± 0.4 5.1 ± 0.8 97 ± 10 -- -- -- 
 TOB 5.4 ± 2.1 5.5 ± 1.1 4.9 ± 1.2 68 ± 10 -- 3.0 ± 0.4 -- 
-- Indicates that no enzymatic activity was detected. 
X Indicates that the Au3+ precipitated in HEPES pH 7.5 buffer in the presence of DTDP. 
a Reactions monitored by absorbance of reacted DTNB at 412 nm. 
b Reactions monitored by absorbance of reacted DTDP at 324 nm. 
 
To investigate if the metal salts would react similarly under physiological conditions, we 
tested our best overall inhibitor candidates, Cu2+ and Zn2+ salts, in the presence of 100 mM 
NaCl (Figures 3.2 and 3.3). We observed no significant difference between the enzyme 
activity with and without physiological concentration of NaCl in the presence of different 
metal ions. AAC(6')-Ie, as well as AAC(6')-Ib' and AAC(6')-IId (with Zn2+ salts), showed 
complete inhibition when tested against AMK and KAN in the presence of NaCl, indicating 
 
 77 
that at physiological conditions these metal salts could be even better inhibitors. It is 
important to note that AAC(6')-Ib' and AAC(6')-IId were not tested with Cu2+ salts due to 
solubility issues. 
 
We next determined the half maximum inhibitory concentration (IC50) values for selected 
salts that showed complete inhibition in our UV-Vis assays (Table 3.2 and Figure 3.5). 
With the exception of AAC(3)-IV in the presence of NEO where the IC50 values for ZnCl2, 
Zn(OAc)2, and ZnBr2 were 44 ± 19 µM, 34 ± 8 µM, and 17 ± 5 µM, respectively, Zn2+ 
salts were found to display low IC50 values ranging from 0.04 ± 0.01 µM to 7.8 ± 1.7 µM 
against all enzymes. For the inhibition of AAC(3)-IV by Cd2+ salts, IC50 values of 7.3 ± 
2.7 µM and 8.7 ± 1.7 µM were determined for CdCl2 in the presence NEO and CdSO4 in 
the presence of netilmicin (NET), respectively. Cd2+ salts were found to be much better 
inhibitors of AAC(6')-Ib' and Eis with IC50 values ranging from 0.41 ± 0.03 µM to 0.79 ± 
0.10 µM. AuCl3 was found to display the biggest range of IC50 values (0.010 ± 0.003 µM 
to 121 ± 26 µM). 
 
Finally, to elucidate the potential mechanism by which these metal ions inhibit the AAC 
activities, we tested whether the effect metal ions exert on AAC activity is reversible. We 
added EDTA to the reactions to chelate the metal inhibitors and found that the presence of 
EDTA can restore enzyme activity against AG substrates, potentially by chelating the metal 
ions and preventing them from interfering with the enzymatic reaction between the AACs 
and AGs (a representative graph was shown in Figure 3.5). 
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Table 3.2. IC50 values of some for the various metal ions that have 
shown complete inhibition in UV-Vis assays against various AACs 
in combination with different AGs. 
Enzyme AG Metal ion IC50 (µM) 
AAC(2')-Ica GEN AuCl3 12 ± 3 
AAC(3)-Iaa GEN ZnCl2 1.4 ± 0.3 
AAC(3)-Iba SIS ZnCl2 0.13 ± 0.02 
  ZnSO4 1.4 ± 0.2 
AAC(3)-IVa NEO ZnCl2 44 ± 19 
  Zn(OAc)2 34 ± 8 
  ZnBr2 17 ± 5 
  CdCl2 7.3 ± 2.7 
 NET CdSO4 8.7 ± 1.7 
 TOB CuSO4 0.35 ± 0.14 
AAC(6')-Ib'b AMK CdSO4 0.41 ± 0.08 
  AuCl3 0.41 ± 0.07 
 SIS Zn(OAc)2 7.8 ± 1.7 
AAC(6')-Iea SIS ZnBr2 0.41 ± 0.08 
 TOB ZnSO4 5.2 ± 1.3 
Eisa KAN AuCl3 7.7 ± 2.3 
 NET AuCl3 18 ± 1 
 SIS CdCl2 0.78 ± 0.09 
  CdSO4 0.79 ± 0.10 
  AuCl3 121 ± 26 
 TOB Zn(OAc)2 0.04 ± 0.01 
  CdCl2 0.41 ± 0.03 
  AuCl3 0.010 ± 0.003 
a Reactions were monitored by recording the absorbance at 412 nm 
with DTNB. bReactions were monitored by recording the 
absorbance at 324 nm with DTDP. 
 
 
Figure 3.4. Representative IC50 plot. The example provided is that of the IC50 value of AuCl3 against Eis 
in combination with NET. 
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Figure 3.5. Representative graph demonstrating that addition of EDTA restored the ability of AACs to 
acetylate AGs as the metal ions were chelated. The green squares represent the reaction where EDTA 
chelated the metal ions. The orange circles indicate the reaction where the N-acetylation of AGs was 
inhibited by metal ions. The yellow triangles represent the standard N-acetylation of AGs by AACs. 
 
3.2.2. Profiling of resistance enzymes in clinical isolates of various bacterial strains 
To gain a better understanding of the profile of AMEs that are present in the different 
bacterial strains involved in our study, we performed PCR with primers that amplify the 
genes for four different AMEs, AAC(6')-Ib, AAC(3)-IV, ANT(2")-Ia, and APH(3')-Ia, in 
twelve bacterial strains from ATCC and clinical isolates (Figure 3.6). In all the A. 
baumannii strains (ATCC 19606, clinical isolates #75 and #81), we identified the presence 
of aac(6')-Ib and aph(3')-Ia. In the E. cloacae ATCC 13047 strain, we did not find any of 
the four AME genes. However, we found ant(2")-Ia gene in E. cloacae clinical isolates 
#41 and #61, and aph(3')-Ia in clinical isolate #52. For the five K. pneumoniae strains, we 
found aac(6')-Ib, aac(3)-IV, and aph(3')-Ia in clinical isolate strains #22, #34, and #44. 
The K. pneumoniae ATCC 27736 strain only possessed aph(3')-Ia. Clinical isolate #24 
possessed aac(6')-Ib and aac(3)-IV. 
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3.2.3. Activity of AGs in combination with ZnPT in various bacterial strains 
Since Zn2+ was overall a great metal ion inhibitor in our study, we decided to further 
investigate Zn2+ for its effect on the MIC values of AMK or TOB against strains of A. 
baumannii, E. cloacae, and K. pneumoniae. After discovering that ZnCl2 had no effect on 
the MIC values of AMK and TOB against A. baumannii, possibly due to poor intracellular 
Zn2+ concentration, we decided to use ZnPT, an organic zinc complex, that was previously 
reported to have improved membrane permeability.17 This study showed that the presence 
of ZnPT significantly reduced the MIC values of AMK and TOB in most of the twelve 
bacterial strains that we tested (Tables 3.3 and 3.4).	
 
Table 3.3. MIC values of AMK (µg/mL) in the presence of various concentrations of ZnPT against various Gram-negative bacterial 
strains. 
 A. baumannii E. cloacae K. pneumoniae 
[ZnPT] (µM) ATCC 19606 #75 #81 ATCC 13047 #41 # 52 #61 ATCC 27736 #22 #24 #34  #44 
80 ≤0.06 NG NG NG NG NG NG NG NG NG NG NG 
40 ≤0.06 NG NG NG NG NG NG 0.5 NG NG NG NG 
20 0.25 ≤0.25 0.25 NG NG NG 4 0.5 NG 4 NG NG 
10 0.5 >128 1 0.5 1 NG 4 2 8 4 NG NG 
5 2 >128 2 2 8 1 4 4 8 4 0.25 1 
2.5 2 >128 1 2 8 >2 8 8 32 8 0.5 16 
1.25 2 >128 1 2 8 >2 >8 8 32 16 0.5 16 
0 4 >128 4 2 8 >2 >8 16 32 16 2 >16 
NG = no growth. 
 
Table 3.4. MIC values of TOB (µg/mL) in the presence of various concentrations of ZnPT against various Gram-negative bacterial 
strains. 
 A. baumannii E. cloacae K. pneumoniae 
[ZnPT] (µM) ATCC 19606 #75 #81 ATCC 13047 #41 # 52 #61 ATCC 27736 #22 #24 #34  #44 
80 NG NG NG NG NG NG NG NG  NG NG NG NG 
40 ≤0.0313 NG NG NG NG NG 8 ≤0.0313 NG NG NG NG 
20 ≤0.0313 NG NG NG >8 NG 8 ≤0.0313 NG NG NG NG 
10 ≤0.0313 NG NG 1 >8 4 >8 ≤0.0313 8 4 NG 8 
5 0.5 >8 1 1 >8 4 >8 0.5 128 128 0.0094 128 
2.5 0.5 >8 1 1 >8 8 >8 0.5 >128 128 0.038 128 
1.25 1 >8 1 1 >8 8 >8 0.5 >128 128 0.075 128 
0 1 >8 2 1 >8 8 >8 2 >128 128 0.038 >128 
NG = no growth. 
 
 81 
 
Figure 3.6. Agarose gels of PCR reactions probing for AME genes in various ATCC strains and 
clinical isolates. Strains of A. A. baumannii, B. E. cloacae, and C. K. pneumoniae tested for aac(6')-
Ib (lanes 1), aac(3)-IV (lanes 2), ant(2")-Ia (lanes 3), and aph(3')-Ia (lanes 4) genes. L1 and L2 
represent 100 bp and 1 kb DNA ladders, respectively. Expected band sizes are as follow: aac(6')-
Ib = 482 bp; aac(3)-IV = 230 bp; ant(2")-Ia = 534 bp; and aph(3')-Ia = 624 bp. 
 
Against A. baumannii ATCC 19606 as well as clinical isolate #81, the MIC value of AMK 
was reduced from 4 µg/mL to 0.25 µg/mL in the presence of 20 µM ZnPT (Table 3.3). 
With the same amount of ZnPT, the MIC value of AMK was reduced from >128 µg/mL to 
≤0.25 µg/mL against A. baumannii clinical isolate #75. The same trend held true against 
the E. cloacae and K. pneumoniae strains. Against E. cloacae clinical isolate #41, the MIC 
value of AMK was reduced from 8 µg/mL to 1  µg/mL in the presence of 10 µM ZnPT. 
Against the other strains (E. cloacae ATCC 13047, #52, and #61), the AMK MIC values 
were reduced from 2  µg/mL to 0.5  µg/mL, >2  µg/mL to 1 µg/mL, and >8  µg/mL to 4 
 µg/mL in the presence of 5-10 µM ZnPT, respectively. Against K. pneumoniae strains, 4-
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32-fold reductions in the MIC values of AMK were observed in the presence of 5-20 µM 
ZnPT. 
 
The reduction in MIC values in the presence of ZnPT was also observed for TOB against 
most strains tested (Table 3.4). Against the different A. baumannii strains, the MIC values 
of TOB were reduced from 1  µg/mL to ≤0.0313  µg/mL (ATCC 19606), and from 2 
 µg/mL to 1  µg/mL (clinical isolate #81) in the presence of 10 µM and 1.25 µM ZnPT, 
respectively. Yet, against clinical isolate #75, the MIC value of TOB went from >8  µg/mL 
to no growth in the control wells, suggesting that ZnPT had no effect on the MIC of TOB 
in this strain. This was similarly observed against the E. cloacae ATCC 13047 and clinical 
isolates #41 and #61. Against the E. cloacae clinical isolate #52, the MIC value of TOB 
was reduced from 8  µg/mL to 4  µg/mL with 5 µM ZnPT. Against K. pneumoniae ATCC 
27736 and clinical isolates #22, #24, and #44, 10 µM ZnPT effectively reduced the MIC 
values of TOB from 2  µg/mL to ≤0.0313  µg/mL, >128  µg/mL to 8 µg/mL, 128  µg/mL 
to 4  µg/mL, and >128  µg/mL to 8  µg/mL, respectively. Against K. pneumoniae clinical 
isolate #34, the MIC value of TOB was reduced from 0.038  µg/mL to 0.0094  µg/mL in 
the presence of 5 µM ZnPT. 
 
3.3. DISCUSSION 
To investigate their inhibitory effect on eight AACs, we tested a panel of nine metal ions 
(in different salt forms) and studied their interference in modifying seven AGs (AMK, 
GEN, KAN, NEO, NET, SIS, and TOB) (Figures 3.2 and 3.3, and Table 3.1). By UV-Vis 
assays, we demonstrated that Cu2+ is overall the best at inhibiting the different AACs 
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studied. We found Zn2+ and Cd2+, which also showed significant inhibition of most 
enzymes, to be the second best candidates as AAC inhibitors. Although metal salts were 
found to be good inhibitors of AACs, the inherent toxicity of some of these metals can 
render them less desirable regardless of their high inhibitory effect. Despite Zn2+ salts 
falling short in their inhibitory ability compared to Cu2+ salts, Zn2+ salts remain more 
desirable for their potential development into clinical AAC inhibitors as they are amongst 
the least toxic metal salts based on LD50 values (e.g., 794 mg/kg in rats oral intake for 
Zn(OAc)2 compared to 501 mg/kg for Cu(OAc)2; and 1710 mg/kg in rats oral intake for 
ZnSO4 compared to 361 mg/kg for NiSO4, 482 mg/kg for CuSO4, and 280 mg/kg for 
CdSO4). Even though Zn2+ and Cd2+ showed similar inhibitory activity in vitro and 
displayed similar ranges of IC50 values (0.04 ± 0.01 µM to 44 ± 19 µM for Zn2+ salts 
compared to 0.41 ± 0.03 µM to 8.7 ± 1.7 µM for Cd2+ salts; Table 3.2), Zn2+ salts remain 
more clinically relevant, as Cd2+ salts display higher toxicity (LD50 values of 107 mg/kg 
and 280 mg/kg for CdCl2 and CdSO4, respectively, in rats oral intake). 
 
It is known that Cl- salts are inherently more toxic than some other salt forms. Within the 
Zn2+ salt family, the toxicity of ZnCl2 and Zn(OAc)2 (LD50 values of 359 mg/kg, 794 mg/kg, 
1447 mg/kg, and 1710 mg/kg for ZnCl2, Zn(OAc)2, ZnBr2, and ZnSO4, respectively, in rats 
oral intake) and the failure of the less toxic ZnSO4 at inhibiting some AACs render ZnBr2 
the most desirable amongst the Zn2+ salts studied. Within the Cu2+ salts, NO3- seems to be 
a safer counter ion than SO42- and OAc- (LD50 values of 482 mg/kg, 501 mg/kg, and 940 
mg/kg for CuSO4, Cu(OAc)2, and Cu(NO3)2, respectively). As for gold salts, even though 
gold is generally known to be toxic and expensive, it is currently part of therapies for 
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diseases such as rheumatoid arthritis.29 Given that no other metal ions worked as well as 
gold at inhibiting the AAC(2')-Ic enzyme, gold should not be dismissed as a potential 
candidate to combat the resistance associated with this enzyme. 
 
Having established Zn2+ salts as top candidates for AAC inhibition, we set to determine 
their effect on the activity of AGs in various bacterial strains of A. baumannii, E. cloacae, 
and K. pneumoniae. Prior to working in bacterial cells, we demonstrated that the presence 
of NaCl, at concentration mimicing that of physiological conditions, did not interfere with 
the inhibitory effect of the metal ion salts on AACs (Figures 3.2 and 3.3). We also showed 
that in the presence of EDTA, the inhibitory effect of the metal ions on the AACs could be 
reversed as EDTA, a strong metal chelating agent, sequestered the metal ions from the 
enzymatic reactions (Figure 3.5). 
 
Within each bacterial species selected for our studies with Zn2+ salts, we included one 
commercially purchased ATCC strain as well as a few clinical isolates. We chose some 
clinical isolates displaying susceptibility to the three commonly prescribed AGs (AMK, 
GEN, and TOB) and some displaying resistance to these drugs (Table 3.5). Overall, all 
clinical isolates selected displayed a complex resistance profile to a variety of clinically 
relevant antibiotics, including different classes and generations of b-lactams, 
fluoroquinolones, tetracycline, etc. With their specific resistance against AGs in mind, we 
probed these strains for four AME genes, aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia 
(Figure 3.6). The aph(3')-Ia gene was found to be the most prevalent, and was present in 
eight out of twelve strains. The second most prevalent AME gene was aac(6')-Ib, which 
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was present in seven strains. In addition, different species seemed to possess distinct 
profiles of AME genes. All A. baumannii strains tested possessed aac(6')-Ib and aph(3')-
Ia, but not aac(3)-IV and ant(2")-Ia. In the five K. pneumoniae strains, we found that 
aac(6')-Ib, aac(3)-IV, and aph(3')-Ia were the most predominant AME genes, whereas 
ant(2")-Ia was not found. In contrast to the first two bacterial species, which mostly rely 
on aph(3')-Ia and aac(6')-Ib for resistance, the E. cloacae that were tested clearly possessed 
a different set of AMEs. None of the E. cloacae strains tested encoded either AACs, only 
one clinical isolate contained aph(3')-Ia, and two contained ant(2")-Ia. These data, when 
compared to the MIC values of AMK and TOB (Tables 3.3 and 3.4), suggested that these 
strains possess additional AMEs that we did not probe for, or alternative resistance 
mechanisms. 
 
Table 3.5. Resistance profiles of clinical isolates (isolate # into parenthesis) against the three AGs used for treatment of systemic 
infections in the U.S.A. as well as other clinically relevant antibiotics. 
Strain AMK GEN TOB AZA CFPM CFX CFZ CEFX CIP LEV MEM NTF TET 
A. baumannii (75) >128 >8 >8 >16 >16 >16 >16 >32 0.2 >4 >8 >64 >8 
A. baumannii (81) 4 8 ≤2 >16 >16 >16 >16 >32 >2 >4 >8 >64 >8 
E. cloacae (41) 8 >8 >8 >16 >16 >16 >16 >32 1 ≤1 >8 64 >8 
E. cloacae (52) 1-2 8 >8 >16 16 >16 8 >32 >2 >4 >8 32 8 
E. cloacae (61) 4-8 >8 8 >16 ≤1 >16 >16 16 >2 >4 ≤1 >64 8 
K. pneumoniae (22) 32 >8 >8 >16 >16 >16 >16 >32 >2 >4 ≤1 >64 >8 
K. pneumoniae (24) 16 8 >8 >16 16 >16 >16 >32 >2 >4 2 >64 4 
K. pneumoniae (34) 1 ≤2 ≤2 ≤2 ≤1 ≤4 2 >32 ≤0.5 ≤1 ≤1 64 ≤2 
K. pneumoniae (44) 16 >8 >8 >16 ≤1 >16 >16 >32 >2 >4 >8 >64 >8 
AZA = aztreonam; CFPM = cefepime; CFX = cefoxitin; CFZ = ceftazidime; CEFX = ceftriaxone; CIP = ciprofloxacin; LEV = 
levofloxacin; MEM = meropenem; NTF = nitrofurantoin; TET = tetracycline. 
 
When we tried to determine the MIC values of AMK and TOB against A. baumannii in the 
presence of ZnCl2, we quickly realized that the Zn2+ salts studied had no effect on the MIC 
values of these AGs. We postulated that this could possibly be due to poor intracellular 
Zn2+ concentration resulting from the poor membrane permeability of these salts. We 
therefore decided to use ZnPT, a membrane permeable organic zinc complex. We found 
ZnPT to significantly reduce the MIC values for both AGs in most strains tested. Of the A. 
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baumannii strains, the ATCC 19606 and clinical isolate #81 are both susceptible to AMK. 
Co-treating with 40 µM of ZnPT reduced the MIC value of AMK by 67-fold against the 
ATCC 19606 strain, whereas using 20 µM of ZnPT reduced the MIC value of AMK by 
16-fold against clinical isolate #81. The most significant effect was observed against 
clinical isolate #75, which was resistant to AMK (>128 µg/mL) and became highly 
sensitive to this AG (≤0.25 µg/mL) in the presence of 20 µM ZnPT. Against E. cloacae 
and K. pneumoniae strains, which were all sensitive or displayed intermediate level of 
resistance to AMK to start with, the MIC values of AMK showed as much as a 32-fold 
reduction with 20 µM ZnPT. The resistance profile to TOB is different from that to AMK 
in the strains that we studied. Most of the K. pneumoniae strains (#22, #24, and #44) are 
resistant to TOB while ATCC 27736 and clinical isolate #34, as well as all A. baumannii 
and E. cloacae strains are susceptible to this AG. Although not as significant as those 
observed in AMK, the reductions in the MIC values of TOB were still observed against 
most of these strains. Although we established the benefit of co-administering metal ions 
with AGs for the purpose of re-activating AGs in resistance bacterial strains, we believe 
that it is critical to not dismiss the bacteriostatic attribute of ZnPT. We postulate that in 
addition to the inhibitory effect from the Zn2+, there may also be a synergistic effect from 
the bacteriostatic feature of ZnPT. Further studies outside of the scope of this chapter will 
be required to help elucidate the intracellular mechanism of ZnPT in the presence or 
absence of AGs. 
 
 
 
 
 87 
3.4. CONCLUSIONS 
In sum, we showed that Zn2+ and other metal ions are capable of inhibiting the AG N-
acetyltransferase activity of a variety of AACs in vitro. Developing metal salts into AAC 
inhibitors for combinatorial therapies with AGs is potentially a promising avenue for 
improving the clinical outcomes of AGs in treatment of resistant bacterial infections 
resulting from the action of AAC enzymes. The mechanism(s) by which these metal ions 
inhibit AACs is still unknown. Future studies aimed at elucidating the potential 
mechanism(s) underlying this inhibition would further enhance our understanding and help 
combat bacterial resistance in clinical therapeutic regiments. 
 
3.5. MATERIALS AND METHODS 
3.5.1. Materials and instrumentation 
With the exception of AAC(3)-Ia for which the cloning, overexpression, and purification 
is described below, all of the enzymes involved in this study, AAC(2')-Ic,8 AAC(3)-Ib,30 
AAC(3)-IV,31 AAC(6')-Ie/APH(2'')-Ia,31 AAC(6')-Ib',30 AAC(6')-IId,32 and Eis8 were 
expressed and purified as previously described. Herein, AAC(6')-Ie/APH(2'')-Ia was 
studied solely for its AAC(6') activity and is referred to as AAC(6')-Ie throughout the 
manuscript. The S. marcescens genomic DNA used to clone AAC(3)-Ia was a gift from Dr. 
Paul H. Roy (Université Laval, QC, Canada). Primers for PCR were purchased from IDT 
(Coralville, IA). Ladders for DNA agarose gels as well as cloning enzymes, including 
Phusion DNA polymerase, restrictive endonucleases, and T4 DNA ligase were purchased 
from New England BioLabs (NEB; Ipswich, MA). The pET28a vector was purchased from 
Novagen (Gibbstown, NJ). TOP10 and BL21 (DE3) chemically competent E. coli cells 
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were purchased from Invitrogen (Carlsbad, CA). The NiII-NTA resin used for affinity 
chromatography was purchased from Qiagen (Valencia, CA). The AcCoA, DTDP, DTNB, 
all metal salts (MgCl2, CrCl3, CrO3, MnSO4, CoCl2, NiCl2, NiSO4, Cu(OAc)2, Cu(NO3)2, 
CuSO4, Zn(OAc)2, ZnCl2, ZnBr2, ZnSO4, CdCl2, CdSO4, and AuCl3), and the AGs AMK, 
GEN, and SIS were purchased from Sigma-Aldrich (Milwaukee, WI). The AGs KAN, 
NEO, NET, and TOB were purchased from AK Scientific (Mountain View, CA). 96-Well 
plates were purchased from Thermo Fisher Scientific (Waltham, MA). UV-Vis assays were 
monitored on a multimode SpectraMax M5 plate reader. 
 
Previously identified bacterial strains were obtained from the ATCC, including A. 
baumannii ATCC 19606, E. cloacae ATCC 13047, and K. pneumoniae ATCC 27736. 
Clinical isolates of A. baumannii (isolates #75 and #81), E. cloacae (isolates #41, #52, and 
#61), and K. pneumoniae (isolates #22, #24, #34, and #44) were obtained from the 
microbiology laboratory at the University of Kentucky Hospital System. Known resistance 
profiles of the clinical isolates are presented in Table 3.5. 
 
3.5.2. Cloning, overexpression, and purification of AAC(3)-Ia (NHis) 
The aac(3)-Ia gene was PCR amplified from S. marcescens genomic DNA by using 
forward primer 5'-CGATACCATATGTTACGCAGCAGCAACGATG-3' and reverse 
primer 5'-TTGAACCTCGAGTTAGGTGGCGGTAC-3'. The amplified fragment was 
digested by using the NdeI and XhoI restriction enzymes (cut sites are underlined in the 
primer sequences) and ligated into the linearized pET28a vector. The ligated pAAC(3)-Ia-
pET28a plasmid was transformed into E. coli TOP10 chemically competent cells for 
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plasmid replication and then into E. coli BL21 (DE3) chemically competent cells for 
protein overexpression. After confirmation of its DNA sequence, a fresh transformant of 
the pAAC(3)-Ia-pET28a plasmid was grown in LB broth (KAN 50 µg/mL) (3 L) at 37 °C 
with shaking at 200 rpm until the optical density at an attenuance of 600 nm reached 0.6. 
The protein expression was induced with 1 mM IPTG (final concentration). After induction, 
bacteria were kept growing overnight at 20 °C. The desired AAC(3)-Ia protein was then 
purified using NiII-NTA affinity column chromatography in 25 mM Tris-HCl pH 8.0 
(adjusted at rt), 200 mM NaCl, and 10% glycerol with a gradient of imidazole (10 mL of 5 
mM, 3 × 5 mL each of 20 mM, 40 mM and 200 mM). Pure fractions, as determined by 
SDS-PAGE (Figure 3.7), were dialyzed in Tris-HCl (50 mM, pH 8.0), NaCl (300 mM), 
and glycerol (10%), flash-frozen in liquid nitrogen and stored at -80 °C after concentrating 
using an Amicon (10,000 MWCO) ultra centrifugal filter cellulose protein concentrator. 
Protein purification yielded 0.5 mg of AAC(3)-Ia per L of culture. 
 
 
Figure 3.7. SDS-PAGE gel of NHis6-tagged AAC(3)-Ia (19.4 kDa) purified by NiII-NTA 
chromatography. 
 
3.5.3. Determination of inhibition of AAC enzymes by various metal salts 
To determine the inhibition of various AACs by different metal salts, we performed UV-
Vis assays in 96-well plates. Each reaction (200 µL) contained metal salts (1 mM), AGs 
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(100 µM), AcCoA (500 µM for Eis and 150 µM for all other AACs), indicator (DTNB or 
DTDP, 2 mM), and enzyme (0.5 µM for AAC(6') enzymes, AAC(3)-Ib, AAC(3)-Ia, and 
Eis or 0.125 µM for AAC(2')-Ic and AAC(3)-IV) in the appropriate buffer (100 mM 
K2HPO4 for AAC(2')-Ic, 50 mM Tris-HCl pH 8.0 for Eis, 50 mM MES pH 6.6 for AAC(3)-
Ia, AAC(3)-Ib, AAC(3)-IV, and AAC(6')-Ie, and 50 mM HEPES pH 7.5 for AAC(6')-Ib' 
and AAC(6')-IId). The pH of all buffers was adjusted at rt. Reactions were carried out at 
25 °C for all enzymes except for AAC(6')-Ie where reactions were performed at 37 °C. 
DTNB was used to monitor reaction progress with all enzymes, except with AAC(6')-Ib' 
and AAC(6')-IId where DTDP was used. Reactions containing DTDP were monitored at 
324 nm (e = 19,800 M-1cm-1) and those containing DTNB were monitored at 412 nm (e = 
14,150 M-1cm-1). Absorbance was recorded every 30 s for 20 min. Enzyme activities were 
determined by calculating the initial reaction rates using the first 2-5 min of the reaction 
(Figures 3.2 and 3.3, and Table 3.1). NEO and TOB are not substrates of AAC(3)-Ia and 
AAC(3)-Ib. In addition, NET is not a substrate of AAC(3)-Ib. Therefore, these AGs were 
not tested with the two AAC(3)s listed above. All experiments were performed in triplicate. 
 
3.5.4. Determination of potential inhibition mechanism using EDTA 
To investigate whether the inhibition of various AACs by different metal ions is reversible 
and establish whether AAC enzyme activity could be restored by sequestering the metal 
ions from the reactions, we performed assays with EDTA, which served as a strong metal 
ion scavenger. Reactions (200 µL) contained metal salt (1 mM), AG (100 µM), AcCoA 
(150 µM), DTNB (2 mM), EDTA (2 µM, pH 8.0), and AAC(3)-Ib (0.5 µM) or AAC(3)-
IV (0.125 µM). Reactions were carried out in 50 mM MES pH 6.6. The AAC(3)-Ib enzyme 
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was tested with SIS and the metal salts Cu(OAc)2, ZnCl2, and AuCl3. AAC(3)-IV was 
tested with TOB and the salts Cu(OAc)2, ZnCl2, CdSO4, and AuCl3. After the addition of 
the enzyme, the absorbance of each reaction was recorded every 30 s for 20 min (Figure 
3.5). All reactions were performed in triplicate. Three control reactions were performed in 
which the following components were lacking: (i) EDTA (which represented the inhibited 
reactions), (ii) EDTA and metal salts (which represented the standard N-acetylation 
reactions of AGs by AACs to which all other reactions were compared in this study), and 
(iii) EDTA and AGs (which showed that the metal salts did not interfere with the assay 
conditions). 
 
3.5.5. Inhibition of AACs by metal salts at near physiological salt concentration 
To establish if the metal inhibition of AACs is unaffected by the salt concentration found 
physiologically, experiments were performed in the presence of 100 mM NaCl. 
Experiments with Cu2+ and Zn2+ were performed as above for each enzyme, except for Eis 
as its activity is inhibited in the presence of salt, and therefore, was not tested with NaCl. 
AAC(6')-Ib' and AAC(6')-IId were not tested with the Cu2+ salts in the presence of NaCl 
due to solubility issues. Results of these control experiments are presented in Figures 3.2 
and 3.3.  
 
3.5.6. Determination of IC50 values by UV-Vis assays 
For selected metal salts that showed complete inhibition of the AAC activities against 
certain AGs, we determined the IC50 values in combination with the corresponding AGs. 
Assays were performed in 96-well plates with DTNB or DTDP as indicators for specific 
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enzymes as described above. The metal salts were dissolved in appropriate buffers (100 
µL) for each enzyme and a five-fold dilution was performed, making the final 
concentration of the metal salts range from 2.6 pM to 1 mM in the assay. AG and enzyme 
in buffer (50 µL) were then added into each well and incubated for 10 min to allow potential 
positioning or binding of the substrate and/or inhibitor into the enzyme active site. 
Reactions were then initiated by the addition of AcCoA and indicator (50 µL). Reactions 
with AAC(6')-Ie were performed at 37 °C. All other enzymatic reactions were performed 
at 25 °C. Absorbance at 412 nm (for DTNB) or 324 nm (for DTDP) was recorded every 
30 s for 20 min. Initial rates of reaction were calculated using the first 10 min of the reaction 
and expressed as a percentage of the rate of the reaction containing no metal salt inhibitors. 
IC50 values were then calculated using a Hill plot fit with KaleidaGraph 4.1. Experiments 
were performed in duplicate or triplicate. The data with standard errors are summarized in 
Table 3.2 and a sample graph for the IC50 value of AuCl3 against Eis with NET is presented 
in Figure 3.4. 
 
3.5.7. Identification of AMEs in twelve bacterial strains 
To determine the AME genes present in each of the twelve bacterial strains selected (three 
strains of A. baumannii, four of E. cloacae, and five of K. pneumoniae), colonies were 
picked and subjected to PCR analysis. Primer probes used for the aac(6')-Ib, aac(3)-IV, 
ant(2")-Ia, and aph(3')-Ia genes were as previously reported.33 An initial 5 min at 95 °C 
was used to lyse the bacterial cells and denature the DNA. For 35 cycles the samples were 
subjected to 2 min at 95 °C, 1 min at 58 °C, and 1 min at 72 °C. After the 35 cycles, the 
reactions were held at 72 °C for 10 min and then analyzed on a 1.5% agarose gel. Expected 
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band sizes were 482 bp (aac(6')-Ib), 230 bp (aac(3)-IV), 534 bp (ant(2")-Ia), and 624 bp 
(aph(3')-Ia) (Figure 3.6). 
 
3.5.8. Determination of MIC values for combinations of metals and AGs 
MIC values were determined using the double-microdilution method. Various 
concentrations of AGs were combined with different concentrations of ZnPT (0-80 µM) 
and bacteria were grown for 16 h prior to MIC value determination. The AG concentrations 
used varied with each bacterial strain as follow: AMK (0.06-32 µg/mL) with A. baumannii 
ATCC 19606, (0.25-128 µg/mL) with #75, (0.015-8 µg/mL) with #81, (0.063-16 µg/mL) 
with E. cloacae ATCC 13047, (0.015-8 µg/mL) with #41, (0.004-2 µg/mL) with #52, 
(0.015-8 µg/mL) with #61, (0.031-16 µg/mL) with K. pneumoniae ATCC 27736, (0.125-
64 µg/mL) with #22, (0.031-16 µg/mL) with #24, (0.004-2 µg/mL) with #34, and (0.031-
16 µg/mL) with #44; TOB (0.031-16 µg/mL) with A. baumannii ATCC 19606, (0.015-8 
µg/mL) with #75, (0.004-2 µg/mL) with #81, (0.008-4 µg/mL) with E. cloacae ATCC 
13047, (0.015-8 µg/mL) with #41, (0.015-8 µg/mL) with #52, (0.015-8 µg/mL) with #61, 
(0.031-16 µg/mL) with K. pneumoniae ATCC 27736, (0.25-128 µg/mL) with #22, (0.25-
128 µg/mL) with #24, (0.0006-0.3 µg/mL) with #34, and (0.25-128 µg/mL) with #44. For 
combinational studies, the concentration of AGs was varied horizontally on the plate, while 
the metal concentration was varied vertically on the plate. Observed bactericidal 
concentrations were then compared to that of AG or ZnPT (Tables 3.3 and 3.4). 
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Chapter 4. Nucleoside triphosphate cosubstrates control the substrate profile and 
efficiency of aminoglycoside 3'-O-phosphotransferase type IIa 
Aminoglycosides (AGs) are broad-spectrum antibiotics that play an important role in the 
control and treatment of bacterial infections. Despite the great antibacterial potency of AGs, 
resistance to these antibiotics has been limiting their clinical applications. The AG 3'-O-
phosphotransferase of type IIa (APH(3')-IIa) encoded by the neoR gene is a common 
bacterial AG resistance enzyme that inactivates AG antibiotics. This enzyme is used as a 
selection marker in molecular biology research. APH(3')-IIa catalyzes the transfer of the g-
phosphoryl group of ATP to an AG at its 3'-OH group. Although APH(3')-IIa has been 
reported to utilize exclusively ATP as a cosubstrate, we demonstrate that this enzyme can 
utilize a broad array of NTPs. By substrate profiling, TLC, and enzyme kinetics 
experiments, we probe AG phosphorylation by APH(3')-IIa with an extensive panel of 
substrates and cosubstrates (13 AGs and 10 NTPs) for the purpose of gaining a thorough 
understanding of this resistance enzyme. We find, for the first time, that the identity of the 
NTP cosubstrate dictates the set the AGs modified by APH(3')-IIa and the phosphorylation 
efficiency for different AGs. 
 
4.1. INTRODUCTION 
The 2-deoxystreptamine aminoglycosides (2-DOS AGs, Figure 4.1A) are broad-spectrum 
antibiotics that display excellent potency against Gram-positive and Gram-negative 
bacteria as well as Mycobacteria.1-4 As one of the most effective weapons in the combat 
against bacterial infections, these aminocyclic sugars are classified as 4,5- or 4,6-
disubstituted AGs based on the positions of substitution on the 2-DOS core.5 In the U.S.A., 
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amikacin (AMK), gentamicin (GEN), and tobramycin (TOB) are administered 
systemically.6 European countries also employ netilmicin (NET) and sisomicin (SIS) in 
their antibacterial regimens.7 Kanamycin (KAN) is used globally against drug-resistant M. 
tuberculosis infections. In addition to their use as antibiotics, AGs have been widely 
explored as therapeutic options for premature termination codon (PTC) diseases for the 
ability of these drugs to promote readthrough of a PTC to allow biosynthesis of functional 
full-length proteins.8-12 
 
 
Figure 4.1. Structures of A. AGs with their 2-DOS core highlighted in orange, and B. (d)NTPs used in 
this chapter. 
 
Unfortunately, incorrect or non-compliant use of antibiotics or overuse of certain 
antibiotics gave rise to one of the greatest global health threats: antibiotic resistance. 
Bacteria can acquire resistance to AG antibiotics via three mechanisms: by changing the 
cell wall composition, modifying the antibiotic target (in this case the ribosome), and 
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acquiring or upregulating AG-modifying enzymes (AMEs).13 AMEs represent the 
prevalent mechanism of AG resistance. AMEs are represented by three types of enzymes, 
each catalyzing a distinct chemistry: AG N-acetyltransferases (AACs), AG O-
nucleotidyltransferases (ANTs), and AG O-phosphotransferases (APHs).14 APHs transfer 
a phosphoryl group from an NTP (Figure 4.1B) onto a specific OH group of an AG yielding 
a phosphorylated AG and an NDP.15-16 This transfer occurs with the regiospecificity 
dictated by the specific class of the APH indicated in the enzyme name according to the 
AME nomenclature. Such phosphorylation abrogates AG binding to the ribosome, making 
the bacteria highly resistant to that AG. 
 
Harnessing their AG resistance function, researchers have been using APH enzymes as 
antibiotic selection markers in recombinant DNA technology. A subject of the present 
study, APH(3')-IIa, encoded by the neomycin resistance (neoR) gene aph(3')-IIa, has been 
used as an AG resistance marker in molecular biology for decades, providing robust 
selection in AG-containing media.17-19 
 
A key issue to considering AGs as therapies or genetic selection tools is their modification 
by APHs. Therefore, a systematic investigation of the substrate-cosubstrate profile of APH 
enzymes is necessary. As indicated by the nomenclature, APH(3')-IIa and other APH(3') 
enzymes phosphorylate AGs at their 3'-OH group. A partial AG substrate profile of 
APH(3')-IIa was previously reported.20-21 It was previously reported that APH(3')-IIa used 
exclusively ATP, whereas another APH(3') enzyme, APH(3')-Ia, also transferred a 
phosphate from GTP.22 In fact, GTP was used in some in vitro studies of these enzymes.22-
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26 In contrast to APH(3'), some APH(2") enzymes, such as APH(2")-Ia,27 APH(2")-If,28 
and APH(2")-IIIa27, showed a clear preference for GTP. The study of APH(3')-IIa 
described herein addresses the enzyme activity for different substrate-cosubstrate pairs in 
order to help us better understand this resistance enzyme. 
 
4.2. RESULTS AND DISCUSSION 
4.2.1. Determination of AG profile of APH(3')-IIa with various NTPs 
To examine whether and if so, how different NTPs may dictate the AG substrate profile of 
APH(3')-IIa, we measured its AG phosphorylation activity by a well-established UV-Vis 
assay. In this assay, we monitored the conversion of NADH to NAD+ by lactate 
dehydrogenase (LDH) coupled with pyruvate kinase (PK), converting the NDP coproduct 
of the AG phosphorylation back to NTP (Figure 4.2).20, 22, 26, 29 We tested 13 AGs (AMK, 
apramycin (APR), GEN, geneticin (G418), hygromycin (HYG), KAN, neamine (NEA), 
neomycin B (NEO), NET, paromomycin (PAR), ribostamycin (RIB), SIS, and TOB) along 
with 9 NTPs (ATP, dATP, GTP, dGTP, UTP, dUTP, dCTP, TTP, and ITP). Due to the 
lack of a commercially available CTP of sufficient purity for this assay, we had to exclude 
CTP from our assay. In addition to ATP, we found APH(3')-IIa to use 7 out of the 9 
(d)NTPs tested as cosubstrates. We discovered that purine-containing NTPs generally 
supported phosphorylation of a larger number of AGs than did pyrimidine-containing 
NTPs. When ATP was used as a cosubstrate, APH(3')-IIa phosphorylated 7 AGs (AMK, 
G418, KAN, NEA, NEO, PAR, and RIB), amongst which PAR and RIB have not been 
reported previously (Table 4.1). Interestingly, when using GTP as a cosubstrate, we noticed 
that while KAN, NEA, NEO, PAR, and RIB could be readily phosphorylated by APH(3')-
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IIa, the enzyme displayed a much lower activity for G418 and no activity for AMK. Among 
the purine-containing NTPs, ITP supported the narrowest AG profile, with only NEA, NEO, 
PAR, and RIB being efficiently phosphorylated. It was also notable that KAN, while being 
efficiently phosphorylated with ATP or GTP as cosubstrates, was a poor substrate when 
the enzyme was provided with ITP. 
 
 
Figure 4.2. Schematic of the coupled UV-Vis assay used in this study for determination of substrate and 
cosubstrate profiles and kinetics. 
 
Table 4.1. AG substrate profile of APH(3')-IIa with various (d)NTPs. 
 AMK APR GEN G418 HYG KAN NEA NEO NET PAR RIB SIS TOB 
ATP ✓ ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
GTP ✕ ✕ ✕ -- ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
UTP ✕ ✕ ✕ ✕ ✕ -- ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
ITP ✕ ✕ ✕ ✕ ✕ -- ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
dATP -- ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
dGTP -- -- ✕ ✓ -- ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
dCTP ✕ ✕ ✕ ✕ ✕ ✕ -- -- ✕ -- -- ✕ ✕ 
dUTP ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✓ -- ✕ ✕ 
TTP ✕ ✕ ✕ ✕ ✕ ✕ -- -- ✕ -- -- ✕ ✕ 
✓ = Absorbance at 340 nm > 0.1, -- = Absorbance at 340 nm between 0.05-0.1, ✕ = Absorbance at 340 nm < 0.05. 
 
Even though UTP was a pyrimidine-containing NTP, potentially interacting suboptimally 
with the base binding site compared to a purine-containing NTP, such as ITP, the AG 
substrate profile for UTP was identical to that observed for ITP. These observations 
indicate that different perturbations of base structure and size can have similar effects of 
limiting the substrate profile. 
 
To test the effect of the 2'-OH group on the ribose ring, we compared the AG profiles for 
NTP and dNTP as cosubstrates. We found that the AG profiles of the enzyme were similar 
AG AG-
ATP ADP
PEP Pyruvate
NADH
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P
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for dATP and ATP, dGTP and GTP, and dUTP and UTP. As one minor exception, with 
dUTP the enzyme was slightly more active with KAN and slightly less active with RIB 
than with UTP. We found that the dNTPs that were cosubstrates for the most limited sets 
of AGs were dCTP and TTP (note that TTP naturally contains a deoxyribose sugar). This 
was not surprising since both dNTPs contained a monocyclic base that may not engage 
optimally with the enzyme NTP binding site. 
 
4.2.2. Thin-layer chromatography 
In order to visualize directly the phosphoryl transfer activity of APH(3')-IIa, we performed 
TLC experiments (Table 4.2 and Figures 4.3 and 4.4). We first used ATP as a 
representative cosubstrate and carried out reactions with all 13 AGs. For the AGs that were 
observed to be modified by the UV-Vis assay, we made two time-point observations, at 2 
h and at 24 h. For the other AGs, we quenched the reactions only after 24 h. For each AG, 
we also included an AG substrate standard as well as a full reaction that we quenched 
immediately after initiating it (time 0) to confirm that the reaction conditions did not 
interfere with AG migration on TLC plates. 
 
Table 4.2. Summary of TLC results based on whether each AG was phosphorylated by various (d)NTPs with APH(3')-IIa enzyme. 
 AMK APR GEN G418 HYG KAN NEA NEO NET PAR RIB SIS TOB 
ATP ✓ ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
GTP ✓ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
CTP p ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
UTP ✓ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
ITP ✓ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
dATP ✓ ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
dGTP p ✕ ✕ ✓ ✕ p ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
dCTP ✕ ✕ ✕ ✕ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
TTP ✓ ✕ ✕ ✓ ✕ ✓ ✓ p ✕ ✓ ✓ ✕ ✕ 
dUTP ✕ ✕ ✕ ✓ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✕ ✕ 
✓ = phosphorylated, p = partially phosphorylated, ✕ = not phosphorylated. 
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Upon the enzymatic modification of the AGs that were previously found to be accepted by 
the enzyme as a substrate (AMK, G418, KAN, NEA, NEO, PAR, and RIB) we observed 
product species with significantly larger Rf values than those of the respective substrates. 
The AGs that were not observed to be substrates by the UV-Vis assay (APR, GEN, HYG, 
NET, SIS, and TOB) did not display a shift in their Rf values after enzymatic reactions. 
These AGs were either highly structurally distinct (APR, HYG) or they did not contain a 
3'-OH group (GEN, NET, SIS and TOB). These observations were in agreement with the 
AG phosphorylation results obtained by the UV-Vis assay. 
 
 
Figure 4.3. Pictures of TLC plates of APH(3')-IIa reacting with ATP and various AGs as well as the 
corresponding Rf values for each lane. 
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Figure 4.4A. Pictures of TLC plates of APH(3')-IIa reacting with various (d)NTPs and AGs. The 
corresponding Rf values for each lane are listed in Figure 4.4B presented on next page. Note: TLC images 
with ATP and the corresponding Rf values are summarized in Figure 4.3. 
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Figure 4.4B. Rf values for each lane of TLC sample listed in Figure 4.4A presented on the previous page. 
Note: TLC images with ATP and the corresponding Rf values are summarized in Figure 4.3. 
 
As the UV-Vis assay relies on the activity of a coupled enzyme, PK, for conversion of the 
NDP product back to the respective NTP, the inability to observe activity by this assay for 
some nucleotides could be due to the NDP specificity of PK, and not APH(3')-IIa. 
Therefore, we performed TLC with the rest of NTP cosubstrates (24 h time point only, 
Table 4.2 and Figure 4.4). As expected, we found that for all the cosubstrates that were 
shown to support phosphorylation by the UV-Vis assay, the reaction was also observed by 
TLC. In addition, we observed that APH(3')-IIa transferred a phosphoryl group from CTP 
(not tested in previous UV-Vis substrate profile assays) as well as dCTP and TTP, 
indicating that the minimal UV-Vis signal from the coupled enzyme assay was due to PK 
not accepting dCDP and TDP as substrates. Indeed, we did not observe the activity of PK 
when we tested this enzyme with dCDP and TDP in the absence of APH(3')-IIa and AG. 
Furthermore, we observed phosphorylation of AGs in some AG-NTP combinations where 
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no phosphorylation was observed previously in substrate profiling experiment, including 
AMK with GTP, UTP, ITP, dATP, and dGTP (partial), G418 with dUTP, and KAN with 
UTP and ITP. This likely occurred due to the much higher reactant and enzyme 
concentrations as well as a longer reaction time used in the TLC assays. 
 
4.2.3. Determination of enzyme kinetics by UV-Vis assays 
To characterize quantitatively the reaction kinetics for different substrates and cosubstrates, 
we determined the Michaelis-Menten kinetic parameters (Km and kcat) for APH(3')-IIa with 
respect to representative AGs using ATP, GTP, and UTP as cosubstrates at a fixed 
saturating concentration (2 mM). We chose NEO and KAN as representative 4,5- and 4,6-
disubstituted AGs, as they were shown to be good substrates for most NTP cosubstrates. 
We also selected the 4,6-disubstituted AGs AMK and G418, because APH(3')-IIa 
displayed the highest variation in its phosphorylation activity with these AGs among 
different NTPs as cosubstrates. Because APH enzymes characterized to date follow either 
an ordered sequential mechanism, where the NTP binds the enzyme prior to the AG, or a 
random sequential mechanism,15 Km in these experiments can be interpreted in terms of the 
binding affinity of the AG to the enzyme-NTP complex. 
 
We found that with ATP as a cosubstrate, APH(3')-IIa displayed the highest affinity for 
KAN with a Km value of 3.1 ± 0.9 µM (Table 4.3 and Figure 4.5). Of note, even though 
APH(3')-IIa is often referred to as the product of the neoR gene, the Km value for NEO is 
nearly 6-fold higher, 17 ± 4 µM. APH(3')-IIa displayed similar maximum turnover rates of 
phosphorylation of NEO and KAN (kcat = 49 ± 3 min-1 and 34 ± 2 min-1, respectively). As 
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a result, when using ATP as a cosubstrate, the enzyme was found to be more efficient with 
KAN (kcat/Km = 11 ± 3 min-1µM-1) than with NEO (kcat/Km = 2.9 ± 0.7 min-1µM-1). APH(3')-
IIa showed much lower binding affinities for G418 (Km = 113 ± 12 µM) and AMK (Km = 
1040 ± 260 µM) than for NEO and KAN. A likely structural explanation for the lack of 
affinity for AMK and G418 is that the bulky substitutions, such as the (S)-4-amino-2-
hydroxybutyryl (AHB) group at the 1-position of AMK might not fit well into the substrate 
binding pocket (Figure 4.7A). The 6'-amino group of KAN and presumably NEO is bound 
in a negatively-charged environment of the C-terminal carboxyl group, Asp154 and 
Asp157. G418 does not contain a 6'-amino group, lacking a positive charge at this position. 
In addition, the 3"-amino group of G418 is methylated and does not bear a positive charge, 
unlike its non-methylated counterpart in KAN and NEO. This amino group in KAN is in a 
negatively-charged environment of Glu230 (Figure 4.7A). The absence of positive charges 
at 6'- and 3"-positions in G418 is predicted to disfavor its binding. Despite the drastically 
higher Km values, the maximum turnover rates for G418 (kcat = 89 ± 3 min-1) and AMK 
(kcat = 51 ± 7 min-1) were found to be comparable to those for NEO and KAN, indicating 
that the geometry of the phosphoryl transfer reaction was unchanged. Consequently, the 
catalytic efficiencies of the enzyme with AMK (kcat/Km = 0.049 ± 0.014 min-1µM-1) and 
G418 (kcat/Km = 0.79 ± 0.09 min-1µM-1) were lower than with NEO and KAN. 
 
Table 4.3. Kinetic parameters of APH(3')-IIa with respect to AGs. 
AG NTP Km (µM) kcat (min-1) kcat/Km (min-1µM-1) 
KAN ATP 3.1 ± 0.9 34 ± 2 11 ± 3 
 GTP 69 ± 9 6.3 ± 0.3 0.09 ± 0.01 
 UTP 40 ± 6 2.8 ± 0.1 0.07 ± 0.01 
NEO ATP 17 ± 4 49 ± 3 2.9 ± 0.7 
 GTP 23 ± 5 43 ± 2 1.9 ± 0.4 
 UTP 5.4 ± 1.1 10.0 ± 0.4 1.9 ± 0.4 
G418 ATP 113 ± 12 89 ± 3 0.79 ± 0.09 
 GTP 2,172 ± 732 12 ± 2 0.006 ± 0.002 
AMK ATP 1,040 ± 260 51 ± 7 0.05 ± 0.01 
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Interestingly, when we switched the cosubstrate from ATP to GTP, we observed a change 
in the AG binding preference. With GTP, APH(3')-IIa had the highest affinity for NEO 
(Km = 23 ± 5 µM), which was similar to that observed with ATP. Furthermore, the enzyme 
turnover and overall efficiency (kcat = 43 ± 2 min-1 and kcat/Km = 1.9 ± 0.4 min-1µM-1) were 
similar to those observed with ATP as the cosubstrate. These observations indicate that 
GTP binds the enzyme and acts as a phosphoryl donor similarly to ATP in the presence of 
NEO. With GTP, the enzyme had a much weaker, 20-fold lower affinity for KAN (Km = 
69 ± 9 µM) than it did with ATP (see next section for structural rationale). GTP also had a 
deleterious (6-fold) effect on the maximum turnover rate of phosphoryl transfer from GTP 
to KAN: kcat = 6.3 ± 0.3 min-1. It is possible that the dissociation of GDP, if rate limiting, 
as observed for APH(3’)-IIIa,30-31 was slower than that of ADP. The different kcat values 
for the same AG and different NTP cosubstrates can be rationalized as a consequence of 
minor shifts in the positioning and orientation of the g-phosphate of different NTPs, the 
differences in Km values suggest that an allosteric effect of these small changes on 
interactions of the AG with the enzyme. 
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Figure 4.5. Michaelis-Menten graphs with the determined kinetics parameters of APH(3')-IIa with various 
AG substrates and NTP cosubstrates. 
 
When GTP was used as a cosubstrate with G418, the Km value for G418 was 20-fold higher 
(Km = 2172 ± 732 µM) than that measured with ATP as a cosubstrate, indicating that G418 
was a poor substrate for this enzyme. With the much larger Km and smaller kcat (12 ± 2 min-
1) values, the catalytic efficiency for G418 with GTP became more than 100-fold smaller 
than that with ATP as a cosubstrate (kcat/Km = 0.006 ± 0.002 min-1µM-1). Phosphoryl 
transfer from GTP to AMK was below the detection limit. This again indicated that the 
minor chemical differences in NTP transmit to both the catalytic center and the AG binding 
pocket. Overall, these kinetic measurements were consistent with those observed during 
the substrate profile determination (Table 4.1). 
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When we explored the enzyme kinetics for UTP as a cosubstrate, we found that APH(3')-
IIa displayed higher binding affinity and lower turnover rates than with GTP for both KAN 
and NEO, which resulted in similar overall catalytic efficiencies to those observed with 
GTP. It is possible that the pyrimidine base of UTP, while having a favorable allosteric 
effect on the AG binding site, resulted in a slower dissociation of UDP. Alternatively, the 
change from a purine to a pyrimidine base may have resulted in slight mispositioning of 
the g-phosphate group, slowing the phosphoryl transfer step. APH(3')-IIa did not accept 
G418 and AMK as substrates when UTP was used. 
 
The underlying assumption of these kinetic measurements is that the observed coupled 
reaction is not rate-limited by a coupled enzyme, PK, acting on the NDP product of the 
reaction of interest. We tested this directly by carrying out representative kinetic assays for 
all relevant nucleotides with 2x higher concentrations of the coupled enzymes than those 
used in the above measurements (Figure 4.6). The progress curves with the original and 
with the doubled concentrations of the coupled enzymes were the same within 
experimental uncertainty, indicating that, indeed, the above kinetics were not affected by 
potential variations in activity of PK with different NDP substrates. 
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Figure 4.6. Time course reaction for each NTP with APH(3')-IIa enzyme with either 1´ or 2´ PK-LDH 
concentration in the reaction in order to prove that APH(3')-IIa kinetics shown in Table 4.3 and Figure 4.5 
were not limited by the coupled reaction used in UV-Vis assays. 
 
4.2.4. Structural insight into the NTP effect of the AG profile 
We examined available crystal structures of APH(3')-IIa in complex with KAN (PDB ID: 
1ND4)25 as well as two crystal structures of APH(3')-IIIa, a thoroughly characterized 
homologous APH, in complexes with ADP and KAN (PDB ID: 1L8T)32 and with ADP 
and NEO (PDB ID: 2B0Q)32 to help us understand the effects of NTP on the AG profile. 
 
The structures of APH(3')-IIa in complex with KAN and that of APH(3')-IIIa in complex 
with ADP and KAN are highly superimposable (Figure 4.7A). Nevertheless, differences 
can be observed between the two superimposed structures, specifically at the different 
accommodation of KAN ring III of the two proteins. For instance, APH(3')-IIa contains a 
salt bridge formed by Glu160 and Arg229 that is absent in APH(3')-IIIa. The salt bridge 
could help stabilize the flexible loop (Asp150-Phe165 in APH(3')-IIIa)32 at the AG-binding 
site in a closed form upon KAN binding. Another difference in binding of KAN ring III 
between the two enzymes is in that the larger Asp227 in APH(3')-IIa than Ser227 in 
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APH(3')-IIIa positions ring III of KAN further away from the protein core, consequently 
forcing the AG-gating flexible loop outward into a seemingly looser conformation in 
APH(3')-IIa. 
 
 
Figure 4.7. Computational superimposition of the protein structures of A. APH(3')-IIa (in beige) with 
KAN (in bright yellow) bound (PDB ID: 1ND4)25 and APH(3')-IIIa (in pale blue) with KAN (in teal) 
bound (PDB ID:1L8T).32 D154, D157, D227, E230, and F264 in APH(3')-IIa are shown in bright orange. 
S227 in APH(3')-IIIa as well as the two residues forming the salt bridge, E160 and R229, are shown in 
dark teal. B. APH(3')-IIa (in beige) with KAN (in bright yellow) bound (PDB ID: 1ND4)25 and APH(3')-
IIIa (in pale green) with ADP (in dark green) and NEO (in bright green) bound (PDB ID:2B0Q).32 L103, 
C192, P194, and E231 of APH(3')-IIa are shown in bright orange. The Na+ ion coordinating C192 and the 
2'- and 3'-OH of KAN is shown in purple. 
 
Next, we superimposed the crystal structures of APH(3')-IIa in complex with KAN and 
APH(3')-IIIa in complex with ADP and NEO  (Figure 4.7B). Please note that NEO is a 4,5-
disubstited AG with rings III and IV positioned in a different orientation from that of ring 
III of the 4,6-disubstituted KAN. APH(3')-IIIa was previously reported to be the most 
substrate promiscuous amongst all APH(3') enzymes.32-33 For APH(3')-IIa , the 2'- and 3'-
OH of KAN are coordinated, through a Na+ ion, to the side chain of Cys192. This highly 
restrained binding mode, not observed for APH(3')-IIIa, could be an AG-selection 
mechanism for APH(3')-IIa. The AGs that do not satisfy this coordination, such as NEO, 
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which bears an NH2 group instead of OH at its 2'-position, may be less favored than KAN. 
In addition, we can see that Leu103, Pro194, and Cys192 in APH(3')-IIa form a 
hydrophobic wall that may prevent binding of NEO, which contains an extra ring (IV). 
Specifically, Leu103, Pro194, and Glu231 sterically clash the with ring IV of NEO bound 
to APH(3')-IIIa in the superimposition. This steric hindrance may contribute to the reason 
why NEO is a less favored substrate than KAN for APH(3')-IIa when using ATP as a 
cosubstrate. This surface, especially Pro194, is located close to the ATP binding site, 
apparently to bind AGs in a U-shaped conformation. Due to this proximity, the binding of 
a different NTP may induce structural shifts propagated via this surface to the AG-binding 
cavity to affect AG selection. 
 
In addition, we compared APH(3')-IIa to another APH enzyme known for its dual 
cosubstrate specificity, APH(2")-IVa.34 We superimposed the crystal structure of APH(3')-
IIa (PDB ID: 1ND4)25 with the two structures of APH(2")-IVa bound to adenosine (PDB 
ID: 4DT8) and guanosine (PDB ID: 4DT9) (Figures 4.8 and 4.9).34 The dual nucleotide 
specificity in APH(2")-IVa was attributed to a shift in the hydrogen bonding network when 
adenine was replaced by guanine. Specifically, the N6 of adenine donates a hydrogen to 
the carbonyl oxygen of Thr96 of APH(2")-IVa and the N1 of adenine accepts the hydrogen 
from the amide nitrogen of Ile96 of APH(2")-IVa (Figure 4.9A). The O6 and N1 of guanine 
form hydrogen bonds with the amide nitrogen and carbonyl oxygen Ile98, respectively 
(Figure 4.9B). We asked if a similar shift could occur with APH(3')-IIa. We found potential 
hydrogen bond donors and acceptors for both adenine and guanine in this case as well. The 
N6 and N1 of adenine could serve as hydrogen bond donor and acceptor, respectively, to 
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interact with the backbone oxygen of Gly95 and the backbone nitrogen of Val97 in 
APH(3')-IIa (Figure 4.9C). On the other hand, guanine could interact with APH(3')-IIa by 
forming hydrogen bonds between O6, N1, and N2 and the backbone nitrogen and oxygen 
of Val97, as well as the backbone oxygen of Gly99 (hydrogen bond accepter) of APH(3')-
IIa, respectively (Figure 4.9D). This structural model provides a potential explanation for 
the broad cosubstrate promiscuity of APH(3')-IIa. 
 
 
Figure 4.8. Superimposition of APH(3')-IIa (in pale yellow) with KAN (in bright yellow) bound 
(PDB ID: 1ND4)25 and two crystal structures of APH(2")-IVa with adenosine (APH(2")-IVa in light 
blue, adenosine in dark green, PDB ID: 4DT8) and guanosine (APH(2")-IVa in light purple, 
guanosine in purple, PDB ID: 4DT9) bound.34 Residues of APH(3')-IIa are colored in orange whereas 
the residues in APH(2")-IVa are colored in teal and dark purple. The specific interactions between 
each enzyme and nucleoside are shown in four separate panels in Figure 4.9. 
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Figure 4.9. Superimposition of crystal structures of APH(3')-IIa with KAN (PDB ID: 1ND4)25 and 
APH(2")-IVa with adenosine and guanosine (PDB IDs: 4DT8 and 4DT9, respectively)34. A. APH(2")-IVa 
(in light teal) and adenosine in dark green with the backbones of T96 and I98 colored in dark teal, B. 
APH(2")-IVa (in light purple) and guanosine in purple with the backbone of T96 and I98 colored in dark 
purple, C. APH(3')-IIa (in pale yellow) with KAN (in bright yellow) and the adenosine from APH(2")-
IVa structure in dark green and the backbone of G95, V97, and G99 in orange, D. APH(3')-IIa (in pale 
yellow) with KAN (in bright yellow) and the guanosine from APH(2")-IVa structure in purple and the 
backbone of G95, V97, and G99 in orange. 
 
4.3. CONCLUSIONS 
In this chapter, we investigated for the first time how cosubstrate NTPs define the AG 
profile for APH(3')-IIa. A complex dependence of the AG profile on the identity of the 
base of the NTP strongly suggests allosteric communication between the cosubstrate and 
the substrate binding sites. Even though ATP is the most abundant NTP in vivo, this study 
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indicates other NTPs should not be disregarded as potential cosubstrates in the context of 
AG antibiotic overuse. 
 
4.4. MATERIALS AND METHODS 
4.4.1. Materials and instrumentation 
The enzymes and buffers used for the molecular cloning of APH(3')-IIa, were purchased 
from New England BioLabs (NEB; Ipswich, MA), whereas primers for PCR were 
purchased from Sigma-Aldrich (Milwaukee, WI). All AGs used in this study were 
purchased from AK Scientific (Union City, CA). ATP, dATP, dCTP, GTP, UTP, TTP, and 
ITP were purchased from Sigma-Aldrich. dGTP and dUTP were purchased from Promega 
(Madison, WI). TLC plates (silica gel 60 F254 coated) were purchased from VWR (Radnor, 
PA). UV-Vis assays were performed on a SpectraMax M5 plate reader. Kinetics 
parameters were determined using SigmaPlot 13.0 (SysStat Software, San Jose, CA). 
 
4.4.2. Cloning, expression, and purification of APH(3')-IIa 
Cloning of aph(3')-IIa-pET28a was performed in E. coli TOP10. The aph(3')-IIa gene was 
PCR amplified by using the forward primer 5'-
GCGTTTCATATGATTGAACAAGATGG-3' and reverse primer 5'-
CCAGAGCTCGAGTCAGAAGAACTCGTC-3' using the pcDNA3.1 vector from 
Invitrogen. After PCR, the amplified aph(3')-IIa gene (817 bp) was purified, digested, with 
NdeI and XhoI (restriction sites are underlined above) and ligated into an NdeI/XhoI 
digested pET28a vector. The DNA sequence was confirmed (sequencing performed by 
Eurofins Genomics, Louisville, KY). The aph(3')-IIa-pET28a vector was transformed into 
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E. coli BL21 (DE3). An overnight culture was grown at 37 °C from a fresh transformant 
colony. The protein was overexpressed starting with a 1% inoculum in Luria-Bertani (LB) 
broth (2 L) containing KAN (50 µg/mL) at 37 °C with shaking at 200 rpm until the 
attenuance of 0.6 at 600 nm. The protein expression was then induced with IPTG (1 mM) 
and the cells were grown overnight at 25 °C with shaking at 200 rpm. The cell pellet was 
resuspended in 50 mL of lysis buffer (25 mM Tris-HCl, pH 8.0, 200 mM NaCl, and 10% 
glycerol) and the cells were lysed by intermittent sonication. The protein was purified using 
NiII-NTA affinity column chromatography in lysis buffer with a gradient of imidazole (10 
mL of 5 mM, 3×5 mL of 20 mM, 40 mM, and 250 mM). Pure fractions were then dialyzed 
in 3×2 L of Tris-HCl (50 mM, pH 8.0), NaCl (300 mM) and 10% glycerol before being 
concentrated to 100 µM using a 10 kDa molecular weight cut-off Millipore Amicon Ultra 
centrifugual device. The pure 32.1 kDa NHis6-tagged protein was flash-frozen in liquid 
nitrogen and stored at -80 °C. Protein yield was 8 mg per L of culture. 
 
4.4.3. Determination of AG profile of APH(3')-IIa with various NTPs 
To determine the substrate profiles of APH(3')-IIa for different NTP cosubstrates, we used 
a protocol previously described.20, 22, 26, 29 In a 96-well plate, each 200 µL reaction 
contained AG (100 µM), Tris-HCl (50 mM, pH 8.0), MgCl2 (10 mM), KCl (40 mM), 
NADH (0.5 mg/mL freshly prepared), phosphoenolpyruate (PEP, 2.5 mM), NTP (2 mM), 
PK-LDH (4 µL of 10 mg/mL solution) (P0294, Sigma Aldrich), and APH(3')-IIa (1 µM), 
which was added last to the plate to initiate the reaction. The assay was carried out at 37 °C 
and absorbance at 340 nm was recorded every 30 s for 20 min to monitor the disappearance 
of NADH. After subtraction from the final absorbance of each reaction that measured for 
 116 
a control reaction in the absence of AG, the absorbance values greater than 0.1 were 
considered significant and indicated accordingly in Table 4.1. The AGs for which the 
corrected absorbance values were in the range of 0.05-0.1 were considered poor substrates 
for a given NTP. The AGs for which the absorbance values were below 0.05 were 
considered not to be substrates for APH(3')-IIa. 
 
4.4.4. Thin-layer chromatography 
The TLC assays with stains that detected AGs and their phosphorylated products were 
performed in order to confirm directly that the reactions we observed from the UV-Vis 
assay resulted from phosphorylation of AGs. We first used ATP as a representative NTP. 
Each reaction contained Tris-HCl (50 mM, pH 8.0), AG (1 mM), NTP (2 mM), MgCl2 (10 
mM), KCl (40 mM), and APH(3')-IIa (5 µM). The eluent system for each AG consisted of 
different ratios of MeOH and NH4OH as follows: 3:2/MeOH:NH4OH for AMK and NEO, 
5:2 for APR, HYG, and SIS, 15:2 for GEN, G418, NET, and TOB, 7:3 for KAN, and 3:1 
for NEA, PAR, and RIB. TLC plates for most AGs were stained with ninhydrin, with the 
exception of G418 and RIB, which were stained with 10% sulfuric acid in MeOH. The 
stained plates were heated for visualization (Figure 4.3). We then performed TLC for the 
rest of (d)NTPs in the same reaction condition (24 h reactions). The results were 
summarized in Figure 4.4. 
 
4.4.5. Determination of enzyme kinetics by UV-Vis assays with respect to AGs 
The reaction conditions were the same as those described in the AG profile by UV-Vis 
assay section and the data collected were processed as previous published.5 The first 3 min 
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were used to determine the initial rate of reaction. The best-fit kinetic parameters with 
respect to each AG are summarized in Table 4.3 with the Michaelis-Menten curves shown 
in Figure 4.5. 
 
4.4.6. Validation of PK efficiency in kinetics UV-Vis assays 
To confirm that kinetic parameters determined for APH(3')-IIa in the UV-Vis assay with 
PK-LDH were not affected by the activity of PK, we used NEO as a representative AG and 
performed time course reactions containing 1x and 2x (compared to the concentration of 
the coupled enzymes used in the kinetic assays above) with each relevant nucleotide 
cosubstrate. Specifically, each reaction contained NEO (250 µM) and the rest of the 
ingredients at concentrations described in the kinetics assays. We used either 1x (as in the 
kinetics analysis) or 2x PK-LDH to test whether the concentration of PK-LDH in our 
kinetics analysis was limiting the rate of APH(3')-IIa enzymes (Figure 4.6). 
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Chapter 5. Evaluation of aminoglycoside and carbapenem resistance in a collection 
of drug-resistant Pseudomonas aeruginosa clinical isolates 
Pseudomonas aeruginosa, a Gram-negative bacterium, is a member of the ESKAPE 
pathogens and one of the leading causes of healthcare-associated infections worldwide. 
Aminoglycosides (AGs) are recognized for their efficacy against P. aeruginosa. The most 
common resistance mechanism against AGs is the acquisition of AG-modifying enzymes 
(AMEs) by the bacteria, including AG N-acetyltransferases (AACs), AG O-
phosphotransferases (APHs), and AG O-nucleotidyltransferases (ANTs). In this study, we 
obtained 122 multidrug-resistant P. aeruginosa clinical isolates and evaluated the 
antibacterial effects of six AGs and two carbapenems alone against all clinical isolates, and 
in combination against eight selected strains. We further probed for four representatives of 
the most common AME genes (aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia) by PCR 
and compared the AME patterns of these 122 clinical isolates to their antibiotic resistance 
profile. Amongst the diverse antibiotics resistance profile displayed by these clinical 
isolates, we found correlations between the resistance to various AGs as well as between 
the resistance to one AG and the resistance to carbapenems. PCR results revealed that the 
presence of aac(6')-Ib renders these isolates more resistant to a variety of antibiotics. The 
correlation between resistance to various AGs and carbapenems partially reflects the 
complex resistance strategies adapted in these pathogens and encourages the development 
of strategic treatment for each P. aeruginosa infection by considering the genetic 
information of each isolated bacteria. 
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5.1. INTRODUCTION 
Pseudomonas aeruginosa is a member of a group of Gram-negative (-) and Gram-positive 
(+) bacterial pathogens known as ESKAPE (where E stands for Enterococcus faecium (+), 
S for Staphylococcus aureas (+), K for Klebsiella pneumoniae (-), A for Acinetobacter 
baumannii (-), P for Pseudomonas aeruginosa (-), and E for Enterobacter species (-)) due 
to their ability to escape a broad array of antimicrobial agents.1 Its pathogenicity, 
transmission, and resistance have caused the currently available antibiotics to rapidly lose 
activity against these pathogens.2-7  
 
As an opportunistic pathogen, P. aeruginosa is a leading cause of healthcare-associated 
infections and poses great threat in critically ill and immunocompromised patients.8-9 
According to the Center for Diseases Control and Prevention, P. aeruginosa is estimated 
to cause 51,000 infections in U.S.A. every year amongst which 13% are caused by 
multidrug-resistant strains. It is the most common cause of nosocomial pneumonia (17%); 
third most common cause of urinary track infections (7%); fourth most common cause of 
surgical site infections (8%); as well as the fifth common isolate overall from all sites 
(9%).10 P. aeruginosa is also one of the greatest challenges faced by military healthcare 
professionals, since it is often isolated among antibiotic-resistant bacteria in such settings 
in patients with military injuries and wounds.11 
 
Due to their excellent efficacy against Gram-negative bacteria, aminoglycosides (AGs) are 
widely used to treat infections caused by P. aeruginosa. In addition to AMK, GEN, and 
TOB that are currently approved in the U.S.A. for systemic administration, netilmicin 
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(NET) and sisomicin (SIS) are widely employed in AG treatment regiments in European 
countries. Apramycin (APR), which is currently used in veterinary treatment, is another 
AG that has shown excellent antibacterial efficacy, limited toxicity, and was found to be 
less prone to the development of resistance over time.12-14 Nonetheless, resistance has 
quickly developed to these antimicrobial agents with a significant portion of clinical 
isolates identified now resistant to clinically used AG antibiotics.14-16 Resistance to AGs 
results from a variety of mechanisms including (i) changes in bacterial cell envelope 
composition, (ii) modification on RNA target, (iii) upregulation of efflux pumps, and (iv) 
acquisition of AG-modifying enzymes (AMEs), with the last accounting for most of the 
resistance cases. AMEs comprise three different types of enzymes: AG N-
acetyltransferases (AACs), AG O-nucleotidyltransferases (ANTs), and AG O-
phosphotransferases (APHs). These enzymes transfer an acetyl, a nucleotidyl, or a 
phosphate group onto AGs, respectively. AACs, which target the 6'-, 2'-, and 3-amine 
moieties on AG molecules, are the most common AMEs in resistant organisms. A more 
recently discovered multiacetylating AAC, the enhanced intracellular survival protein 
(Eis),17-22 could become highly problematic in the future with its ability to acetylate more 
than one site on AGs. Most APHs, on the other hand, attack the 3'- and 2"-positions. ANTs 
are the least common AMEs and attack the 4'- or the 2"-hydroxyl groups.23 
 
Our laboratory, as well as many other research groups, is dedicated to developing AG 
antibiotics and understanding resistance mechanisms.24-39 Previously, researchers have 
observed discrepant results over whether AG and carbapenem combination therapies yield 
positive outcomes for the killing of P. aeruginosa.40-43 In an effort to understand in greater 
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detail the underlying resistance mechanisms in P. aeruginosa, in this study, we obtained 
122 multidrug-resistant P. aeruginosa clinical isolates from the University of Kentucky 
Hospital System and evaluated the in vitro activity of various clinically-relevant AGs, 
including AMK, APR, GEN, NET, SIS, and TOB, and two carbapenem antibiotics, 
meropenem (MEM) and imipenem (IPM), against these clinical isolates. We evaluated the 
bactericidal effect of AG and carbapenem alone against all clinical isolates, and in 
combination against eight selected strains. We have also performed PCR probing for four 
of the most common AME genes, aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia, and 
compared the AME patterns of these 122 clinical isolates to their antibiotic resistance 
profiles. 
 
5.2. RESULTS AND DISCUSSION 
5.2.1. Susceptibility of various antibiotics against 122 P. aeruginosa clinical isolates 
We first determined the MIC values of various AGs (AMK, APR, NET, SIS, and TOB) 
and MEM against all 122 P. aeruginosa strains (Table 5.1).44-45 The breakpoint 
concentrations for APR are yet to be determined. Therefore, for all analyses in this study, 
APR was not categorized based on susceptibility or resistance. As summarized in Table 
5.2, 117 strains were susceptible to AMK and only 3 strains were resistant to AMK. The 
susceptibility of all strains showed a similar distribution to GEN, NET, SIS, and TOB: 
~55% of the strains susceptible and ~40% resistant. Approximately 60% of these 122 
strains were susceptible to MEM and less than 20% of them were resistant to MEM. 
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Table 5.1. MIC values (µg/mL) of various AGs and MEM against all clinical isolates studied. 
 AGs   AGs  
Strain # AMK APR GENa NET SIS TOB MEM Strain # AMK APR GENa NET SIS TOB MEM 
1 2 4 ≤2 1 ≤0.25 1 1 62 4 16 ≤2 16 4 0.5 1 
2 2 8 8 2 0.5 1 1 63 2 4 16 8 16 2 2 
3 16 2-4 >8 >128 >128 128 16 64 4 8 >8 >128 >128 32 4 
4 1 2 ≤2 0.5 ≤0.25 0.5 1 65 8 16 >8 >128 >128 32 2-4 
5 1-2 8 8 1 ≤0.25 0.5 ≤0.25 66 4 2 128 >128 >128 32 4 
6 0.5 8 ≤2 0.5 ≤0.25 0.5 ≤0.25 67 1-2 1-2 ≤2 2 0.5 ≤0.25 ≤0.25 
7 2 4-8 >8 4 ≤0.25 64-128 2-4 68 4 8 4 16 4 0.5 ≤0.25 
8 1 4 >8 2 128 128 2-4 69 2 8 ≤2 4-8 1-2 ≤0.25 1 
9 4 2 ≤2 4 1 0.5 0.5 70 2 8 ≤2 4 2-4 0.5-1 0.5 
10 0.5-1 2 ≤2 ≤0.25 ≤0.25 0.5 ≤0.25 71 4 8 >8 16 >128 32 4 
11 1 4 >8 2 >128 64 2-4 72 4 8 >8 16 >128 64 2 
12 0.5 2 ≤2 ≤0.25 ≤0.25 1 0.5 73 8 16-32 >8 32 >128 >128 16 
13 8 8 >8 >128 >128 128 2 74 2-4 4 ≤2 8 2 0.5-1 2 
14 4 8 ≤2 4 2 0.5 1 75 8 16 >8 16 >128 16-32 4-8 
15 8 16 >8 >128 >128 64 16 76 1 2-4 ≤2 8 2-8 4-8 8 
16 8 8 >8 >128 >128 64 16 77 2-4 4-8 ≤2 4 2 0.5 0.5 
17 1 4 ≤2 4 1 1 2 78 8 8 ≤2 8 2-4 0.5-2 0.5 
18 1 4 ≤2 2 2 1 ≤0.25 79 1 2 1 2 1 64 4 
19 1-2 4 ≤2 1-4 1-2 1 ≤0.25 80 1-2 4 4 4 1 0.5 0.5 
20 4 8 >8 >128 >128 64 4 81 8 8 >8 16 >128 16-32 4 
21 2 4 ≤2 4 2 1-2 0.5 82 8 8 >8 16 >128 64 4 
22 1 4 ≤2 2 2 0.5 ≤0.25 83 4 8 >8 8 128 16 4 
23 2-4 4-8 >8 8-16 >128 64 2 84 2 2 ≤2 4 128 4 2 
24 1 2-4 ≤2 2 1-2 0.5-1 0.5-1 85 16 32 >8 32 4-8 4 2 
25 2 4 ≤2 4 1 1 ≤0.25 86 0.5-1 4 ≤2 2 0.5 ≤0.25 ≤0.25 
26 128 >128 >8 >128 >128 >128 0.5 87 8 8 >8 8 >128 128 ≤0.25 
27 16 8 >8 >128 >128 64 16 88 2 4-8 4 8 1 ≤0.25 ≤0.25 
28 32 8 >8 >128 >128 128 16 89 2 2 ≤2 2 0.5 ≤0.25 1 
29 4 8 ≤2 2 1 1 0.5 90 32-64 8 >8 >128 >128 >128 4 
30 2 8 ≤2 4 2 1 0.5 91 2 8 >8 >128 >128 32 4 
31 4 4-8 ≤2 8 1 1 2 92 0.5 2 ≤2 0.5 1 ≤0.25 2 
32 2 4 ≤2 4 1-2 0.5 8 93 2 8 ≤2 4 2 0.5 2 
33 4 4 ≤2 4 1-2 0.5-1 32-64 94 2 8 >8 16-32 >128 64 4-8 
34 4 4 ≤2 4 1-2 0.5-1 ≤0.25 95 4-8 32 >8 >128 >128 64 4 
35 8 8 >8 >128 >128 64 2 96 2 4 ≤2 4-8 2 ≤0.25 ≤0.25 
36 4 4-8 ≤2 8-16 2 0.5 2 97 4 8 ≤2 4 2 ≤0.25 ≤0.25 
37 4 4-8 2 8 4 0.5 1-2 98 8 8 >8 >128 >128 64 2 
38 4 8-16 1 8-16 2 0.5 4 99 8 8 ≤2 8 2-4 0.5 0.5 
39 8 16 >128 >128 >128 64 4 100 8 8 >8 >128 >128 32 4 
40 4 8 2 4 2 1 ≤0.25 101 2 4 ≤2 4 4 4 2 
41 4-8 4 1 1-2 2-4 2 ≤0.25 102 8 8 ≤2 >128 128 1-2 2 
42 1 1 ≤2 1 0.5 0.5 ≤0.25 103 4 8 ≤2 8 1-2 0.5 0.5 
43 8 8 >8 >128 >128 64 4 104 4 8-16 ≤2 8 2 ≤0.25 ≤0.25 
44 1 2 8 2 1 1 4 105 8 8-16 >8 16 >128 64 8 
45 1 2 ≤2 2 1 2 0.5 106 4 4-8 ≤2 16 >128 16 4 
46 1 1 >8 2 1 32 2 107 16 16 >8 16 8 2 ≤0.25 
47 1-2 4 1 4 1 0.5 0.5 108 8 16 >8 32 >128 32 8 
48 16 8-16 ≤2 16 4 0.5 ≤0.25 109 8-16 8 >8 >128 >128 64 16 
49 4 4 ≤2 8 2 0.5 ≤0.25 110 0.5 0.5-1 ≤2 ≤0.25 ≤0.25 ≤0.25 8 
50 8 4-8 4 >128 >128 8 64 111 8 16 ≤2 128 >128 32 16 
51 32 2 2 64-128 32 8 128 112 4 8 >8 4 4-8 4 ≤0.25 
52 8 8-16 4 8 4 0.5 4 113 8 8 >8 128 128 32 2 
53 2 4-8 ≤2 16 4 0.5 ≤0.25 114 16 16 >8 >128 128 32-64 >128 
54 4 8 ≤2 8 2 0.5 ≤0.25 115 16 16-32 ≤2 128 128 16-32 2 
55 0.5-1 2-4 ≤2 4 2 0.5 4 116 16 16 >8 32 16 8-16 1 
56 2-4 8-16 >8 >128 >128 32 2 117 8-16 16 >8 >128 >128 32 4 
57 4 16 8 32 4 1 2 118 4 4 ≤2 4 2 ≤0.25 4 
58 2 8 ≤2 8 2 0.5 0.5 119 64 8-16 >8 >128 >128 128 >128 
59 1-2 8 ≤2 4-8 2 ≤0.25 ≤0.25 120 4 4 128 >128 >128 64 8 
60 8 16 >8 >128 >128 32 2-4 121 8 4-8 >8 >128 >128 64 64 
61 4 4 ≤2 128 64 ≤0.25 0.5 122 8 8 ≤2 64 >128 4 8-16 
S, I, and R are depicted as green, yellow, and orange cells respectively. The resistance cutoff values for various antibiotics against P. 
aeruginosa are: AMK (S ≤16, I = 32, R ≥64), GEN (S ≤4, I = 8, R ≥16), MEM (S ≤2, I = 4, R ≥8), NET (S ≤8, I = 16, R ≥32), and 
TOB (S ≤4, I = 8, R ≥16) according to the CLSI.44 The resistance cutoff values for SIS against P. aeruginosa are not established in the 
U.S.A. and are considered to be S ≤4 and R >4.46 a Most MIC values for GEN against the strains studied were obtained from the 
University of Kentucky Hospital System. 
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Table 5.2. Susceptibility of 122 P. aeruginosa clinical isolate strains to various antibiotics. 
 Susceptible (S) Intermediate (I) Resistant (R) 
Antibiotic No. of strains % No. of strains % No. of strains % 
AMK 117 95.9 2 1.0 3 2.5 
GEN 68 55.8 5 4.1 49 40.2 
NET 66 54.1 15 12.3 41 33.6 
SIS 65 53.3 -- -- 57 46.7 
TOB 70 57.4 3 2.5 49 40.2 
MEM 72 59.0 27 22.1 23 18.9 
The resistance cutoff values for various antibiotics against P. aeruginosa are AMK (S ≤16, I = 32, R ≥64), GEN (S ≤4, I = 8, R ≥16), 
NET (S ≤8, I = 16, R ≥32), TOB (S ≤4, I = 8, R ≥16), and MEM (S ≤2, I = 4, R ≥8) according to the CLSI. The resistance cutoff 
values for SIS against P. aeruginosa are not established in the U.S.A. and are considered to be S ≤4 and R >4 in this study. APR is 
not included in this analysis due to lack of established resistance cutoff. 
 
To further explore if the resistance to these antibiotics occur mostly individually or in 
groups of antibiotics, we next categorized the P. aeruginosa strains studied based on the 
number of antibiotics that they were resistant to (Figure 5.1). We found that over half of 
the strains (58 strains) were susceptible to all of the antibiotics tested in this study. We 
observed that simultaneous resistance to all six antibiotics is rare (1 strain only). Moreover, 
we found 20 strains that concurrently resisted the action of four antibiotics. 
 
In order to establish the correlations between the susceptibility/resistance to one antibiotic 
to the resistance to another drug in these P. aeruginosa strains, we further categorized these 
clinical isolates based on their susceptibility/resistance to each individual antibiotic (AMK, 
GEN, NET, SIS, TOB, and MEM) and analyzed their resistance patterns to other antibiotics 
within this group. First, we separated the 122 strains based on their susceptibility/resistance 
to a first antibiotic, then analyzed the median MIC values, range of MIC values, and the 
resistance rate for a second antibiotic within each group (Table 5.3). Then, we plotted the 
MIC values of the second antibiotic based on the susceptibility/resistance to the first 
antibiotic in order to see the distribution of the MIC values of all the clinical isolates. The 
data based on GEN susceptibility/resistance were presented in Figure 5.2, whereas those 
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based on the susceptibility/resistance to the rest of the antibiotics were displayed in Figures 
5.3 and 5.4. 
 
 
Figure 5.1. Number of strains grouped by the number of antibiotics to which the P. aeruginosa strains are 
resistant. The specific antibiotic to which each strain is resistant to are marked in the legend with the 
number of strains with each resistance profile in parentheses. The resistance cutoff values for each 
antibiotic are as follow: AMK (S ≤16, I = 32, R ≥64), GEN (S ≤4, I = 8, R ≥16), MEM (S ≤2, I = 4, R ≥8), 
NET (S ≤8, I = 16, R ≥32), and TOB (S ≤4, I = 8, R ≥16) according to the CLSI.44 The resistance cutoff 
values for SIS against P. aeruginosa are not established in the U.S.A. and are considered to be S ≤4 and 
R >4 in this study based on ref 45. 
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Table 5.3. Summary of the median MIC values, the range of MIC values, and the rate of resistance to each antibiotic based 
on the susceptibility to AMK, GEN, NET, SIS, TOB, and MEM. 
 AMK susceptible (n = 117) AMK resistant (n = 3) 
 MIC (µg/mL)  MIC (µg/mL)  
Antibiotic Median Range Resistance rate % Median Range Resistance rate % 
GEN ≤2 ≤2 - >8 38.5 >8 >8 100 
NET 8 ≤0.25 - >128 60.7 >128 >128 100 
SIS 4 ≤0.25 - >128 38.5 >128 >128 100 
TOB 2 ≤0.25 - >128 38.5 >128 ≥128 100 
MEM 1 ≤0.25 - >128 17.1 4 0.5 - >128 33 
 GEN susceptible (n = 69) GEN resistant (n = 49) 
 MIC (µg/mL)  MIC (µg/mL)  
Antibiotic Median Range Resistance rate % Median Range Resistance rate % 
AMK 2 0.5 - 32 0 8 1-128 6.1 
NET 4 ≤0.25 - >128 10.1 >128 2 - >128 67.4 
SIS 2 ≤0.25 - >128 14.5 >128 ≤0.25 - >128 95.9 
TOB 0.5 ≤0.25 - 64 6.3 64 2 - >128 91.8 
MEM 0.5 ≤0.25 - >128 11.6 4 ≤0.25 - >128 30.6 
 NET susceptible (n = 66) NET resistant (n = 41) 
 MIC (µg/mL)  MIC (µg/mL)  
Antibiotic Median Range Resistance rate % Median Range Resistance rate % 
AMK 2 0.5 - 8 0 8 1-128 7.3 
GEN ≤2 ≤2 - >8 12.1 >8 ≤2 - >8 80.5 
SIS 2 ≤0.25 - >128 12.1 >128 1 - >128 97.6 
TOB 0.75 ≤0.25 - 128 10.6 64 ≤0.25 - >128 12.2 
MEM 0.5 ≤0.25 - 64 6.1 4 ≤0.25 - >128 41.5 
 SIS susceptible (n = 65) SIS resistant (n = 57) 
 MIC (µg/mL)  MIC (µg/mL)  
Antibiotic Median Range Resistance rate % Median Range Resistance rate % 
AMK 2 0.5 - 16 0 8 1-128 5.3 
GEN ≤2 ≤2 - >8 3.1 >8 ≤2 - >8 82.5 
NET 4 ≤0.25 - >128 1.4 >128 2 - >128 70.2 
TOB 0.5 ≤0.25 - >128 4.6 32 ≤0.25 - >128 80.7 
MEM 0.5 ≤0.25 - 64 4.6 4 ≤0.25 - >128 35.1 
 TOB susceptible (n = 70) TOB resistant (n = 49) 
 MIC (µg/mL)  MIC (µg/mL)  
Antibiotic Median Range Resistance rate % Median Range Resistance rate % 
AMK 2 1 - 128 0 8 1-128 2.0 
GEN ≤2 ≤2 - >8 5.7 >8 ≤2 - >8 91.8 
NET 4 ≤0.25 - >128 7.1 >128 2 - >128 57.6 
SIS 2 ≤0.25 - 128 11.4 >128 ≤0.25 - >128 93.9 
MEM 0.5 ≤0.25 - 64 5.7 4 ≤0.25 - >128 32.7 
 MEM susceptible (n = 73) MEM resistant (n = 23) 
 MIC (µg/mL)  MIC (µg/mL)  
Antibiotic Median Range Resistance rate % Median Range Resistane rate % 
AMK 4 0.5 - 128 1.4 8 0.5 - 64 4.4 
GEN ≤2 ≤2 - >8 20.6 >8 ≤2 - >8 65.2 
NET 4 ≤0.25 - >128 16.4 128 ≤0.25 - >128 73.9 
SIS 2 ≤0.25 - >128 24.7 >128 ≤0.25 - >128 87.0 
TOB 1 ≤0.25 - >128 16.4 32 ≤0.25 - >128 69.6 
* Intermediate (I) strains are not included in this analysis. Results of APR are not shown in this table due to lack of 
susceptibility cutoff standards. 
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Figure 5.2. Distribution of MIC values of each antibiotic based on the susceptibility to GEN. The median 
MIC of each antibiotic is marked by a horizontal bar. Additional distribution plots of MIC values of each 
antibiotic based on the susceptibility to other antibiotics (NET and SIS, and TOB and MEM) are presented 
in Figures 5.3-5.4. We did not plot the MIC values of each antibiotic based on the susceptibility to AMK 
as the vast majority of the 122 P. aeruginosa strains tested are susceptible to AMK and only 3 strains are 
resistant to this AG. Significance was defined as P value ≤0.05 (0.033 (*), 0.002 (**), <0.001 (***)). 
 
Lo
g 2
 A
M
K 
M
IC
.25
5
1
2
4
8
16
32
64
128
>128
GEN (S) GEN (R)
.25
5
1
2
4
8
16
32
64
128
>128
GEN (S) GEN (R)
Lo
g 2
 A
PR
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
GEN (S) GEN (R)
Lo
g 2
 N
ET
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
GEN (S) GEN (R)
Lo
g 2
 S
IS
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
GEN (S) GEN (R)
Lo
g 2
 T
O
B 
M
IC
.25
5
1
2
4
8
16
32
64
128
>128
GEN (S) GEN (R)
Lo
g 2
 M
EM
 M
IC
*** *** ***
*** *** ***
 
	 128 
 
Figure 5.3. Distribution of MIC values of each antibiotic based on the susceptibility to NET and SIS. The 
median MIC value of each antibiotic is marked by a horizontal bar. Note: Additional distributions of MIC 
values of each antibiotic based on the susceptibility to other antibiotics (GEN, and TOB and MEM) are 
presented in Figures 5.2 and 5.4, respectively. We did not plot the MIC values of each antibiotic based on 
the susceptibility to AMK as the vast majority of the 122 P. aeruginosa strains tested are susceptible to 
AMK and only 3 strains are resistant to this AG. Significance was defined as P value ≤0.05 (<0.001 (***)). 
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Figure 5.4. Distribution of MIC values of each antibiotic based on the susceptibility to TOB and MEM. 
The median MIC value of each antibiotic is marked by a horizontal bar. Note: Additional distributions of 
MIC values of each antibiotic based on the susceptibility to other antibiotics (GEN, and NET and SIS) are 
presented in Figures 5.2-5.3, respectively. We did not plot the MIC values of each antibiotic based on the 
susceptibility to AMK as the vast majority of the 122 P. aeruginosa strains tested are susceptible to AMK 
and only 3 strains are resistant to this AG. Significance was defined as P value ≤0.05 (0.033 (*), <0.001 
(***)). 
 
Taking GEN as an example, we found that within the GEN-susceptible group (n = 69 
strains), the median MIC values for AMK, APR, NET, SIS, TOB, and MEM were 2, 4, 4, 
2, 0.5, and 0.5 µg/mL, respectively, which were lower than those in the GEN-resistant 
group (n = 49 strains) where the median MIC values for the above antibiotics were 8, 8, 
.25
5
1
2
4
8
16
32
64
128
>128
TOB (S) TOB (R)
Lo
g 2
 A
M
K 
M
IC
.25
5
1
2
4
8
16
32
64
128
>128
MEM (S) MEM (R)
Lo
g 2
 A
M
K 
M
IC
.25
5
1
2
4
8
16
32
64
128
>128
TOB (S) TOB (R)
Lo
g 2
 A
PR
 M
IC
1
2
4
8
.25
5
16
32
64
128
>128
MEM (S) MEM (R)
Lo
g 2
 A
PR
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
TOB (S) TOB (R)
Lo
g 2
 N
ET
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
MEM (S) MEM (R)
Lo
g 2
 N
ET
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
TOB (S) TOB (R)
Lo
g 2
 S
IS
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
MEM (S) MEM (R)
Lo
g 2
 S
IS
 M
IC
.25
5
1
2
4
8
16
32
64
128
>128
MEM (S) MEM (R)
Lo
g 2
 T
O
B 
M
IC
.25
5
1
2
4
8
16
32
64
128
>128
TOB (S) TOB (R)
Lo
g 2
 M
EM
 M
IC
***
***
*** ***
***
*** *
***
*** ***
 
	 130 
>128, >128, 64, and 4 µg/mL, respectively (Table 5.3). We observed that the range of MIC 
values in GEN-susceptible and GEN-resistant categories did not differ much, potentially 
due to the large sample size in this study. However, the resistance rates to the other five 
antibiotics in the GEN-resistant groups were prominently higher than in the GEN-
susceptible groups. The differences in median MIC values and overall distributions of MIC 
values between the GEN-susceptible and GEN-resistant groups can be clearly observed in 
Figure 5.2. For instance, the median MIC values for NET, SIS, TOB, and MEM were all 
significantly different (≥8-fold difference) between the GEN-susceptible (lower median 
MIC) and GEN-resistant (higher median MIC) groups. In contrast, the median AMK and 
APR MIC values between the GEN-susceptible and GEN-resistant groups only differed by 
4-fold and 2-fold, respectively. Similarly, the overall distributions of MIC values (looking 
at individual dots on the plots) of NET, SIS, TOB, and MEM were significantly different 
between the GEN-susceptible and GEN-resistant groups, whereas these differences were 
less extensive for AMK and practically absent for APR. 
 
It is important to note that the trends observed in resistance rates, median MIC values, and 
overall distributions of MIC values in the GEN-susceptible and GEN-resistant groups were 
also observed when the data were analyzed based on the susceptibility/resistance to all 
other antibiotics (Table 5.3, Figures 5.3-5.4), with the exception of the resistance rates to 
TOB between the NET-susceptible (10.6%) and NET-resistant (12.2%) groups, which 
were not significantly different from each other (Table 5.3). Furthermore, in the case of 
AMK, we observed that the median MIC values and the resistance rates to all other 
antibiotics in the AMK-resistant group looked profoundly different from those in the 
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AMK-susceptible group. However, the small sample size of the AMK-resistant group (3 
strains) would not necessarily allow us to generalize this observation to most P. aeruginosa 
strains.  
 
Based on the results above, we postulated that the correlations observed between the 
susceptibility/resistance to one AG with that of other AGs could be explained by different 
resistance mechanisms affecting multiple AGs, which was not surprising given that the 
presence of AMEs is the most common resistance mechanism against AG antibiotics. For 
instance, if the bacteria acquired an AME, the most common mechanism of resistance to 
AGs, then it would likely be resistant to any AGs that can be inactivated by this particular 
AME due to the structural similarities between the AG molecules. Furthermore, given that 
all AGs tested in this study possess a 6'-amine group, except for APR, it is not hard to 
explain what we observed in Table 5.3 and Figures 5.1-5.4, where we found that the strains 
that are resistant to one AG also have higher resistance rates and overall higher MIC values 
to other AGs. Moreover, the correlations established between the resistance to MEM and 
those to AGs, which are two distinct classes of antibiotics with discrete chemical structures, 
although not surprising, may suggest the presence of other resistance mechanisms that are 
less structurally specific, and therefore, work against different classes of antibiotics. 
Another possibility to explain this phenomenon is the resistance elements to various 
antibiotics that could have accumulated simultaneously in bacteria, i.e., the resistance 
element to carbapenems could have accumulated inside these P. aeruginosa isolates at the 
same time as resistance elements to AG antibiotics develop.47 Furthermore, since both 
classes of antibiotics are often used in patients infected with P. aeruginosa, the resistance 
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to both classes of antibiotics could potentially result from previous antibiotics exposure.48-
50 
 
5.2.2. Screen for AME genes by PCR 
Having established that half of the P. aeruginosa clinical isolates studied displayed 
resistance to AGs, we further investigated whether the observed AG resistance could be 
explained by the presence of one or multiple AME resistance genes. Therefore, we 
performed PCR with lysed bacteria probing for four of the most common AME genes 
(aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia) as previously described.51 A 
representative PCR result for each gene is presented in Figure 5.5 and a summary of the 
AMEs present in all clinical isolates is presented in Table 5.4. 
 
 
Figure 5.5. Sample agarose gel of representative PCR products for each AME gene probed. L1 and L2 
represent 1-kb and 100-bp ladders, respectively. The expected sizes for each AME gene are 482 bp, 230 
bp, 534 bp, and 624 bp for aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia, respectively. 
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Table 5.4. Patterns of the four common AME genes in all clinical P. aeruginosa strains as detected by PCR. 
 AME  AME 
Strain aac(6')-Ib aac(3)-IV ant(2")-Ia aph(3')-Ia Strain aac(6')-Ib aac(3)-IV ant(2")-Ia aph(3')-Ia 
1 0 0 0 1 62 0 0 0 1 
2 0 0 0 1 63 0 0 0 0 
3 0 0 0 1 64 1 0 0 0 
4 0 0 0 1 65 1 0 0 0 
5 0 0 0 1 66 0 0 0 0 
6 0 0 0 0 67 0 0 0 1 
7 0 0 1 1 68 0 1 0 0 
8 1 0 1 1 69 1 0 0 1 
9 0 0 0 1 70 0 0 0 1 
10 0 1 0 1 71 0 0 0 1 
11 0 1 1 0 72 1 0 0 1 
12 0 1 0 1 73 0 0 0 1 
13 1 1 0 0 74 0 0 0 1 
14 0 0 0 0 75 0 0 0 1 
15 1 1 0 0 76 1 0 0 1 
16 1 0 0 0 77 0 0 0 1 
17 1 0 0 1 78 0 0 0 1 
18 0 0 0 1 79 1 0 0 1 
19 0 0 0 1 80 0 0 0 1 
20 1 0 0 1 81 0 0 0 1 
21 0 1 0 0 82 1 0 0 0 
22 0 0 0 0 83 0 0 0 1 
23 0 0 0 1 84 0 0 0 1 
24 0 0 0 1 85 0 0 0 0 
25 0 0 0 0 86 1 0 0 1 
26 0 0 0 1 87 0 0 0 1 
27 0 0 0 1 88 0 0 0 1 
28 1 1 0 0 89 0 0 0 0 
29 0 1 0 0 90 0 0 0 1 
30 0 1 0 0 91 1 0 0 1 
31 1 1 1 0 92 0 0 0 1 
32 0 1 0 1 93 0 0 0 1 
33 1 1 0 0 94 0 0 1 1 
34 1 0 0 1 95 1 0 0 1 
35 1 0 0 1 96 0 0 0 1 
36 0 0 0 1 97 0 0 0 1 
37 0 0 0 1 98 1 0 0 0 
38 0 0 0 1 99 0 0 0 1 
39 1 0 0 1 100 1 0 0 1 
40 0 0 0 0 101 1 0 0 1 
41 0 0 0 0 102 1 0 0 1 
42 0 0 0 0 103 0 0 0 1 
43 0 0 0 0 104 1 0 0 1 
44 0 0 0 0 105 1 0 1 1 
45 0 0 0 0 106 1 0 0 1 
46 1 0 0 0 107 0 0 0 1 
47 0 0 0 0 108 1 0 0 1 
48 0 0 0 1 109 1 0 0 1 
49 1 0 0 1 110 0 0 0 1 
50 0 0 0 1 111 1 0 0 1 
51 0 0 0 0 112 0 0 0 1 
52 1 0 0 0 113 1 0 0 1 
53 1 0 0 1 114 1 0 0 1 
54 1 0 0 0 115 1 0 1 1 
55 0 0 0 1 116 1 0 0 1 
56 1 0 0 1 117 1 0 0 1 
57 0 0 0 0 118 0 0 0 1 
58 1 0 0 1 119 1 0 0 1 
59 0 0 0 1 120 1 0 0 1 
60 1 0 0 0 121 1 0 0 1 
61 1 0 0 1 122 1 0 0 1 
0 Denotes that the AME gene is not present by PCR. 
1 Denotes that the AME gene is present by PCR. 
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Overall, 50 (41.0%), 13 (10.7%), 7 (5.7%), and 86 (70.5%) of the 122 P. aeruginosa 
clinical isolates possessed aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia genes, 
respectively. These statistics agree with the common understanding of aac and aph being 
the most common AME genes and ant being the least common. Contrary to what was 
observed in a previous study that identified aac(6')-Ib as the most common AME in 
Klebsiella pneumoniae strains,51 we found aph(3')-Ia to be the most common AME gene 
harbored by the P. aeruginosa clinical isolates in our study. The 122 clinical isolates 
displayed 11 different AME patterns (Table 5.5). There were 17 strains (13.9%) that 
contained no AME genes. 58 strains (47.5%) contained one AME gene only, among which, 
9 (7.4%), 4 (3.3%), and 45 (36.9%) strains contained aac(6')-Ib only, aac(3)-IV only, and 
aph(3')-Ia only, respectively. Not surprisingly, zero strains contained ant(2")-Ia by itself. 
Furthermore, 43 (35.3%) strains contained two AME genes: 4 (3.3%) strains contained the 
combination of aac(6')-Ib and aac(3)-IV, 33 (27.0%) strains contained aac(6')-Ib and 
aph(3')-Ia, 1 (0.8%) strain contained aac(3)-IV and ant(2")-Ia, 3 (2.5%) strains contained 
aac(3)-IV and aph(3')-Ia, and 2 (1.6%) strains contained ant(2")-Ia and aph(3')-Ia. There 
were also 4 (2.5%) strains that possessed three AME genes: either aac(6')-Ib, aac(3)-IV, 
and ant(2")-Ia (1 (0.8%) strain; #31 in Table 5.4) or aac(6')-Ib, ant(2")-Ia, and aph(3')-Ia 
(3 (2.5%) strains; #8, #105, and #115 in Table 5.4). It is important to note that none of the 
clinical isolates studied contained all four AME genes probed for. 
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Table 5.5. The median MIC values of each antibiotic based on the presence and absence of different AME gene patterns. 
  AMK APR GEN* NET SIS TOB MEM 
  Median MIC 
(µg/mL) 
Median MIC 
(µg/mL) 
Median MIC 
(µg/mL) 
Median MIC 
(µg/mL) 
Median MIC 
(µg/mL) 
Median MIC 
(µg/mL) 
Median MIC 
(µg/mL) 
AME pattern No. of 
strains 
Patten 
present 
Pattern 
absent 
Patten 
present 
Pattern 
absent 
Patten 
present 
Pattern 
absent 
Patten 
present 
Pattern 
absent 
Patten 
present 
Pattern 
absent 
Patten 
present 
Pattern 
absent 
Patten 
present 
Pattern 
absent 
No AMEs 17 2 4 4 8 ≤2 ≤2 4 8 2 4 1 4 0.5 2 
AAC(6')-Ib only 9 8 4 8 8 >8 ≤2 >128 8 >128 4 32 1 4 2 
AAC(3)-IV only 4 3 4 8 8 ≤2 ≤2 4 8 2 4 1 2 0.5 2 
APH(3)-Ia only 45 4 4 8 8 ≤2 4 8 8 2 16 1 8 1 2 
AAC(6')-Ib + AAC(3)-IV 4 8 4 8 8 >8 ≤2 >128 8 >128 4 64 2 16 2 
AAC(6')-Ib + APH(3')-Ia 33 4 4 8 8 >8 ≤2 128 8 >128 2 32 1 2 1 
AAC(3)-IV + ANT(2")-Ia 1 1 4 4 8 >8 ≤2 2 8 >128 4 64 2 4 2 
AAC(3)-IV + APH(3')-Ia 3 1 4 2 8 ≤2 ≤2 ≤0.25 8 ≤0.25 4 0.5 2 0.5 2 
ANT(2")-Ia + APH(3')-Ia 2 2 4 8 8 >8 ≤2 18 8 - 4 96 2 6 2 
AAC(6')-Ib + AAC(3)-IV + ANT(2")-Ia 1 4 4 8 8 ≤2 ≤2 8 8 1 4 1 2 2 2 
AAC(6')-Ib + ANT(2")-Ia + APH(3')-Ia 3 8 4 16 8 >8 ≤2 16 8 128 4 64 2 4 2 
*Most GEN MIC values were obtained from the University of Kentucky Hospital System, ranging from ≤2 to >8. 
Note: - indicates that it was impossible to determine the median MIC value as the values involved were a combination of ≤0.25 and >128. 
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In order to determine if the presence of the AME genes found in the clinical isolates 
correlated with the MIC values that were observed for the AGs and to see if they had a 
potential influence on the MIC values of MEM, we categorized all P. aeruginosa strains 
based on their AME gene patterns and compared the median MIC values of each antibiotic 
between the pattern present and the pattern absent groups (e.g., for the group of strains that 
contained aph(3')-Ia only, the pattern present group consisted of the 45 strains that 
possessed only aph(3')-Ia, whereas the pattern absent group included the rest of the 77 P. 
aeruginosa strains that either did not contain this gene or contained other AME genes in 
addition to aph(3')-Ia) (Table 5.5). 
 
For the no AME group, the median TOB and MEM MIC values showed a mild difference 
(4-fold) between the pattern present and absent groups, not surprisingly with the pattern 
present (no AMEs) group showing lower MIC values. No significant difference (≥8-fold) 
was observed between the pattern present and absent groups for other antibiotics in this no 
AME group. 
 
For the three different groups that possessed a single AME gene, the group that contained 
aac(6')-Ib only showed significant differences (≥8-fold) in the median MIC values of GEN, 
NET, SIS, and TOB between the pattern present and absent groups, with the median MIC 
values of the pattern absent group for each of the four antibiotics lying in the susceptible 
range and the pattern present median MIC values falling in the resistant range for each 
antibiotics. The other single AME gene pattern groups did not display as significant a 
contrast with the exceptions of a mild difference (4-fold) in the median MEM MIC values 
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between the aac(3)-IV only pattern present and absent groups, and 8-fold differences in the 
median MIC values of SIS and TOB between the aph(3')-Ia only pattern present and absent 
groups. Counterintuitively, the aph(3')-Ia only pattern present group displayed lower MIC 
values than those in the pattern absent group for SIS and TOB. These interesting 
observations may suggest that AAC(6')-Ib could be the most significant AME contributing 
to the resistance to AGs in this study. Additionally, considering the subtle differences in 
the chemical structures of these AGs, AMK and APR are the only two AGs in this study 
that possess 3' hydroxyl groups to be targeted by APH(3')-Ia, yet, differences in the median 
MIC values in the aph(3')-Ia only pattern present and absent groups were not observed for 
those AGs. However, for SIS and TOB, which contain hydrogen atoms at their 3' position, 
and therefore, do not allow inactivation by the APH(3')-Ia enzyme, the 8-fold lower in the 
median MIC values observed between the aph(3')-Ia only pattern present and absent 
groups potentially indicate that other resistance mechanisms are contributing to resistance 
to these AG antibiotics in the P. aeruginosa clinical isolates tested. 
 
In the five different groups that possessed two AME genes, substantial differences could 
be observed between the pattern present and absent groups for GEN, NET, SIS, TOB, and 
MEM, with the exceptions of the median MEM MIC values between the pattern present 
and absent groups harboring aac(6')-Ib and aph(3')-Ia or aac(3)-IV and ant(2")-Ia, the 
median GEN MIC values for the groups harboring aac(3)-IV and aph(3')-Ia, and the 
median NET and SIS MIC values for the groups harboring ant(2")-Ia and aph(3')-Ia. As 
for the two groups that contained three AME genes, the only significant differences 
between the pattern present and absent groups were observed in median GEN, SIS, and 
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TOB MIC values for the P. aeruginosa strains that contained aac(6')-Ib, ant(2")-Ia, and 
aph(3')-Ia. Another interesting observation was that the one strain containing aac(6')-Ib, 
aac(3)-IV, and ant(2")-Ia showed slightly lower MIC to SIS and TOB in the pattern present 
group when compared to the pattern absent group. However, the differences between the 
MIC values were not significant (≤4-fold difference). Additionally, having only one strain 
in the pattern present group also made it hard to generalize this observation to all P. 
aeruginosa strains harboring this particular AME pattern. In addition to the above 
observations, it is also important to note that none of these AME patterns correlated with 
significant differences in median AMK and APR MIC values between the pattern present 
and absent groups, which agrees with previous studies suggesting that AMK and APR are 
less vulnerable to AMEs and, therefore, less prone to developing resistance due to the 
acquisition of AMEs.51 These two AGs can, therefore, greatly help patients infected with 
resistance microorganisms. Furthermore, the much weaker correlation between MEM MIC 
values and AME gene patterns could easily be explained by the structural difference 
between AGs and carbapenems and the fact that AMEs do not chemically modify 
carbapenems. 
 
Although these P. aeruginosa clinical isolates possessed diverse patterns of AME genes, 
we next decided to further analyze the clinical isolates harboring three of the most 
significant/common AME patterns: aac(6')-Ib, aph(3')-Ia, and aac(6')-Ib + aph(3')-Ia. We 
first separated all the clinical isolates based on the exclusive (gene only) and non-exclusive 
(gene present) presence and absence (gene absent) of the three gene patterns above and 
compared the MIC value distributions of each antibiotic (Figures 5.6-5.8). These findings 
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are in agreement with the previous observations from Table 5.5 and with a previous report 
stating that aph(3')-Ia in combination with another AME correlated with higher resistance 
rates against various antibiotics.51 It is also important to note that the presence of AME 
genes studied does not necessarily equate to the expression and function of the AME 
proteins. Therefore, the presence of certain AME genes, if the gene was not expressed, 
would not contribute to a resistant phenotype. 
 
 
Figure 5.6. Distribution of MIC values of each antibiotic grouped by the presence or absence of the 
aac(6')-Ib gene. The median MIC value in each group, aac(6')-Ib only, aac(6')-Ib present, and aac(6')-Ib 
absent, is represented by a horizontal bar. Note: Plots depicting the distribution of MIC values of each 
antibiotic group by the presence and absence of aph(3')-Ia, and aac(6')-Ib + aph(3')-Ia genes are presented 
in Figure 5.7. Significance was defined as P value ≤0.05 (0.033 (*), 0.002 (**), <0.001 (***)). 
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Figure 5.7. Distribution of MIC values of each antibiotic grouped by the presence and absence of aph(3')-
Ia, and aac(6')-Ib + aph(3')-Ia. The median MIC value in each group is represented by a horizontal bar. 
Note: Additional plots depicting the distribution of MIC values of each antibiotic group by the presence 
and absence of aac(6')-Ib are presented in Figure 5.6. Significance was defined as P value ≤0.05 (0.033 
(*), 0.002 (**), <0.001 (***)). 
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Figure 5.8. Number of P. aeruginosa clinical isolates harboring various AME gene patterns. A. aac(6')-
Ib, B. aph(3')-Ia, and C. aac(6')-Ib + aph(3')-Ia. The percentage of P. aeruginosa strains, which are 
resistant to each antibiotic within each AME pattern group are marked at the top of each column. 
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that were susceptible to AMK and MEM, susceptible to AMK and resistant to MEM, 
susceptible to MEM and resistant to AMK, and resistant to both AMK and MEM, and four 
that were susceptible to TOB and MEM, susceptible to TOB and resistant to MEM, 
susceptible to MEM and resistant to TOB, and resistant to both TOB and MEM, and 
performed combination studies to investigate potential synergistic effects between AGs 
(AMK and TOB) and carbapenems (MEM and IPM (Note: MIC values for IPM alone are 
presented in Table 5.6)) via standard checkerboard assays. Our results, however, suggested 
no synergistic effects between these two classes of antimicrobial agents with the fractional 
inhibitory concentration index (FICI) ranging from 0.625 to 2. This result added on to the 
existing dispute on whether AG and carbapenem combination therapy could be potentially 
helpful to patients with P. aeruginosa infections, and the answer is embedded in the 
intrinsic diversity of P. aeruginosa and the resistance mechanism(s) that it harbors.40-43 
 
Table 5.6. MIC values of IPM (µg/mL) against 
selected P. aeruginosa clinical isolates. 
Strain MIC S/R 
1 4 I 
15 16 R 
26 2 S 
28 16 R 
33 32 R 
50 64 R 
99 2 S 
116 >128 R 
The resistance cutoff values for IPM against P. 
aeruginosa are ≤2 (S) and ≥8 (R) according to the 
Performance Standards for Antimicrobial 
Susceptibility Testing; Twenty-Fourth 
Informational Supplement from CLSI in 2014.44 
 
5.3. CONCLUSIONS 
By evaluating the resistance profile of various AGs and carbapenems of 122 P. aeruginosa 
clinical isolates, we found that the correlation in the resistance between two AGs, and the 
correlation between the resistance to AGs and that to carbapenems suggested a variety of 
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antibiotic resistance mechanisms in addition to the presence of AMEs. Specifically, we 
discovered that the presence of aac(6')-Ib, whether alone or in the presence of other AMEs, 
led to higher rates of resistance to various antibiotics involved in this study, whereas the 
presence of aph(3')-Ia did not, even though the latter was present at a higher frequency in 
these P. aeruginosa strains. However, these observations only revealed a small portion of 
the complex resistance mechanisms to various antibiotics. Thus, our study confirmed the 
unlikeliness of a single “standard treatment” for all P. aeruginosa infections. Instead, 
personalized therapies that take advantage of the genetic information of the isolated 
bacteria, such as resistance gene screening, should be utilized to aid in the selection of 
antimicrobial agents for determination of treatment regiment in order to account for the 
complex nature of P. aeruginosa. 
 
5.4. MATERIALS AND METHODS 
5.4.1. Materials and instrumentation 
All P. aeruginosa strains involved in this study were obtained from the University of 
Kentucky Hospital System. All PCR reagents, including Phusion DNA polymerase, as well 
as ladders for DNA gel electrophoresis were purchased from New England BioLabs (NEB, 
Ipswich, MA). Primers used in PCR reactions and Mueller Hinton broth were purchased 
from Sigma-Aldrich (Milwaukee, WI). InstaGene Matrix was manufactured by Bio-Rad® 
(Hercules, CA). All antibiotics used in this study, including AGs (AMK, APR, GEN, NET, 
SIS, and TOB) and carbapenems (MEM and IPM) were purchased from AK Scientific 
(Mountain View, CA). Data were analyzed and plotted in Sigma Plot 12.3 and Prism 7. 
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5.4.2. Susceptibility testing for AGs and carbapenems 
The MIC values of all AGs and MEM were determined against all 122 clinical isolates 
(Table 5.1), and the MIC values of IPM were determined for a small portion of the clinical 
isolate library (Table 5.6) comprising the strains used for MEM and IPM combination 
study with AGs. Using the broth microdilution method according to guidelines from the 
CLSI,55 a 100 µL aliquot of a bacterial culture in its exponential phase were incubated with 
100 µL of the various antibiotics (final concentration range of 0.5-128 µg/mL) for 16 h and 
then visually inspected for growth. The resistance breakpoint values for each of the various 
antibiotics against P. aeruginosa strains were as follows: AMK (S ≤16, I = 32, R ≥64), 
GEN (S ≤4, I = 8, R ≥16), NET (S ≤8, I = 16, R ≥32), TOB (S ≤4, I = 8, R ≥16), MEM (S 
≤2, I = 4, R ≥8), and IPM (S ≤2, I = 4, R ≥8) according to the CLSI.44 The resistance cutoff 
values for SIS against P. aeruginosa have not been established in U.S.A. and are 
considered to be S ≤4 and R >4 in this study.45, 56 Statistical analyses were performed by 
using Prism 7 and all values were transformed to log2 scale prior to analysis. Comparisons 
between groups of clinical isolates susceptible or resistant to a certain antibiotic were made 
by two-tailed Mann-Whitney test. Significance was defined as P ≤0.05. Significance levels 
were defined in further detail as 0.033, 0.002, <0.001, which were marked in figures by *, 
**, and ***, respectively. Please note that in order to use the Mann-Whitney test for 
continuous variable, we considered all MIC values that were >128 µg/mL to be 256 µg/mL 
for the sake of the test and all that were ≤0.25 µg/mL to be 0.25 µg/mL. 
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5.4.3. Screen for AME genes by PCR 
The presence of aac(6')-Ib, aac(3)-IV, ant(2")-Ia, and aph(3')-Ia genes was evaluated by 
PCR using specific primers, as previously described.51, 57 A 40 µL aliquot of an overnight 
Mueller Hinton liquid culture of each P. aeruginosa strain were centrifuged at 13,000 rpm 
for 1 min to collect the bacteria, which were then mixed with 100 µL of InstaGene Matrix 
and heated up at 100 °C for 30 min. The PCR program was also previously described.51, 57 
The expected sizes were 482 bp, 230 bp, 534 bp, and 624 bp for aac(6')-Ib, aac(3)-IV, 
ant(2")-Ia, and aph(3')-Ia, respectively (Figure 5.7 and Table 5.4). Statistical analyses were 
performed by using GraphPad Instat and Prism 7 software as described in the section above. 
Comparisons between two groups or three groups of clinical strains were made by two-
tailed Mann-Whitney test or Kruskal Wallis test. 
 
5.4.4. Combination studies of AGs and carbapenem by checkerboard assays 
In order to assess the interactions between AGs and carbapenem antibiotics, combination 
studies were performed using standard checkerboard assays with the concentration of AGs 
varied horizontally and that of MEM/IPM varied vertically. For each of AMK and TOB, 
we selected four distinct clinical isolates: one that was susceptible to both AG and MEM, 
one that was susceptible to AG and resistant to MEM, one that was resistant to AG and 
susceptible to MEM, and one that was resistant to both AG and MEM. The concentrations 
of antibiotics for each strain varied as follows: #1 (AMK: 0.008-4 µg/mL, MEM: 0.03-2 
µg/mL, IPM: 0.13-8 µg/mL), #26 (AMK: 4 µg/mL, MEM: 0.06-4 µg/mL, IPM: 0.13-8 
µg/mL), #50 (AMK: 0.03-16 µg/mL, MEM: 2-128 µg/mL, IPM: 2-128 µg/mL), #28 (AMK: 
0.13-64 µg/mL, MEM: 0.5-32 µg/mL, IPM: 1-64 µg/mL), #99 (TOB: 0.004-2 µg/mL, 
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MEM: 0.06-4 µg/mL, IPM: 0.13-8 µg/mL), #116 (TOB: 0.06-32 µg/mL, MEM: 0.06-4 
µg/mL), #33 (TOB: 0.004-2 µg/mL, MEM: 2-128 µg/mL, IPM: 1-64 µg/mL), and #15 
(TOB: 0.25-128 µg/mL, MEM: 0.5-32 µg/mL, IPM: 1-64 µg/mL). The combination of 
TOB and IPM was not tested against strain #116 due to a higher than 128 µg/mL IPM MIC. 
After 16 h of incubation at 37 °C, bacterial growth was inspected visually and FICI values 
were calculated by adding the fractions of MIC of each drug in combination over MIC 
value of that drug alone for each of the two drugs. Drug interaction is defined as synergistic 
if FICI ≤0.5, indifferent if 0.5<FICI<4, antagonistic if FICI >4.58 
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Chapter 6. Repurposing antipsychotic drugs into antifungal agents: synergistic 
combinations of azoles and bromperidol derivatives in the treatment of various 
fungal infections 
As the number of hospitalized and immunocompromised patients continues to rise, 
invasive fungal infections, such as invasive candidiasis and aspergillosis, threaten the life 
of millions of patients every year. The azole antifungals are currently the most prescribed 
drugs clinically that display broad-spectrum antifungal activity and excellent oral 
bioavailability. Yet, the azole antifungals have their own limitations and are unable to meet 
the challenges associated with increasing fungal infections and the accompanied 
development of resistance against azoles. Exploring combination therapy that involves the 
current azoles and another drug has been shown to be a promising strategy. Haloperidol 
and its derivative, bromperidol, were originally discovered as antipsychotics. Herein, we 
synthesize and report a series of bromperidol derivatives and their synergistic antifungal 
interactions in combination with a variety of current azole antifungals against a wide panel 
of fungal pathogens. We further select two representative combinations and confirm the 
antifungal synergy by performing time-kill assays. Furthermore, we evaluate the ability of 
selected combinations to destroy fungal biofilm. Finally, we perform mammalian 
cytotoxicity assays with the representative combinations against three mammalian cell 
lines. 
 
6.1. INTRODUCTION 
Fungal infections are an ever-growing global health problem. Even though fungal 
infections can affect both the healthy and the sick, they pose a much greater threat to 
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chronically ill and immunocompromised patients.1 As the number of hospitalized and 
immunocompromised patients increases, the rise of fungal infections and the associated 
resistance problems are raising alarm. Candida albicans is a leading cause of fungal 
infections and accounts for up to 70% of total incidents worldwide.2 Invasive candidiasis, 
a bloodstream infection of Candida species, is one of the most common nosocomial fungal 
diseases with an estimate of 350,000 incidents worldwide every year and a 30-55% 
mortality rate.3-4 From 2000 to 2005, the number of invasive candidiasis in the U.S.A. rose 
by 52% and inevitably much more in less developed countries, such as Brazil and India. In 
addition to Candida species, some filamentous fungi, such as Aspergillus, also cause life-
threatening infections. If left untreated, invasive aspergillosis can result in a 99% mortality 
rate, and therefore, is another fungal infection that is calling for immediate attention 
worldwide. For instance, the increasing use of corticosteroid in 4.8 million asthma patients 
is linked to over 400,000 patients developing chronic pulmonary aspergillosis.5 
 
Fungi infect not only humans but also various food sources. From the Irish potato famine 
in the 19th century6-7 to today’s spread of Puccina graminis tritici Ug99, which is 
responsible for stem or black rust diseases on wheat,8 fungal infections have never been 
solely a burden to clinical healthcare providers, but also to food production and quality 
control professionals. By infecting crops and livestock, fungi not only result in severe 
damage in the food production industry but can be spread to humans through food and 
cause diseases. 
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The challenges we face with fungal infections are evident and urgent, yet, our repertoire of 
antifungals is limited.3 Currently, there are only few antifungal drugs for the treatment of 
systemic infections, including polyenes (e.g., amphotericin B (AmB)), azoles (e.g., 
fluconazole (FLC), itraconazole (ITC), ketoconazole (KTC), posaconazole (POS), and 
voriconazole (VOR); Figure 6.1A), and echinocandins (e.g., caspofungin (CAS)), each of 
which has severe limitations. The intravenous drug AmB was the first antifungal agent 
approved for systemic use for invasive fungal infections over 50 years ago.9 However, its 
dose-limiting toxicity and other adverse effects often result in interruption of treatment 
courses.10 Another intravenous antifungal drug family, the echinocandins, was shown to 
possess lower toxicity and to be better tolerated than AmB in various formulations.3 The 
broad-spectrum nature of the echinocandins has made them a better alternative to AmB for 
treating invasive fungal infections. 
 
The azoles are the only class of oral antifungals identified due to their excellent oral 
bioavailability.11-12 By targeting the sterol 14a-demethylase, azoles inhibit the biosynthesis 
of ergosterol, which is a vital component of the fungal cell membrane.13-14 Inhibition of 
this enzyme causes the methylated sterol side products to accumulate inside the fungal 
cells, which is toxic to fungi and results in cell death. In addition to excellent 
bioavailability, the azole antifungals also exhibit fewer adverse effects than AmB. 
Consequently, the azole antifungals quickly became the most clinically prescribed 
antifungal class worldwide since their introduction to the market. However, azoles have 
their own limitations. Azoles inhibit cytochrome P450 enzymes, which results in undesired 
interference with the metabolism of numerous other drugs, making it difficult for patients 
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being treated with multiple concurrent medications.15 Moreover, azoles are often found to 
be fungistatic towards many fungi, resulting in only temporary inhibition of fungal 
growth.16 The lack of fungicidal activity has made it challenging to prevent fungal regrowth 
and the accompanied development of antimicrobial resistance to azoles. 
 
 
Figure 6.1. Structures of A. the common azole antifungals with the triazole pharmacophore highlighted in 
pink as well as B. the chemical synthesis of bromperidol series compounds (1-5) involved in this chapter. 
 
Due to the clinical importance of azole antifungals, many research groups have tried to 
develop new azole antifungal therapies with broader antifungal spectra, reduced undesired 
O
R
+
Na2CO3
NaI
Cl
O
N
OH
Br
R
1: R  = H 
2: R  = F
3: R  = Cl
4: R  = Br
5: R  = OMe
HN
OH
Br
F F
HO
N
N
N
R2
R1
NN R2OO
X
N
YN
R1
R1
ITC: R1 = Cl, X = O, Y = N, R2 = 
KTC:  R1 = Cl, X = O, Y = CH, R2 = Ac
POS: R1 = F, X = CH2, Y = N, R2 =
N N
N
O
N N
N
O
OH
FLC:  R1 = H, R2 = 
VOR: R1 = Me, R2 =
N
NN
N
N
F
A
B
	 151 
drug-drug interactions, and diminished other adverse effects. Besides developing new 
azole derivatives,17-19 exploring various combination therapies that work synergistically 
with the current azole antifungals has proved fruitful.20-22 For instance, various azoles were 
shown to display synergistic antifungal activity with a series of amphiphilic tobramycin 
derivatives with azoles inhibiting ergosterol biosynthesis and the tobramycin derivatives 
proposed to act on the fungal membrane integrity.23-24 Sertraline, an antidepressant, was 
also found to work synergistically with FLC against cryptococcal infections.25 
 
The benefits of repurposing existing drugs that have already been approved by the US Food 
and Drug Administration (FDA) for a new application against fungal infections extend 
beyond yielding potentially new antifungal therapies. The previous evaluations of the 
approved drugs from years of clinical studies can also provide valuable information about 
these drugs, such as their pharmacokinetics, pharmacodynamics, metabolism, and toxicity 
profiles. In the effort of repurposing existing drugs, several non-antifungal drugs were 
identified with antifungal activity and were summarized in a previous review article.26 
Haloperidol (trade name Haldol) is an FDA-approved oral antipsychotic that was recently 
discovered to possess antifungal activity towards a drug-sensitive C. albicans strain (C. 
albicans SC5314).27 Bromperidol, a haloperidol derivative also with antipsychotic 
properties, was reported to kill mycobacteria in a synergistic manner with spectinomycin,28 
further suggesting that this antipsychotic drug may possess antimicrobial properties. 
Although the cellular antifungal target of haloperidol/bromperidol is still in debate, this 
antipsychotic drug can potentially be developed into a combination therapy with azoles as 
a new antifungal strategy. 
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Herein, we synthesized a series of bromperidol (2) and a series of its derivatives (1 and 3-
5) (Figure 6.1B) and evaluated the combinational antifungal properties of these compounds 
with a variety of clinical azole antifungal drugs. We tested the combinations of five azoles 
(FLC, ITC, KTC, POS, and VOR) and compounds 1-5 against a wide selection of fungal 
strains, including seven C. albicans, one non-albicans Candida (C. glabrata), and one 
filamentous fungus (A. terreus). After assessing the synergistic effect between the azole 
antifungals and compounds 1-5, we further performed time-kill assays to evaluate this 
antifungal strategy in a time- and dose-dependent manner. Moreover, we evaluated the 
combination of bromperidol (2) and selected azole antifungals for its ability to disrupt yeast 
biofilm in a representative C. albicans strain. Finally, we performed mammalian 
cytotoxicity assay with three selected mammalian cell lines in order to estimate the 
mammalian cytotoxicity exerted by the combinations of compounds 1-5 and azole 
antifungals. 
 
6.2. RESULTS AND DISCUSSION 
6.2.1. Chemical synthesis of bromperidol and its derivatives 
In this study, we aim to evaluate the antifungal activity of the combination of common 
azole antifungals (FLC, ITC, KTC, POS, and VOR, Figure 6.1A) and bromperidol (2) as 
well as its derivatives (1 and 3-5) (Figure 6.1B) against nine fungal pathogens. Each of the 
nine fungal strains tested in this study also presents distinct biology and a complex 
resistance profile. The bromperidol series compounds (1-5) were synthesized by a reaction 
of 4-(4-bromophenyl)-4-hydroxypiperidine with different 4-chlorobutyrophenone 
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derivatives in the presence of sodium iodide and sodium carbonate (Figure 6.1B). The 
substituents at the R position of the five compounds varied in size and included a hydrogen 
atom, halogens (e.g., fluorine, chlorine, and bromine), and a methoxy group. 
 
6.2.2. Antifungal synergy of the combinations of azole antifungals and bromperidol 
series compounds 1-5 by checkerboard assays 
Prior to evaluating the combinational antifungal effect of azoles and compounds 1-5, we 
first determined the minimum inhibitory concentration (MIC) values of each drug against 
a variety of fungal pathogens to examine their innate antifungal effect and better gauge for 
an appropriate concentration range to use for the following checkerboard assay (Tables 6.1 
and 6.3, displayed as MICalone). We first selected two representative C. albicans strains 
(strains B and F) (Table 6.1). C. albicans ATCC 10231 (strain B) is sensitive to most azoles 
whereas C. albicans ATCC 64124 (strain F) displays resistance to most azoles tested. The 
MIC values of the azole antifungals against some fungal strains determined in this study 
were in agreement with previously reported values.17 Furthermore, we observed no 
antifungal effect for compounds 1-5 when tested alone. 
 
We then tested the synergistic antifungal effects of the five azoles and compound 1-5 in 
combination by checkerboard assays and calculated the fractional inhibitory concentration 
index (FICI) against strains B and F (Table 6.1). The FICI cutoff values for determining 
synergy are: synergistic (SYN) if FICI ≤0.5, additive (ADD) if 0.5<FICI≤4, antagonistic 
(ATG) if FICI >4.29 In some cases where the FICI was >0.5, however, we observed a 
significant decrease in the MIC values of at least one of the drugs in the combinations. In 
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such cases, we further defined partial synergy (pSYN) as 0.5<FICI≤0.75 (indicating that 
both drugs showed reduction in MIC values and one drug showed ≥2-fold reduction in 
MIC value), and strong additive effect (ADD*) where one drug showed ≥2-fold reduction 
in MIC value. We deemed defining these two categories necessary, as with these 
combinations, we would still be able to use low level of azoles in combination to achieve 
a similar antifungal effect as using high concentrations of azoles alone, which would 
alleviate azole-induced toxicity and side effects. One thing to note is that due to the resistant 
nature of some fungal strains and the insufficient antifungal activity of the tested drugs, we 
were unable to achieve full inhibition of fungal growth with some drugs, therefore, 
resulting in unbound MIC values such as >32 µg/mL for most azoles and >128, >64, and 
>32 µg/mL for most bromperidol derivatives. In these cases, we considered the MIC values 
to be 32 µg/mL for the azoles and 128, 64, and 32 µg/mL for compounds 1-5, respectively, 
in order to calculate a bound FICI value. However, this approximation would produce 
overestimated FICI values that are higher than the true FICI values if the real MIC values 
could be determined. Hence, the amount of synergy observed in this study (both in terms 
of the FICI value for each combination and in terms of the percentage of combinations with 
synergy) would be an underestimation of the real potential synergy. 
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Table 6.1. The combinational effect of various azoles and compounds 1-5 against two representative C. albicans strains. 
Cpd Azole Strain MIC alone 
(µg/mL) 
MIC in 
combo 
(µg/mL) 
FICI Interp. Cpd Azole Strain MIC alone 
(µg/mL) 
MIC in 
combo 
(µg/mL) 
FICI Interp. 
Azole Cpd Azole Cpd Azole Cpd Azole Cpd 
1 FLC B >32 >64 32 64 2.00 ADD 4 FLC B >32 >64 >32 >64 2.00 ADD 
F >32 >64 >32 >64 2.00 ADD  F >32 >64 >32 >64 2.00 ADD 
ITC B 1 >64 0.5 64 1.50 ADD ITC B 1 >64 0.5 64 1.50 ADD 
F >32 >64 >32 >64 2.00 ADD  F >32 >64 >32 >64 2.00 ADD 
KTC B 1 >64 1 >64 2.00 ADD KTC B 2 >64 1 1 0.52 pSYN 
F 8 >64 4 32 1.00 ADD  F 8 >64 4 1 0.52 pSYN 
POS B 1 >64 0.5 16 0.75 pSYN POS B 1 >64 0.5 32 1.00 ADD 
F >32 >64 2 8 0.19 SYN  F >32 >64 4 16 0.38 SYN 
VOR B 1 >64 0.5 8 0.63 pSYN VOR B 1 >64 0.5 32 1.00 ADD 
F >32 >64 8 32 0.75 pSYN  F >32 >64 4 32 0.63 pSYN 
2 FLC B >32 128 32 64 1.50 ADD 5 FLC B >32 >128 >32 >128 2.00 ADD 
F >32 128 32 64 1.50 ADD  F >32 >128 >32 >128 2.00 ADD 
ITC B 1 128 0.25 64 0.75 pSYN ITC B 1 >128 1 >128 2.00 ADD 
F >32 128 2 64 0.56 pSYN  F >32 >128 >32 >128 2.00 ADD 
KTC B 1 >128 0.5 32 0.75 pSYN KTC B 1 >128 1 >128 2.00 ADD 
F 16 >128 4 64 0.75 pSYN  F 8 >128 4 64 1.00 ADD 
POS B 0.5 128 0.125 64 0.75 pSYN POS B 1 >128 1 >128 2.00 ADD 
F >32 128 4 4 0.16 SYN  F >32 >128 2 8 0.13 SYN 
VOR B 0.5 128 0.25 32 0.75 pSYN VOR B 1 >128 0.5 32 0.75 pSYN 
F >32 128 4 8 0.19 SYN  F >32 >128 8 128 1.25 ADD* 
3 FLC 
 
B >32 >32 32 16 1.50 ADD          
F >32 >32 >32 >32 2.00 ADD          
ITC 
 
B 1 >32 1 >32 2.00 ADD          
F >32 >32 >32 >32 2.00 ADD          
KTC 
 
B 2 >32 0.5 16 0.75 pSYN          
F 8 >32 4 0.5 0.52 pSYN          
POS 
 
B 1 >32 0.5 4 0.63 pSYN          
F >32 >32 2 4 0.19 SYN          
VOR 
 
B 1 >32 0.25 16 0.75 pSYN          
F >32 >32 4 16 0.63 pSYN          
Strains: B = C. albicans ATCC 10231, F = C. albicans ATCC 64124. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤0.5, additive (ADD) if 0.5<FICI≤4, antagonistic 
(ATG) if FICI >4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone 
value used in the FICI calculation is the highest concentration tested of that compound or azole drug. 
 Indicates synergy (SYN, both drugs showed ≥2-fold reduction in MIC value). 
 Indicates partial synergy (pSYN, both drugs showed decrease in MIC value and one drug showed ≥2-fold reduction in MIC 
value). 
 Indicates strong additive effect (ADD*, only one drug showed ≥2-fold reduction in MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
 
Of the 25 combinations tested against strains B and F in the first round, we found six 
combinations (24% of all combinations) to be synergistic with FICI values ranging from 
0.13 to 0.5 against the azole-resistant strain F. The best combination with the lowest FICI 
value of 0.13 observed was compound 5 and POS, which showed decrease of MICalone of 
azole and compound 5 from >32 and >128 µg/mL to 2 and 8 µg/mL (16-fold reduction in 
MIC values for both drugs), respectively. The second-best combination discovered with an 
FICI value of 0.16 was with compound 2 and POS, which showed decrease of MICalone of 
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azole and compound 2 from >32 and 128 µg/mL to 4 (8-fold MIC reduction) and 4 µg/mL 
(32-fold MIC reduction), respectively. In these cases, we demonstrated that the 
combinations of azoles and bromperidol derivatives could synergistically inhibit the 
growth of an azole-resistant C. albicans that otherwise would not have responded to high 
concentrations of either drugs given in the assay. Amongst the six combinations that 
display synergy, four of them (compound 1 with POS, compound 2 with POS or VOR, and 
compound 3 with POS) were also found to display partial synergy (0.5<FICI≤0.75) against 
strain B. Moreover, partial synergy was also observed against both strains B and F for the 
following combinations: compound 1 with VOR, compound 2 with ITC or KTC, 
compound 3 with KTC or VOR, and compound 4 with KTC. For example, with the 
combination of compound 2 and ITC against strain F (FICI = 0.56), inhibition of fungal 
growth could be achieved with 2 µg/mL of ITC (16-fold MIC reduction) and 64 µg/mL of 
compound 2 (1-fold MIC reduction). Partial synergy was also detected for compound 4 
with VOR against strain F as well as for compound 5 with VOR against strain B. With the 
FICI values calculated in this study likely to be overestimated as explained above, these 
combinations with partial synergy also have great potentials for being developed into 
synergistic antifungal therapies. 
 
Besides the combinations found to exert synergistic or partial synergistic effect between 
the azole antifungals and our bromperidol derivatives, we also found one combination to 
display strong additive effect, which is the combination of VOR and compound 5 against 
strain F. An FICI value of 1.25 indicated that this combination displayed additive effect. 
However, looking at the MIC values of each drug alone and in combination, we found a 
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significant decrease (4-fold reduction) in the MIC of VOR in combination compared to 
that of VOR alone even though the MIC value of compound 5 showed no further decrease 
from 128 µg/mL. This suggested that the addition of compound 5 significantly reduced the 
amount of VOR required to inhibit fungal growth, alleviating the toxicity and other 
undesired side effects of azole antifungals. The rest of the combinations (11 out of 25 
combinations) displayed weak additive effect against both strains B and F with FICI values 
ranging from 1.00 to 2.00. No antagonism was found in any combinations tested in this 
study. 
 
When we collected all FICI values for these 25 combinations in Table 6.2 and analyzed 
them in a heat map style table, it became clear that all synergistic combinations discovered 
so far involve either POS or VOR. Of the five combinations involving POS, 100% 
displayed synergy against the azole-resistant C. albicans strain F, and 60% displayed 
partial synergy against strain B. Of all the combinations involving VOR, only one 
combination (that with compound 2) was found to be synergistic against strain F. 
Meanwhile, four combinations with VOR showed partial synergy against strains B 
(compounds 1-3 and 5) and F (1, 3, and 4). This demonstrated that the combination of 
azoles and bromperidol derivatives showed better results with the more resistant fungal 
strain F. Besides POS and VOR, we found that three combinations, compounds 2-4 with 
KTC, showed partial synergy against both fungal strains, and one combination, compound 
2 with ITC, displayed partial synergy against both fungal strains. All the combinations 
involving FLC only displayed weak additive effect. This suggested that POS and VOR 
might be the best candidates for developing combination therapy with compounds 1-5. 
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Table 6.2. FICI values of the combinations of 5 azoles and compounds 1-5 against two C. albicans strains. 
  FLC ITC KTC POS VOR 
Cpd R B F B F B F B F B F 
1 H 2.00 2.00 1.50 2.00 2.00 1.00 0.75 0.19 0.63 0.75 
2 F 1.50 1.50 0.75 0.56 0.75 0.75 0.75 0.16 0.75 0.19 
3 Cl 1.50 2.00 2.00 2.00 0.75 0.52 0.63 0.19 0.75 0.63 
4 Br 2.00 2.00 1.50 2.00 0.52 0.52 1.00 0.38 1.00 0.63 
5 OMe 2.00 2.00 2.00 2.00 2.00 1.00 2.00 0.13 0.75 1.25 
Strains: B = C. albicans ATCC 10231, F = C. albicans ATCC 64124. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤0.5, additive (ADD) if 0.5<FICI≤4, antagonistic (ATG) 
if FICI >4. 
 Indicates synergy (SYN, both drugs showed ≥2-fold reduction in MIC value). 
 Indicates partial synergy (pSYN, both drugs showed decrease in MIC value and one drug showed ≥2-fold reduction in 
MIC value). 
 Indicates strong additive effect (ADD*, only one drug showed ≥2-fold reduction in MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
 
When looking at the five synergistic combinations of POS and compounds 1-5 against 
strain F, we noticed that smaller R substituents in our compounds seemed to correlate with 
lower FICI values. The FICI values increased as the size of the R substituent increased 
from fluorine to bromine in compounds 2-4. This may indicate that the small size of a 
fluorine atom as the R substituent in our compounds may be optimal for interacting with 
its cellular target in fungal cells and increase in the size of the R substituent may cause loss 
of engagement with the target due to steric hindrance. This postulation could also be 
observed by looking at the overall number of combinations that show synergistic tendency 
(synergy or partial synergy) amongst all 25 combinations tested in the first round. 
Compound 2, with a fluorine substituent, showed the highest number of combinations (four 
out of five combinations) with synergistic tendencies. This number decreases as the size of 
the R substituent increases (from fluorine to bromine in compounds 2-4). Compound 5, 
with a methoxy substituent, showed the best synergistic effect in combination with POS 
with the lowest FICI value identified in this study so far. Although methoxy group is the 
largest R group amongst all five compounds in this study, the presence of an oxygen atom 
and the lowest FICI value of 0.13 might suggest either potential hydrogen bonding 
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involved in the interaction of compound 5 with its target or methoxy group, as a strong 
electron donating group, increased the p-p interaction of the connected phenyl ring with 
the target protein/enzyme. 
 
With POS and VOR appearing to be the best azoles to develop combinational antifungal 
therapy with compounds 1-5, we further expanded our fungal collection and tested the 
combination of either POS or VOR and compounds 1-5 against seven additional strains in 
order to better assess the potential synergy against a wide variety of pathogenic fungi with 
distinct biological features (Table 6.3). Amongst these seven additional fungal strains were 
five extra C. albicans strains, one non-albicans Candida strain (C. glabrata, strain H), and 
one filamentous fungus (A. terreus, strain I). All of these fungi are resistant to POS and 
VOR, except for A. terreus, which is sensitive to both of these azoles. The checkerboard 
assay results for POS and VOR in combination with compounds 1-5 against strain B and F 
from Table 6.1 were also listed in Table 6.3 for easy comparison. 
 
Of the ten combinations listed in Table 6.3, each against nine fungal strains, we found 
seven combinations to display synergistic interactions. Compound 2 in combination with 
POS or VOR showed synergy against strains F, G, and I or F and G, respectively. 
Compound 3 with either POS or VOR exhibited synergistic interactions against strain F. 
The other compounds, 1, 4, and 5, all demonstrated synergistic interactions when combined 
with POS against strains F. Compounds 4 and 5 also were found to be synergistic with 
POS against strains H and I, respectively. Furthermore, all ten combinations exhibited 
partial synergy against at least one fungal strain, four of which also displayed strong 
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additive effect against a variety of fungal strains (compound 1 with POS or VOR, 
compound 3 with POS, and compound 5 with VOR). The best combination appeared to be 
compound 2 and POS, as this combination exhibited synergistic interactions against three 
fungal strains and partial synergy against four out of the nine fungal strains we tested. No 
combinations were discovered to have antagonistic interactions (FICI>4). Additionally, we 
found that more combinations involving POS showed synergistic or partially synergistic 
effect compared to the combinations involving VOR. For instance, all five combinations 
involving POS displayed synergy, whereas only two out of five combinations involving 
VOR tested exhibited synergistic interactions. These data demonstrated better synergy 
from developing combination antifungal therapy with POS and bromperidol series 
derivatives. 
 
In addition to the various C. albicans strains, we also observed synergy in the non-albicans 
Candida, C. glabrata, and the filamentous fungus, A. terreus. Amongst the ten 
combinations against C. glabrata (strain H), we found one combination (compound 4 with 
POS) to display strong synergy, four combinations (compounds 1, 2, and 5 with POS as 
well as compound 2 with VOR) to display partial synergy, and one combination 
(compound 1 with VOR) to display strong additive effect. Amongst the ten combinations 
against A. terreus (strain I), we found two combinations (compounds 2 or 5 with POS) to 
be synergistic, one combination to display partial synergy, and one combination to display 
strong additive effect. Overall, these data further suggested that combining azoles and 
compounds 1-5 as an antifungal strategy would be effective against a variety of fungal 
pathogens and benefit patients suffering from different fungal infections. 
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Table 6.3. Combinational effect of POS or VOR with compounds 1-5 against a variety of fungal strains. 
Cpd Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. Azole Strain MIC alone 
(µg/mL) 
MIC combo 
(µg/mL) 
FICI Interp. 
Azole Cpd Azole Cpd Azole Cpd Azole Cpd 
1 POS A >32 >64 1 64 1.03 ADD* VOR A >32 >64 2 64 1.06 ADD* 
B 1 >64 0.5 16 0.75 pSYN B 1 >64 0.5 8 0.63 pSYN 
C >32 >64 >32 >64 2.00 ADD C >32 >64 >32 >64 2.00 ADD 
D >32 >64 0.25 64 1.01 ADD* D >32 >64 >32 >64 2.00 ADD 
E >32 >64 >32 >64 2.00 ADD E >32 >64 >32 >64 2.00 ADD 
F >32 >64 2 8 0.19 SYN F >32 >64 8 32 0.75 pSYN 
G >32 >64 0.125 64 1.00 ADD* G >32 >64 0.125 64 1.00 ADD* 
H >32 >64 2 32 0.56 pSYN H >32 >64 0.25 64 1.01 ADD* 
I 1 >64 0.25 64 1.25 ADD* I 0.5 >64 0.5 >64 2.00 ADD 
2 POS A >32 >128 8 64 0.75 pSYN VOR A >32 >128 0.5 64 0.52 pSYN 
B 0.5 128 0.125 64 0.75 pSYN B 0.5 128 0.25 32 0.75 pSYN 
C >32 >128 >32 >128 2.00 ADD C >32 >128 >32 >128 2.00 ADD 
D >32 >128 0.5 64 0.52 pSYN D >32 >128 1 64 0.53 pSYN 
E >32 >128 >32 >128 2.00 ADD E >32 >128 >32 >128 2.00 ADD 
F >32 128 4 4 0.16 SYN F >32 128 4 8 0.19 SYN 
G >32 >128 0.0625 64 0.50 SYN G >32 >128 0.125 64 0.50 SYN 
H >32 >128 0.25 64 0.51 pSYN H >32 >128 0.25 64 0.51 pSYN 
I 1 >128 0.25 32 0.5 SYN I 0.5 >128 0.5 >128 2.00 ADD 
3 POS A >32 >32 1 16 0.53 pSYN VOR A >32 >32 8 16 0.75 pSYN 
B 1 >32 0.5 4 0.63 pSYN B 1 >32 0.25 16 0.75 pSYN 
C >32 >32 0.5 32 1.02 ADD* C >32 >32 16 16 1.00 ADD 
D >32 >32 2 16 0.56 pSYN D >32 >32 16 16 1.00 ADD 
E >32 >32 0.5 16 0.52 pSYN E >32 >32 16 16 1.00 ADD 
F >32 >32 2 4 0.19 SYN F >32 >32 4 16 0.63 pSYN 
G >32 >32 0.5 16 0.52 pSYN G >32 >32 2 8 0.31 SYN 
H >32 >32 >32 >32 2.00 ADD H >32 >32 >32 >32 2.00 ADD 
I 0.5 >32 0.5 >32 2.00 ADD I 0.25 >32 0.25 >32 2.00 ADD 
4 POS A >32 >64 >32 >64 2.00 ADD VOR A >32 >64 >32 >64 2.00 ADD 
B 1 >64 0.5 32 1.00 ADD B 1 >64 0.5 32 1.00 ADD 
C >32 >64 >32 >64 2.00 ADD C >32 >64 >32 >64 2.00 ADD 
D >32 >64 >32 >64 2.00 ADD D >32 >64 >32 >64 2.00 ADD 
E >32 >64 >32 >64 2.00 ADD E >32 >64 >32 >64 2.00 ADD 
F >32 >64 4 16 0.38 SYN F >32 >64 4 32 0.63 pSYN 
G >32 >64 >32 >64 2.00 ADD G >32 >64 >32 >64 2.00 ADD 
H >32 >64 8 8 0.38 SYN H >32 >64 >32 >64 2.00 ADD 
I 0.5 >64 0.25 1 0.52 pSYN I 0.25 >64 0.25 >64 2.00 ADD 
5 POS A >32 >128 >32 >128 2.00 ADD VOR A >32 >128 >32 >128 2.00 ADD 
B 1 >128 1 >128 2.00 ADD B 1 >128 0.5 32 0.75 pSYN 
C >32 >128 >32 >128 2.00 ADD C >32 >128 >32 >128 2.00 ADD 
D >32 >128 >32 >128 2.00 ADD D >32 >128 >32 >128 2.00 ADD 
E >32 >128 >32 >128 2.00 ADD E >32 >128 >32 >128 2.00 ADD 
F >32 >128 2 8 0.13 SYN F >32 >128 8 128 1.25 ADD* 
G >32 >128 >32 >128 2.00 ADD G >32 >128 >32 >128 2.00 ADD 
H >32 >128 0.25 64 0.51 pSYN H >32 >128 >32 >128 2.00 ADD 
I 0.5 >128 0.125 32 0.50 SYN I 0.25 >128 0.25 >128 2.00 ADD 
Strains: A = C. albicans ATCC MYA-1003, B = C. albicans ATCC 10231, C = C. albicans ATCC MYA-1237, D = C. albicans ATCC 
MYA-2310, E = C. albicans ATCC MYA-2876, F = C. albicans ATCC 64124, G = C. albicans ATCC 90819, H = C. glabrata ATCC 
2001, I = A. terreus ATCC MYA-3633. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤0.5, additive (ADD) if 0.5<FICI≤4, antagonistic (ATG) 
if FICI >4. 
Note: Where the highest concentration of a compound or azole drug alone did not achieve optical growth inhibition, the MICalone value 
used in the FICI calculation is the highest concentration tested of that compound or azole drug. 
 Indicates synergy (SYN, both drugs showed ≥2-fold reduction in MIC value). 
 Indicates partial synergy (pSYN, both drugs showed decrease in MIC value and one drug showed ≥2-fold reduction in MIC). 
 Indicates strong additive effect (ADD*, only one drug showed ≥2-fold reduction in MIC value). 
 Indicates weak additive effect (ADD, neither of the drugs showed ≥2-fold reduction in MIC value). 
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6.2.3. Time-dependent antifungal activity of the combinations of azole antifungals and 
bromperidol series compounds 
In order to confirm the synergistic interaction between our bromperidol series compounds 
and azole antifungals, we performed time-kill assays against strain F for two representative 
combinations (compound 2 and either POS or VOR) that displayed great synergy in 
previous checkerboard assays (Figure 6.2). In these time-kill assays, we evaluated the 
antifungal effect of each drug alone (POS, VOR, or compound 2) as well as the two 
combinations (POS or VOR with compound 2) at various concentrations (0.5×-8× 
MICcombo of each drug). Overall, the combinations of POS or VOR and compound 2 
showed fungistatic effect at 8× MICcombo concentrations. The colony-forming unit 
(CFU)/mL values did not differentiate amongst various samples until after 6 h. In the first 
combination tested (POS + compound 2), we saw significant growth in the growth control 
(increase in CFU/mL by 4 order of magnitude). Meanwhile, the POS or compound 2 alone 
samples showed slight inhibition of fungal growth similar to that of the 0.5× and 1× 
MICcombo samples (increase in CFU/mL by about 1 order of magnitude). The combination 
sample with 4× MICcombo showed stronger inhibition of fungal growth compared to the 
alone samples as well as the combination samples with less drugs. The combination sample 
with 8× MICcombo showed complete inhibition of fungal growth and the CFU/mL value for 
this sample remained around 1×105 CFU/mL throughout 24 h. The growth of the fungus 
in each sample was further assessed by the addition of resazurin after the 24-h time point, 
which can be metabolized by live fungal cells and turns the solution from blue to pink. The 
combination of VOR and compound 2 showed a similar profile to that of the combination 
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of POS and compound 2, except that the combination sample with 8× MICcombo showed 
slight reduction in CFU/mL by about 1 log10 unit over 24 h. 
 
 
Figure 6.2. Time- and dose-dependent antifungal synergy of the combinations of A. POS or B. VOR and 
compound 2 at various concentrations against C. albicans ATCC 64124 (strain F). Each sample with 
resazurin added for visualization of fungal growth is presented underneath the growth curve for each 
combination. 
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6.2.4. Biofilm disruption with the combinations of representative azole antifungals 
and bromperidol series compounds 
Recent discoveries suggest that fungi in biofilms display drastically different biology and 
antimicrobial susceptibility when compared to free living (planktonic) fungal cells.30 
Biofilm-forming (sessile) fungal cells are protected by extracellular matrices and display 
increased resistance against a variety of antifungal agents.31-34 Using a water soluble 
metabolic dye, XTT (2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-
carboxanilide), the metabolic activity of biofilm (sessile cells) can be measured in 
checkerboard format assays.35 In this study, we selected two representative combinations 
(POS or VOR with compound 2), which showed excellent synergy in the above 
checkerboard assay against strain F, and evaluated the antifungal effect that these 
combinations have on sessile cells (Table 6.4). We reported that the sessile cells of strain 
F are highly resistant to all drugs tested, including POS, VOR, and compound 2 alone with 
sessile MIC (SMIC) values of >32, >32, and >128 µg/mL, respectively. When tested in 
combination, both combinations failed to show strong synergy as observed in checkerboard 
assay in planktonic fungal cells. Instead, both combinations showed strong additive 
antifungal effect with FICI values of 1.02 (the SMIC value of compound 2 in combination 
did not decrease by much compared to that alone, the SMIC values of POS or VOR both 
decreased significantly from >32 to 0.5 µg/mL). This result suggested great antifungal 
potential of the combination of azoles and bromperidol series compounds as well as the 
more resistant nature of the sessile fungal cells compared to planktonic cells. 
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Table 6.4. Inhibition of biofilm formation with azoles and compound 2 combinations. 
Cpd Azole Strain SMIC alone (µg/mL) SMIC combo (µg/mL) FICI Interp. 
   Azole Cpd Azole Cpd   
2 POS F >32 >128 0.5 128 1.02 ADD* 
 VOR F >32 >128 0.5 128 1.02 ADD* 
Strain F = C. albicans ATCC 64124. 
The FICI cutoff values for determining synergy are: synergistic (SYN) if FICI ≤0.5, additive (ADD) if 0.5<FICI≤4, antagonistic 
(ATG) if FICI >4. 
Since the highest concentration of compound 2 or azole alone did not achieve complete growth inhibition, the MICalone value used in 
the FICI calculation is the highest concentration tested of compound 2 or azole drugs. 
ADD* indicates strong additive effect (one drug showed ≥2-fold reduction in MIC value). 
 
6.2.5. Mammalian cytotoxicity of the combinations of representative azole antifungals 
and bromperidol series compounds 
In addition to assessing the time-dependent killing and disruption of fungal biofilm, we 
also evaluated the mammalian cytotoxicity of azole antifungals and bromperidol (2) alone 
and in combination (Figure 6.3). In order to gain a better understanding of the toxicity 
profile towards different mammalian cells, we evaluated representative azoles (POS and 
VOR) and compound 2 against three different mammalian cell lines, including human 
bronchial epithelial cells BEAS-2B, human kidney epithelial cells HEK-293, and the 
murine macrophage J774A.1. Please note that as many xenobiotics stimulate cell growth 
instead of exerting toxicity at sub-IC50 concentrations,23, 36-39 resulting in >100% cell 
survival in the treatment groups, we have considered these >100% cell survival data as no 
observed toxicity and expressed them as 100% cell survival. When testing the azole 
antifungals alone (Figure 6.3A), we observed no cytotoxic effect up to 4 µg/mL. At 
8 µg/mL, we observed 80 ± 9% cell survival with J774A.1 cells, and at 16 µg/mL, we 
observed around 45 ± 12% and 46 ± 3% cell survival POS-treated HEK-293 and J774A.1 
cells, respectively. No cytotoxic effect was observed in any VOR-treated cell lines at any 
concentrations tested. With BEAS-2B and HEK-293 cells being more robust cell lines than 
J774A.1, we were not surprised to see the absence of toxicity in these two cell lines 
compared to that in J774A.1 cells, because macrophages are often short-lived and fragile 
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within the human body. We then assessed the toxicity of compound 2 alone as a 
representative of our bromperidol series derivatives (Figure 6.2B). We found no toxicity 
against BEAS-2B and HEK-293 cells at 64 µg/mL. Compound 2 alone exerted toxicity 
against J774A.1 cells and showed 72 ± 14%, 50 ± 7% and 30 ± 4% cell survival with 16, 
32, and 64 µg/mL compound 2, respectively. These findings suggested that our 
bromperidol series compounds had much better toxicity profiles against various 
mammalian cells and that the strategy of using our bromperidol series compounds in 
combination with azole antifungals can effectively help alleviate azole-induced toxicity by 
reducing the amount of azole antifungals required in treatment. 
 
Since 8 µg/mL compound 2 was the highest concentration at which no cytotoxicity was 
observed with all three cell lines, we performed the cytotoxicity assay of POS and VOR 
against all three cell lines with 8 µg/mL compound 2 supplemented in the media (Figure 
6.3C). We observed similar overall cytotoxic effect as in the azoles alone samples. The 
percent cell survivals were slightly lower at 8 or 16 µg/mL POS in combination compared 
to that of POS alone. Meanwhile, we observed no toxicity at 16 µg/mL VOR in 
combination with 8 µg/mL compound 2. As J774A.1 is the most fragile cell line tested, we 
also tested the combination of azoles and a higher concentration of compound 2 (32 µg/mL) 
against the two epithelial cell lines (BEAS-2B and HEK-293 cells) (Figure 6.3D). Of the 
combination of POS and compound 2 against BEAS-2B cells, we observed 71 ± 11% and 
38 ± 6% cell survival at 8 and 16 µg/mL POS. However, the combination toxicity of POS 
and 32 µg/mL compound 2 was more prominent against HEK-293 cells where we observed 
decreased cell survival from 80 ± 8% to 40 ± 6% as the concentration of POS increased 
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from 1 to 16 µg/mL. With 32 µg/mL compound 2, we still noted no toxicity against either 
cell lines at any concentration of VOR, which proved the better toxicity profile of VOR 
compared to that of POS. 
 
Judging from the results from cytotoxicity assays, POS seemed to be toxic to mammalian 
cells. Thus, developing combinational antifungal therapy that involves less POS and more 
of the nontoxic bromperidol (2) seemed to be a reasonable approach to alleviate azole-
induced toxicity and other related side effects. In addition to the great potential of synergy 
between POS and bromperidol compounds, VOR also has great potential to be developed 
into combinational antifungal therapies due to its nontoxic nature. 
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Figure 6.3. Mammalian cytotoxicity evaluation of A. POS and VOR alone, B. compound 2 alone, C. and D. 
representative combinations of azoles (POS or VOR) at various concentrations along with compound 2 at 8 
µg/mL (panel C) or 32 µg/mL (panel D) supplemented in the media against BEAS-2B, HEK-293, and 
J774A.1 cells. Note: As at 32 µg/mL, compound 2 exerted toxicity against J774A.1 (as seen in panel B), this 
cell line was not tested in panel D. 
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Haloperidol/bromperidol, originally antipsychotic drugs, act on dopamine D2 receptors, 
which is a G protein-coupled receptor with P-glycoprotein properties.40-41 However, as 
newly discovered antifungal candidates, their cellular target in fungal cells remained 
elusive. Although some reports indicated that haloperidol might target the biosynthesis and 
metabolism of amino acids42 or fungal morphogenesis and hyphal formation27, 43 in fungal 
pathogens, others pointed out that the multidrug-resistant transporter (MDR1), a p-
glycoprotein, is more likely to be the antifungal target of this antipsychotic drug.44 
Inhibition of MDR1, an active transporter/efflux pump that contributes to efflux-related 
azole resistance, can further sensitize fungal pathogens to azole antifungals and prolong 
their antifungal effect. The bromperidol series compounds presented in this study, due to 
structural similarity, are also likely to exert their antifungal properties in the same way. 
Although determining the exact mechanism of action of bromperidol is outside of the scope 
of the current study, we wanted to offer a potential explanation for the synergy observed 
herein. This theory could also explain why the bromperidol series compounds possessed 
no antifungal activity by themselves but could produce great antifungal synergy in 
combination with various azoles. A recent study reported synergistic antifungal effect of 
FLC and VOR in combination with haloperidol as an MDR1 inhibitor against two 
Malassezia strains,45 which also demonstrated the feasibility and benefits of developing 
new antifungal therapies with the combination of haloperidol or its derivatives and azole 
antifungals. 
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6.3. CONCLUSIONS 
In this study, we evaluated the antifungal effect of bromperidol and four of its derivatives 
in combination with five clinically relevant azole antifungals against a wide variety of 
pathogenic fungi. From our extensive evaluation of the combinational antifungal effect 
between the two classes of compounds by checkerboard, time-kill, and biofilm disruption 
assays, we observed a wide range of combinational effects ranging from synergistic to 
weak additive effect. A considerable portion of the combinations tested in this study 
displayed synergy or partial synergy. We also found that POS displayed synergy in more 
combinations with bromperidol series compounds than VOR did. However, our 
cytotoxicity evaluation suggested combination therapy with VOR might have superior 
mammalian cytotoxicity profiles. As mentioned above, the FICI calculated in this study 
are likely to be higher than the true FICI values due to the unbound MIC values. Therefore, 
the potential synergy and the number of combinations showing synergistic effects are also 
likely to be underestimated. Even though the exact cellular target by which the bromperidol 
series compounds exert antifungal activity when combined with azole antifungals remains 
unclear, our results suggested that using these bromperidol derivatives in combination with 
clinically relevant azoles can synergistically inhibit fungal growth and effectively reduced 
the amount of azoles required to achieve an equivalent antifungal effect, and therefore, 
alleviate the toxicity and side effects resulted from administering high concentrations of 
azole antifungals. 
 
 
 
	 171 
6.4. MATERIALS AND METHODS 
6.4.1. Chemistry Methodology 
6.4.1.1. Materials and instrumentation for chemistry 
All reagents were bought from commercial sources and no further purification was 
performed before usage. TLC analyses were performed on 0.25-mm thick silica gel plates 
(pre-coated on glass) with fluorescent indicator UV254, and were visualized by UV or 
charring in a KMnO4 stain. 1H and 13C NMR spectra were recorded on a 400 MHz NMR 
spectrometer (VARIAN INOVA) using CDCl3, CD3OD, or (CD3)2SO as solvents. 
Chemical shifts were reported in parts per million (ppm) and were referenced to residual 
solvent peaks. All reactions were carried out under nitrogen gas with all yields reported 
representing isolated yields. All compounds were characterized by 1H and 13C NMR as 
well as mass spectrometry. Although compound 2 has been reported in the literature, its 
characterization has not been published in detail. NMR spectra confirm that all compounds 
are ≥95% pure. Further confirmation of compound purity was obtained by RP-HPLC, 
which was performed on an Agilent Technologies 1260 Infinity HPLC system by using the 
following general method 1: Flow rate = 1 mL/min; l = 254 nm; column = Vydac 201SPTM 
C18, 250 × 4.6 mm, 90A 5 µm; Eluents: A = H2O + 0.1% TFA, B = MeCN; gradient profile: 
starting from 5% B, increasing from 5% B to 100% B over 20 min, holding at 100% B 
from 20-27 min, decreasing from 100% B to 5% B from 27-30 min. The HPLC column 
was equilibrated with 5% B for 15 min prior to each injection. 
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6.4.1.2. Synthesis and characterization of compounds used in this study 
General procedure for the amination reaction (e.g., 
synthesis of compound 1). Compound 1 was prepared 
following a previously published protocol for a similar 
molecule.46 Sodium iodide (0.039 g, 0.260 mmol) and sodium carbonate (0.050 g, 0.472 
mmol) were added to a stirred mixture of 4-chlorobutyrophenone (0.043 g, 0.236 mmol) 
and 4-(4-bromophenyl)-4-hydroxypiperidine (0.060 g, 0.236 mmol) in MeCN (2 mL). The 
reaction mixture was refluxed for 12 h. The mixture was diluted with H2O, and extracted 
with CH2Cl2 (3×10 mL), dried over MgSO4, and concentrated under reduced pressure. The 
residue was purified by column chromatography (SiO2, MeOH:EtOAc/1:9, Rf 0.22), to 
give compound 1 (0.016 g, 17%) as a white solid: 1H NMR (400 MHz, CDCl3, Figure 6.4) 
d 7.97 (d, J = 8.0 Hz, 2H), 7.54 (t, J = 7.2 Hz, 1H), 7.46 (d, J = 7.2 Hz, 2H), 7.42 (d, J = 
8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 3.00 (t, J = 6.8 Hz, 2H), 2.81 (m, 2H), 2.50 (t, J = 
6.8 Hz, 2H), 2.44 (t, J = 12.0 Hz, 2H), 2.04-1.96 (m, 2H), 2.00 (p, J = 6.8 Hz, 2H), 1.66-
1.63 (m, 3H); 13C NMR (100 MHz, CDCl3, Figure 6.5) d 199.9, 147.3, 137.2, 132.9, 131.3, 
128.5, 128.1, 126.4, 120.8, 71.1, 57.8, 49.2, 38.2, 36.2, 21.8; LRMS m/z calcd for 
C21H25BrNO2 [M+H]+: 402.1; found 402.7. Purity of the compound was further confirmed 
by RP-HPLC by using method 1: Rt = 7.75 min (97% pure; Figure 6.6). 
 
Synthesis of compound 2. Following the general procedure 
described for the synthesis of compound 1, sodium iodide 
(0.039 g, 0.260 mmol), sodium carbonate (0.050 g, 0.472 
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mmol), 4'-fluoro-4-chlorobutyrophenone (0.047 g, 0.236 mmol), and 4-(4-bromophenyl)-
4-hydroxypiperidine (0.060 g, 0.236 mmol) in MeCN (2 mL) were used to afford know 
compound 2 (also known as bromperidol)47 (0.024 g, 24%, Rf 0.15 in MeOH:EtOAc/1:9) 
as a white solid: 1H NMR (400 MHz, CDCl3, Figure 6.7) d 7.99 (dd, J = 8.4, 6.0 Hz, 2H), 
7.43 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.11 (app. t, J = 8.4 Hz, 2H), 2.97 (t, J = 
6.8 Hz, 2H), 2.79 (m, 2H), 2.48 (t, J = 6.8 Hz, 2H), 2.42 (t, J = 11.2 Hz, 2H), 2.04-1.94 (m, 
2H), 1.98 (p, J = 6.8 Hz, 2H), 1.67-1.64 (m, 3H); 13C NMR (100 MHz, CDCl3, Figure 6.8) 
d 198.3, 166.9, 164.3, 147.3, 133.61, 133.58, 131.3, 130.7, 130.6, 126.4, 120.9, 115.7, 
115.5, 71.1, 57.8, 49.3, 38.2, 36.2, 21.8; LRMS m/z calcd for C21H24BrFNO2 [M+H]+: 
420.1; found 420.7. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 7.93 min (95% pure; Figure 6.9). 
 
Synthesis of compound 3. Following the general procedure 
described for the synthesis of compound 1, sodium iodide 
(0.039 g, 0.260 mmol), sodium carbonate (0.050 g, 0.472 
mmol), 4'-chloro-4-chlorobutyrophenone (0.051 g, 0.236 mmol), and 4-(4-bromophenyl)-
4-hydroxypiperidine (0.060 g, 0.236 mmol) in MeCN (2 mL) were used to afford 
compound 3 (0.024 g, 23%, Rf 0.21 in MeOH:EtOAc/1:9) as a white solid: 1H NMR (400 
MHz, CDCl3, Figure 6.10) d 7.89 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 4H), 7.31 (d, J 
= 8.4 Hz, 2H), 3.02 (t, J = 6.8 Hz, 2H), 2.97 (m, 2H), 2.77-2.68 (m, 2H), 2.66 (t, J = 6.8 
Hz, 2H), 2.28-2.14 (m, 3H), 2.07 (p, J = 6.8 Hz, 2H), 1.74 (m, 2H); 13C NMR (100 MHz, 
CDCl3, Figure 6.11) d 198.1, 146.6, 139.5, 135.1, 131.4, 129.5, 128.9, 126.4, 121.1, 70.4, 
57.3, 49.1, 37.1, 36.0, 20.5; LRMS m/z calcd for C21H24BrClNO2 [M+H]+: 436.1; found 
O
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436.7. Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt 
= 8.54 min (98% pure; Figure 6.12). 
 
Synthesis of compound 4. Following the general procedure 
described for the synthesis of compound 1, sodium iodide 
(0.039 g, 0.260 mmol), sodium carbonate (0.050 g, 0.472 
mmol), 4'-bromo-4-chlorobutyrophenone (0.062 g, 0.236 mmol), and 4-(4-bromophenyl)-
4-hydroxypiperidine (0.060 g, 0.236 mmol) in MeCN (2 mL) were used to afford 
compound 4 (0.034 g, 30%, Rf 0.24 in MeOH:EtOAc/1:9) as a white solid: 1H NMR (400 
MHz, CDCl3, Figure 6.13) d 7.81 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 7.43 (d, J 
= 8.8 Hz, 2H), 7.33 (d, J = 8.8 Hz, 2H), 3.14-3.07 (m, 2H), 3.06 (t, J = 6.4 Hz, 2H), 2.96-
2.80 (m, 2H), 2.79-2.69 (m, 2H), 2.48-2.24 (m, 2H), 2.12 (p, J = 6.4 Hz, 2H), 1.78 (m, 2H); 
13C NMR (100 MHz, (CD3)2SO, Figure 6.14) d 198.4, 135.9, 131.83, 131.77, 130.8, 130.0, 
129.9, 127.1, 119.6, 68.8, 55.2, 48.5, 36.1, 35.4, 18.9; LRMS m/z calcd for C21H24Br2NO2 
[M+H]+: 480.0; found 480.7. Purity of the compound was further confirmed by RP-HPLC 
by using method 1: Rt = 8.66 min (99% pure; Figure 6.15). 
 
Synthesis of compound 5. Following the general 
procedure described for the synthesis of compound 1, 
sodium iodide (0.039 g, 0.260 mmol), sodium carbonate 
(0.050 g, 0.472 mmol), 4'-methoxy-4-chlorobutyrophenone (0.050 g, 0.236 mmol), and 4-
(4-bromophenyl)-4-hydroxypiperidine (0.060 g, 0.236 mmol) in MeCN (2 mL) were used 
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to afford compound 5 (0.013 g, 13%, Rf 0.20 in MeOH:EtOAc/1:9) as a white solid: 1H 
NMR (400 MHz, CDCl3, Figure 6.16) d 7.95 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 
7.32 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 2H), 3.85 (s, 3H), 2.95 (t, J = 6.8 Hz, 2H), 
2.82 (m, 2H), 2.50 (t, J = 6.8 Hz, 2H), 2.45 (t, J = 11.6 Hz, 2H), 2.08-1.96 (m, 2H), 1.98 
(p, J = 6.8 Hz, 2H), 1.67 (m, 2H), 1.62 (br s, 1H); 13C NMR (100 MHz, CD3OD, Figure 
6.17) d 199.5, 165.6, 148.1, 132.6, 131.7, 131.0, 128.0, 122.3, 115.1, 69.9, 56.2, 50.4, 49.6, 
37.0, 36.1, 20.6; LRMS m/z calcd for C22H27BrNO3 [M+H]+: 432.1; found 432.7. Purity of 
the compound was further confirmed by RP-HPLC by using method 1: Rt = 8.22 min (95% 
pure; Figure 6.18). 
 
6.4.1.3. Compound characterization 
 
Figure 6.4. 1H NMR spectrum for compound 1 in CDCl3. 
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Figure 6.5. 13C NMR spectrum for compound 1 in CDCl3. 
 
 
Figure 6.6. HPLC trace for compound 1. Rt = 7.75 min. 
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Figure 6.7. 1H NMR spectrum for compound 2 in CDCl3. 
 
 
Figure 6.8. 13C NMR spectrum for compound 2 in CDCl3. 
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Figure 6.9. HPLC trace for compound 2. Rt = 7.93 min. 
 
 
Figure 6.10. 1H NMR spectrum for compound 3 in CDCl3. 
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Figure 6.11. 13C NMR spectrum for compound 3 in CDCl3. 
 
 
Figure 6.12. HPLC trace for compound 3. Rt = 8.54 min. 
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Figure 6.13. 1H NMR spectrum for compound 4 in CDCl3. 
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Figure 6.14. 13C NMR spectrum for compound 4 in (CD3)2SO. 
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Figure 6.15. HPLC trace for compound 4. Rt = 8.66 min. 
 
 
Figure 6.16. 1H NMR spectrum for compound 5 in CDCl3. 
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Figure 6.17. 13C NMR spectrum for compound 5 in CD3OD. 
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Figure 6.18. HPLC trace for compound 5. Rt = 8.22 min. 
 
6.4.2. Biological testing methodology 
6.4.2.1. Biological reagents and instrumentation 
The azole antifungal agents FLC, ITC, KCZ, POS, and VOR were purchased from AK 
Scientific (Union city, CA, U.S.A.). The Candida albicans strains, including C. albicans 
ATCC 10231 (strain B), C. albicans ATCC 64124 (strain F), and C. albicans ATCC MYA-
2876 (Strain E) were a generous gift from Dr. Jon Y. Takemoto (Utah State University, 
Logan, UT, U.S.A.). The rest of the C. albicans strains, including C. albicans ATCC 90819 
(strain G), C. albicans ATCC MYA-2310 (strain D), C. albicans ATCC MYA-1237 (strain 
C), and C. albicans ATCC MYA-1003 (strain A), as well as the non-albicans Candida 
fungus C. glabrata ATCC 2001 (strain H) were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, U.S.A.). The filamentous fungus Aspergillus terreus 
ATCC MYA-3633 (strain I) was also purchased from the ATCC. Yeast strains were 
cultured at 35 °C in yeast extract peptone dextrose (YEPD) broth. Filamentous fungi were 
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cultured on potato dextrose agar (PDA, catalog # 110130, EMD Millipore, Billerica, MA, 
U.S.A.) at 25 °C before the spores were harvested. All fungal experiments were carried out 
in RPMI 1640 medium (catalog # R6504, Sigma-Aldrich, St. Louis, MO, U.S.A.) buffered 
to pH 7.0 with 0.165 M MOPS buffer (Sigma-Aldrich, St. Louis, MO, U.S.A.). 
Colorimetric assessments were performed by using a SpectraMax M5 spectrometer 
(Molecular Devices, Sunnyvale, CA, U.S.A.). 
 
6.4.2.2. Determination of MIC values 
To assess the potential synergistic effect between various azoles and our bromperidol (2) 
as well as its derivatives 1 and 3-5, we first needed to determine the individual minimum 
inhibitory concentration (MIC) values of compounds 1-5 and of the azole antifungals 
against each fungal strain of interest to gauge the range of concentrations to use in further 
assays. These MIC values were determined using the broth microdilution method in sterile 
96-well plates with the highest concentrations of drugs used being 128 µg/mL for 
compounds 2 and 5, 64 µg/mL for compounds 1 and 4, and 32 µg/mL for compound 3 and 
for the azole antifungals. Note: The different starting concentrations result from the 
solubility limit of the compounds studied. These compounds were serially diluted (2-fold 
dilutions) horizontally on the plate in 100 µL of RPMI medium. A diluted yeast culture (25 
µL of a fungal stock with OD600 of 0.125 in 10 mL of RPMI medium, which achieves a 
final inoculum size of around 1-5×103 CFU/mL) was plated across the plate (100 µL per 
well), making a final volume of 200 µL total per well. Similarly, in vitro MIC values for 
compounds 1-5 against filamentous fungi were determined as previously described in CLSI 
document M38-A2.48 Briefly, 1×105 spores were seeded in each well in 100 µL of RPMI 
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medium. The MIC value of each compound was observed by visual inspection after 48 h 
of incubation at 35 °C for yeast or 72 h at 35 °C for the Aspergillus strains (Tables 6.1 and 
6.3). 
 
6.4.2.3. Combination studies of azoles and bromperidol series derivatives by 
checkerboard assays 
To assess the potential synergistic effect between the commercially available azoles and 
our compounds 1-5 against various fungal strains, we employed the standard checkerboard 
assay as previously described49-50 with slight variations. The commercially available azoles 
were serially diluted (2-fold dilutions) in the 96-well plates while the second drug, 
compounds 1-5, were double-diluted in tubes outside of the 96-well plates and then later 
added into the plates using a multi-channel pipet. The concentration of azoles varied 
horizontally while that of compounds 1-5 varied vertically. The appropriate range of 
concentrations for each compound was determined based on their corresponding MIC 
values against each fungal strain. The inoculum size for yeast and filamentous fungi were 
the same as in the MIC experiments described in section 2.2. The 96-well plates were 
incubated at 35 °C for 48 h for yeasts and 72 h for the Aspergillus strain before visual 
inspection for growth. The observed MIC values of the azoles and compounds 1-5 alone 
as well as the MIC values for the two compounds in combo were then used to calculate the 
FICI using the formula below. The combinational effect of the two tested compounds were 
considered SYN if FICI ≤0.5, ADD if 0.5<FICI≤4, and ATG if FICI >4 (Tables 6.1-6.3).29 
 
FICI = !"#	%&	'(%)*+,-.,
!"#	%&	'(%)*/0,12
+	!"#	%&	%45	6%78%49:+,-.,
!"#	%&	%45	6%78%49:/0,12
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6.4.2.4. Time-kill assays 
In order to observe the time-dependent killing effect of the combination of azoles and 
bromperidol (2) and its derivatives 1 and 3-5, we selected two representative combinations, 
compound 2 with either POS or VOR, and tested the effect on C. albicans ATCC 64124 
(strain F) as previously described51 with modifications. An overnight culture of C. albicans 
ATCC 64124 (Strain F) in YEPD broth was inoculated at 1×105 CFU/mL density in liquid 
RPMI 1640 medium at 35 °C for each sample, including growth control, azole (POS or 
VOR) alone, compound 2 alone, and the combination of azole (POS or VOR) and 
compound 2 at 0.5× MIC, 1× MIC, 4× MIC, and 8× MIC concentrations (for the 
combination of VOR and compound 2, only 1× MIC and 8× MIC combinations were 
performed). The concentrations of azoles or compound 2 used in the azole or compound 2 
alone samples were equal to the highest concentration of that drug used in the combination 
samples (e.g., the concentration of POS in the 8× MIC combination sample is 32 µg/mL, 
therefore, the concentration of POS in POS alone sample is 32 µg/mL). Each sample was 
incubated at 35 °C with shaking at 200 rpm. At various time points (0, 3, 6, 9, 12, and 24 
h), 100 µL aliquots were taken from each sample and serially diluted (10-fold dilutions) in 
sterile ddH2O. 100 µL of each dilution was spread onto PDA plates and incubated at 35 °C 
for 48 h before colony counts were determined (Figure 6.2). At the end of the 24 h 
experiment, 50 µL of 1 mM sterile resazurin solution was added to each sample for visual 
comparison of growth. Each experiment was performed in duplicate. 
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6.4.2.5. Biofilm disruption assays 
In order to investigate the synergistic effect of azoles and our compounds on inhibiting 
biofilm formation of C. albicans ATCC 64124 (strain F), we performed a biofilm 
disruption assay in a checkerboard setup and used XTT  reduction to examine the metabolic 
activity of the biofilm.35 Briefly, C. albicans ATCC 64124 (strain F) was grown overnight 
in YEPD broth at 35 °C. The culture was then diluted to an OD600 of 0.12 (equivalent to 
1×106 CFU/mL) and 100 µL was placed into each well of a 96-well plate. The cells were 
incubated at 37 °C for 24 h for growth. The following day, the spent medium containing 
planktonic cells was aspirated and each well was carefully washed three times with sterile 
phosphate buffer saline (PBS). We supplemented the washed biofilm with drug-containing 
RPMI 1640 medium with POS or VOR concentrations varying vertically and the 
concentration of compound 2 varied horizontally in a manner similar to that described 
above in the checkerboard assay section. The negative control (medium only) and the 
positive control (biofilm plus medium) wells were also included in the same 96-well plate. 
The plates were then incubated at 37 °C statically for additional 24 h and then washed with 
sterile PBS. 100 µL of a XTT (0.5 mg/mL)/menadione (1 µM) solution was added to each 
well, covered with aluminum foil, and incubated for 2 h at 37 °C. Then, 80 µL of the 
colored supernatant from each well was transferred to a new 96-well plate, and the 
absorption was read at OD490. The percent metabolic activity of the formed biofilm at 
various drug concentration combinations was calculated by dividing the metabolic activity 
of biofilm formed for that well by that of the biofilm formed in the growth control well (in 
the absence of any drug). For these experiments, we determined the sessile MIC (SMIC99), 
which is defined as the drug concentration required to inhibit the metabolic activity of 
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biofilm by 99% compared to the growth control. The SMIC99 values were used to calculate 
the FICI as described above and summarized in Table 6.4. The assay for each combination 
was performed in duplicates. 
 
6.4.2.6. Mammalian cytotoxicity assays 
In order to evaluate the potential cytotoxic effect of the azoles and compounds 1-5 
combinations against mammalian cells, we performed mammalian cytotoxicity assays as 
previously described with minor modifications.52 The human embryonic kidney cell line 
HEK-293 was purchased from ATCC (Manassas, VA), whereas the human bronchial 
epithelial cells BEAS-2B and the murine macrophage cells J774A.1 were generous gifts 
from Prof. David K. Orren (University of Kentucky, Lexington, KY) and Prof. David J. 
Feola (University of Kentucky, Lexington, KY), respectively. HEK-293 and BEAS-2B 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, catalog # 11965-
092, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum 
(FBS, ATCC, Manassas, VA) and 1% penicillin/streptomycin (ATCC, Manassas, VA) at 
37 °C with 5% CO2. J774A.1 was cultured in a different DMEM (catalog # 30-2002, 
ATCC, Manassas, VA) with the same supplements in the medium at 37 °C with 5% CO2. 
HEK-293 and BEAS-2B cells were dislodged by treating with a solution comprised of 
0.05% trypsin and 0.53 mM EDTA (ATCC, Manassas, VA) when passaging, whereas 
J774A.1 cells were dislodged from the culture flask by mechanical scraping. All 
cytotoxicity assays were performed in quadruplicates in 96-well plates where both HEK-
293 and J774A.1 cells were seeded at 1×104 cells per well and BEAS-2B cells were seeded 
at 3×103 cells per well. For the assessment of the toxicity of POS, VOR, and compound 2 
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alone as well as in combination, we performed mammalian cytotoxicity assay as previously 
described.52 The concentration of azoles tested in the assay ranged from 0.06 to 16 µg/mL, 
whereas that of compound 2 ranged from 0.25 to 64 µg/mL. When testing combination 
toxicity between azoles and compound 2, we first tested the combination of various 
concentrations of azoles in the presence of 8 µg/mL of compound 2 for all three cell lines 
due to the higher toxicity that compound 2 exerted on J774A.1 cells. We additionally tested 
combination toxicity between either azoles and compound 2 in the presence of 32 µg/mL 
of compound 2 for BEAS-2B and HEK-293 cells in order to gain a better understanding of 
the toxicity for these two cells at higher concentrations of compound 2. Since many 
xenobiotics stimulate cell growth instead of exerting toxicity at sub-IC50 concentrations,23, 
36-39 resulting in >100% cell survival in the treatment groups, we have considered these 
>100% cell survival data as no observed toxicity and expressed them as 100% cell survival 
(Figure 6.3). 
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Chapter 7. Conclusions and future directions 
7.1. CONCLUSIONS 
In this dissertation, I have explored various strategies to discover new and effective 
antibacterial and antifungal therapies. First of all, my efforts to understand various 
aminoglycoside modifying enzymes (AMEs) have led to the engineering of the 
aminoglycoside N-acetyltransferase AAC(6')-Ie from the bifunctional AME, AAC(6')-
Ie/APH(2")-Ia, by a mutation of D80G and a truncation after amino acid 240 to produce 
three mutant enzymes that contained mutation or truncation either alone or in combination. 
I found that mutation or truncation alone or in combination could cause the enzyme to 
expand its regiospecificity to acetylate a second amine moiety at 1-position of arbekacin 
and amikacin in addition to the original 6'-NH2. This reflected the survival strategy that the 
bacteria might have acquired over time: possessing additional acetylating enzymes to 
further modify the aminoglycoside (AG) antibiotics and ensure their inactivation inside the 
bacteria as AGs had been shown to sometimes retain antibacterial activity after a single 
acetylation. In addition to this enzyme, I also presented that seven more AACs, including 
AAC(2')-Ic, AAC(3)-Ia, AAC(3)-Ib, AAC(3)-IV, AAC(6')-Ib', AAC(6')-IId, and the 
multiacetylating AAC Eis, could be inhibited by various metal salts. The organic complex 
zinc pyrithione further represented a good delivery strategy to increase intracellular Zn2+ 
concentration and further validated metal ions as AAC inhibitors to be used in adjunction 
with AG antibiotics to combat bacterial infections with AAC-associated resistance. 
 
Furthermore, I explored another common AME, the aminoglycoside O-phosphotransferase 
APH(3')-IIa. Upon examining its substrate profiles with different NTPs, I realized that this 
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enzyme displayed diminishing substrate promiscuity as the cosubstrate changed from ATP 
to other NTPs. This revealed the dynamic interactions between the enzyme and the binding 
of the substrate and cosubstrate. Further kinetic analysis demonstrated that using different 
NTPs as cosubstrates did not universally decrease the enzyme’s reactivity to all AGs but 
changed its substrate preference. This discovery could inspire all researchers working with 
AMEs that the substrate and cosubstrate share dynamic relationships with the enzyme and 
the three parties cannot be studied separately when investigating AMEs. 
 
In addition to tackling the resistance problem by studying various AMEs, I also 
investigated the AG and carbapenem resistance in 122 Pseudomonas aeruginosa clinical 
isolates obtained from the University of Kentucky Hospital System. Upon evaluating the 
antibiotic resistance and the presence of various AME genes in these bacteria, we found 
the correlation between the resistance of two AGs and that between the resistance of AGs 
and carbapenems suggested a variety of antibiotic resistance mechanisms in addition to the 
sole presence of AME genes. We identified the lack of drug synergy between the two 
classes of antibiotics, which added to the existing dispute about the drastic variation of 
resistance epidemics based on geographical and other factors. 
 
Lastly, my efforts in repurposing the existing antipsychotic compound, bromperidol, and 
its derivatives into a new combinational antifungal therapy with the azole antifungals was 
proven to be effective against a variety of pathogenic yeasts and filamentous fungi. In 
addition to displaying synergistic effects, the combination of these two classes of 
compounds also showed satisfying mammalian cytotoxicity. Therefore, developing these 
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old antipsychotic drugs as an adjuvant with the azole drugs presented promising outcomes 
as a new antifungal strategy. 
 
7.2. FUTURE DIRECTIONS 
In addition to the published studies, I have also investigated part of my Ph.D. in a few more 
projects. Some of these projects showed high potentials and should continue to be explored 
for future research as summarized herein. 
 
7.2.1. Developing AGs as therapeutics for premature termination codon diseases 
As introduced in Chapter 1.5, AGs along with their newly developed derivatives have 
displayed ability to promote read-through at premature termination codons (PTC) in some 
genetic disorders that are resulted from nonsense mutations. Thanks to Dr. Matthew S. 
Gentry and the collaboration between the two labs, I had the opportunity to explore AGs 
as potential therapeutic options for PTC diseases using Lafora Disease (LD) as an example. 
 
LD is a progressive neurodegenerative disease symptomized by seizure, ataxia, myoclonus, 
and increasing severity of dementia.1-5 This neurological disorder usually onsets in the 
early teenage years with a myoclonus epilepsy and patients survives for about ten years 
after onset. A hallmark of LD is the accumulation of insoluble glycogen granules known 
as the lafora bodies.6 The lafora bodies are hyper-phosphorylated sparsely-branched 
polysaccharides that resemble amylopectin, which is insoluble, rather than the soluble 
glycogen. Consequently, they take up intracellular space, disturb cellular energy 
homeostasis, and lead to neuronal cell death as the disease progresses. 
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Two genes that are most frequently mutated in LD are the EPM2A (epilepsy, progressive 
myoclonus 2A, ~60% of the cases), which encodes for the glucanphosphatase laforin, and 
EPM2B (epilepsy, progressive myoclonus 2B, ~30% of the cases), which encodes for the 
E3 ubiquitin ligase malin.2, 7-8 The laforin enzyme is specifically responsible for 
dephosphorylating phosphoglucans, which is essential for the proper branching of 
glycogen to maintain water solubility, while malin regulates protein turnover associated 
with glycogen synthesis and metabolism. 
 
AGs’ PTC suppressing efficiency is dose-, context-, and mutation-dependent.9 Thus, PTC 
therapies need to be established for each unique disease and specific mutation. During my 
training with Dr. Vikas V. Duhkande in the Gentry lab, we used Western blot analysis 
testing the PTC suppression activity of various concentrations of gentamicin (GEN) in 
HEK-293 cells transiently transfected with laforin wt (negative control, no increase in the 
production of full-length laforin protein upon GEN treatment), laforin Y86X, laforin R241X, 
and MeCP2 R294X (positive control, a PTC mutation in Rett syndrome previously reported 
to produce full-length MeCP2 protein upon GEN treatments)10-11.  
 
Specifically, HEK-293 cells were plated in 6-well cell culture dish with 5 mL of DMEM 
medium supplemented with 1% Penn/Strep solution and 5% FBS at 37 °C with 5% CO2. 
At 70% confluency, cells were transiently transfected with 350 ng of the above-mentioned 
genes constructed in a modified pcDNA3.1 with a N-terminal FLAG tag (for the laforin 
genes) or a modified pTRACER-CMV2 expression vector with an N-terminal 3x FLAG 
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tag (for the MeCP2 R294 gene) with PEIMAX. At 4 h post transfection, cells were treated 
with various concentrations of GEN (0, 1, 1.75, and 3.5 mM) for 40 h. Whole-cell lysate 
were collected by lysis with 3:1 modified RIPA:RIPA buffer mixture solution. After 
determining the total protein concentrations using Bradford assay, SDS-PAGE samples 
were prepared controlling the total amount of protein in each sample and boiled for 10 min 
before loading onto an SDS-PAGE gel. Upon separation of proteins by electrophoresis, the 
proteins from the gel were transferred to a blot. Laforin protein was probed with mouse 
monoclonal anti-FLAG antibody coupled with HRP-conjugated goat-anti-mouse 
secondary antibody. b-actin was probed with a monoclonal anti-b-actin antibody coupled 
with HRP-conjugated goat-anti-mouse secondary antibody as a control for total protein 
level present on the blot for each sample. Assays were performed in triplicates. 
 
I observed that various concentrations of GEN did not induce laforin protein over-
production in the cells transfected with laforin wt gene but did result in upregulation of 
MeCP2 full-length protein production in the sample transfected with MeCP2 R294X gene 
in a dose-dependent manner. Furthermore, I observed that GEN induced the production of 
full-length laforin protein in the samples transfected with laforin R241x gene but not in the 
samples transfected with laforin Y86X (Figure 7.1). 
 
 
Figure 7.1. Western blot analysis of the PTC read-through induction in HEK293 cells transiently 
transfected with laforin wt (negative control), laforin Y86X, laforin R241X, and MeCP2 R294X 
(positive control) by GEN at various concentrations. 
 
GEN (mM)
Laforin wt Laforin Y86X Laforin R241X MeCP2 R294X
0 1 1.75 3.5 0 1 1.75 3.50 1 1.75 3.50 1 1.75 3.5
Laforin wt
β-actin
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Even though Dr. Duhkande and I produced the data as shown in Figure 7.1 during the initial 
training, I was unable to reproduce the same results afterwards except for the controls of 
laforin wt and MeCP2 R294X. Even though my efforts on troubleshooting for Western blot 
experiments have so far been unsuccessful, AGs and their derivatives still present 
promising outcomes as potential therapeutic options for LD and other PTC-related 
disorders as shown in many other publications summarized in Chapter 1.5. Furthermore, 
another potential flaw in the design of the study is the mammalian expression vector used 
in this study. The modified pcDNA3.1 vector contains a neoR gene in the backbone as a 
selection marker. However, as demonstrated in Chapter 4, the product of this neoR gene is 
APH(3')-IIa enzyme that modifies a variety of AGs and their derivatives. Therefore, I have 
used quikchange mutagenesis to mutate the catalytic residue Asp190 into an alanine in the 
pcDNA3.1 laforin wt and laforin R241X with C-terminal FLAG tags. Another option 
would be recloning these genes into a different mammalian expression vector without any 
gene elements that would interfere with potential AG treatments. 
 
7.2.2. Exploring PanD as a potential new target against Mycobacterium tuberculosis 
infections 
Pyrazinamide (PZA) is a vital component of the first-line treatment regimen against 
Mycobacterium tuberculosis infections.12-13 The use of PZA effectively allowed the 
treatment time for all-sensitive Mtb infections to reduce down to 6 months and is the only 
drug in the first-line treatment regimen whose mechanism of action is still in debate. In 
some recent studies, PanD, an aspartate decarboxylase, was proposed to be the target of 
pyrazinoic acid (POA), which is the active form of the prodrug PZA upon activation in 
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Mtb.14-15 Some mutations in PanD were also proposed to be associated with PZA/POA 
resistance.16-17 Although many details remain to be elucidated. Therefore, I would like to 
validate PanD as the target of PZA/POA and a new anti-tubercular target. In addition, I 
would also like to develop an assay for a high-throughput style screening for potential 
PanD inhibitors. 
 
PanD was amplified by PCR from the Mtb H37Rv genomic DNA and cloned into pET22b 
vector for a C-terminal His6 tag.  A double point mutant H21R-I49V that was associated 
with PZA/POA resistance as well as both single mutants were also cloned.17 A previous 
publication demonstrated the expression and purification of PanD enzyme in E. coli.18 
However, this manuscript reported that PanD is expressed as an p-enzyme (expected size 
16.0 kDa) that undergoes self-cleavage at Ser25(expected size of 13.4 kDa after cleavage). 
However, as seen in Figure 7.2, the protein product after NiII affinity column purification 
seemed to correspond to bigger size than what was reported before. My attempts to 
activate/cleave the protein by incubating the protein at various concentrations (4, 20, 37, 
42, 50, and 65 °C) as previously reported did not produce a shorter protein than what I 
originally observed in SDS-PAGE corresponding to the correct size. The expression and 
purification of the PanD H21R-I49V with C-His6 tag seemed to correspond to an even 
bigger molecular weight on SDS-PAGE. This led me to postulate that PanD wt might be 
expressed in the cleaved/active form whereas the double mutant was incapable of self-
cleaving due to the first H21R mutation, and they both ran slower than normal proteins of 
their sizes. Therefore, a future MALDI experiment may be necessary to elucidate the true 
state/sequence of these two proteins. 
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Figure 7.2. SDS-PAGE of PanD wt and H21R-I49V proteins after NiII purification and after incubation 
at various temperatures. 
 
In the meanwhile, I had explored a new assay we could use to screen potential inhibitors 
of PanD enzyme. A previous publication suggested a high-throughput fluorescent assay to 
measure the activity of several amino acid decarboxylases.19 Using O-diacetylbenzene 
(DAB) and b-mercaptoethanol (BME), this assay was reported to distinguish between a 
decarboxylated amine and their amino acid precursors. To test whether this assay system 
would work with PanD, I tested whether the assay would distinguish between various 
concentrations (0.1–1 mM) of L-aspartate (L-Asp) and b-alanine (b-Ala), which are the 
substrate and product of PanD. The assay seemed to detect low levels of product (0.1 mM), 
and therefore, could be used to detect PanD reactions (Figure 7.3). 
 
Using this assay to test the activity of the protein samples with and without incubation at 
higher temperatures, I found that the “uncleaved” protein was indeed active and incubation 
at higher temperatures resulted in reduced activity over time (Figure 7.4). Therefore, the 
protein either was initially expressed as a cleaved protein as I have explained before or the 
uncleaved protein is active in its original state. Furthermore, I tested whether PZA or POA 
would cause inhibition of PanD wt and PanD H21R-I49V (Figure 7.5). We found neither 
PZA nor POA exerted inhibition on PanD wt enzyme at low concentration and POA 
induced ~20% inhibition in Pan Dwt activity. Additionally, the PanD H21R-I49V double 
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mutant was inactive. Therefore, PanD as a target of PZA/POA may require higher 
concentrations but still presents high potential for a new antitubercular strategy in the future. 
 
 
Figure 7.3. DAB and BME quenching various concentrations of L-Asp and b-Ala. 
 
 
Figure 7.4. Enzymatic activity of PanD wt after NiII purification and incubation at 37 or 65 °C. 
 
 
 
Figure 7.5. Enzymatic activity of PanD wt and H21R-I49V double mutant in the presence of 5 or 50 µM 
of PZA or POA as an inhibitor. 
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